>OF116941.1 KR 1020200128125-A/468: METHODS FOR ALTERING BODY COMPOSITION
GATGCATCC
>OF116933.1 KR 1020200128125-A/452: METHODS FOR ALTERING BODY COMPOSITION
GATGCTTCC
>OF116925.1 KR 1020200128125-A/436: METHODS FOR ALTERING BODY COMPOSITION
GAGACATCC
>OF116917.1 KR 1020200128125-A/420: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116909.1 KR 1020200128125-A/404: METHODS FOR ALTERING BODY COMPOSITION
TGGGCATCT
>OF116901.1 KR 1020200128125-A/387: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116893.1 KR 1020200128125-A/371: METHODS FOR ALTERING BODY COMPOSITION
ACTACATCC
>OF116882.1 KR 1020200128125-A/325: METHODS FOR ALTERING BODY COMPOSITION
AAGATTTCT
>OF116878.1 KR 1020200128125-A/317: METHODS FOR ALTERING BODY COMPOSITION
TTGGGTTCT
>OF116870.1 KR 1020200128125-A/301: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116862.1 KR 1020200128125-A/285: METHODS FOR ALTERING BODY COMPOSITION
GGTGCATCC
>OF116854.1 KR 1020200128125-A/269: METHODS FOR ALTERING BODY COMPOSITION
TTGGGTTCT
>OF116846.1 KR 1020200128125-A/253: METHODS FOR ALTERING BODY COMPOSITION
GGTGCATCC
>OF116838.1 KR 1020200128125-A/237: METHODS FOR ALTERING BODY COMPOSITION
GGTGCATCC
>OF116830.1 KR 1020200128125-A/221: METHODS FOR ALTERING BODY COMPOSITION
GGTGCATCC
>OF116822.1 KR 1020200128125-A/205: METHODS FOR ALTERING BODY COMPOSITION
GGTGCATCC
>OF116814.1 KR 1020200128125-A/189: METHODS FOR ALTERING BODY COMPOSITION
GCTACATCC
>OF116806.1 KR 1020200128125-A/173: METHODS FOR ALTERING BODY COMPOSITION
GGTGCATCC
>OF116798.1 KR 1020200128125-A/157: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116790.1 KR 1020200128125-A/141: METHODS FOR ALTERING BODY COMPOSITION
GTTGCATCC
>OF116782.1 KR 1020200128125-A/125: METHODS FOR ALTERING BODY COMPOSITION
CGGATGTCC
>OF116774.1 KR 1020200128125-A/109: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116766.1 KR 1020200128125-A/93: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116758.1 KR 1020200128125-A/77: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116750.1 KR 1020200128125-A/61: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116742.1 KR 1020200128125-A/45: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116734.1 KR 1020200128125-A/29: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
>OF116726.1 KR 1020200128125-A/13: METHODS FOR ALTERING BODY COMPOSITION
GGTGTATCC
>OF116528.1 KR 1020200132893-A/6: SYNTHETIC DNA VECTORS AND METHODS OF USE
GGTCGCCCG
>OF116527.1 KR 1020200132893-A/5: SYNTHETIC DNA VECTORS AND METHODS OF USE
CGGGCGACC
>OF116526.1 KR 1020200132893-A/4: SYNTHETIC DNA VECTORS AND METHODS OF USE
GCCCGGGCG
>OF116525.1 KR 1020200132893-A/3: SYNTHETIC DNA VECTORS AND METHODS OF USE
CGCCCGGGC
>OF116387.1 KR 1020200128703-A/66: HEPATITIS B VACCINES AND USES OF THE SAME
GGAAGCGGA
>OF116330.1 KR 1020200130339-A/66: HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME
GGAAGCGGA
>OF116270.1 KR 1020200116548-A/1365: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GAAGCATCT
>OF116262.1 KR 1020200116548-A/1349: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTACATCC
>OF116254.1 KR 1020200116548-A/1325: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF116246.1 KR 1020200116548-A/1309: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF116238.1 KR 1020200116548-A/1293: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF116230.1 KR 1020200116548-A/1277: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF116222.1 KR 1020200116548-A/1261: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF116210.1 KR 1020200116548-A/1237: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF116110.1 KR 1020200116548-A/1037: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GTTGCATCC
>OF116102.1 KR 1020200116548-A/1021: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>OF116094.1 KR 1020200116548-A/1005: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>OF116086.1 KR 1020200116548-A/989: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GTTGCATCC
>OF116078.1 KR 1020200116548-A/973: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF116070.1 KR 1020200116548-A/957: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>OF116062.1 KR 1020200116548-A/941: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GTTGCATCC
>OF116054.1 KR 1020200116548-A/925: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>OF116046.1 KR 1020200116548-A/909: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>OF116038.1 KR 1020200116548-A/893: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>OF116030.1 KR 1020200116548-A/877: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF116022.1 KR 1020200116548-A/861: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
ACTGCATCC
>OF116014.1 KR 1020200116548-A/845: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
TGGGCATCT
>OF116006.1 KR 1020200116548-A/829: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
AAGGCGTCT
>OF115998.1 KR 1020200116548-A/813: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>OF115990.1 KR 1020200116548-A/797: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>OF115982.1 KR 1020200116548-A/781: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115974.1 KR 1020200116548-A/765: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>OF115966.1 KR 1020200116548-A/749: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>OF115958.1 KR 1020200116548-A/733: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>OF115950.1 KR 1020200116548-A/717: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCGTCC
>OF115942.1 KR 1020200116548-A/701: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115934.1 KR 1020200116548-A/685: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCGTCC
>OF115926.1 KR 1020200116548-A/669: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115918.1 KR 1020200116548-A/653: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115910.1 KR 1020200116548-A/637: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115902.1 KR 1020200116548-A/621: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115894.1 KR 1020200116548-A/605: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115886.1 KR 1020200116548-A/589: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GATGCATCC
>OF115878.1 KR 1020200116548-A/573: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGTATCC
>OF115870.1 KR 1020200116548-A/557: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GAAGCTTCT
>OF115862.1 KR 1020200116548-A/541: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCTTCC
>OF115854.1 KR 1020200116548-A/525: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115846.1 KR 1020200116548-A/509: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115838.1 KR 1020200116548-A/493: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115830.1 KR 1020200116548-A/477: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115822.1 KR 1020200116548-A/461: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115814.1 KR 1020200116548-A/445: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115806.1 KR 1020200116548-A/429: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCAACC
>OF115798.1 KR 1020200116548-A/413: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCAACC
>OF115790.1 KR 1020200116548-A/397: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115782.1 KR 1020200116548-A/381: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115774.1 KR 1020200116548-A/365: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
TGGGCATCT
>OF115766.1 KR 1020200116548-A/349: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115758.1 KR 1020200116548-A/333: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115750.1 KR 1020200116548-A/317: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCAACC
>OF115742.1 KR 1020200116548-A/301: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCAACC
>OF115734.1 KR 1020200116548-A/285: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF036185.1 KR 1020200079300-A/50: VECTOR CONSTRUCT
TTAACTTTA
>OF115726.1 KR 1020200116548-A/269: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115718.1 KR 1020200116548-A/253: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115710.1 KR 1020200116548-A/237: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115702.1 KR 1020200116548-A/221: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115694.1 KR 1020200116548-A/205: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115686.1 KR 1020200116548-A/189: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115678.1 KR 1020200116548-A/173: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115670.1 KR 1020200116548-A/157: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115662.1 KR 1020200116548-A/141: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115654.1 KR 1020200116548-A/125: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115646.1 KR 1020200116548-A/109: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GATGCATCC
>OF115638.1 KR 1020200116548-A/93: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115630.1 KR 1020200116548-A/77: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115622.1 KR 1020200116548-A/61: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115614.1 KR 1020200116548-A/45: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GCTGCATCC
>OF115606.1 KR 1020200116548-A/29: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF115598.1 KR 1020200116548-A/13: ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF
GGTGCATCC
>OF033456.1 KR 1020200121783-A/10: CAR-T CELLS TARGETING IL-1RAP AND THEIR USE
TCGGCATCC
>OF033451.1 KR 1020200090779-A/45: ANTI-TRKB MONOCLONAL ANTIBODIES AND METHODS OF USE
GCTGCATCC
>OF033443.1 KR 1020200090779-A/29: ANTI-TRKB MONOCLONAL ANTIBODIES AND METHODS OF USE
TGGGCATCT
>OF033435.1 KR 1020200090779-A/13: ANTI-TRKB MONOCLONAL ANTIBODIES AND METHODS OF USE
GCTGCATCC
>OF030872.1 KR 1020200090770-A/122: NON-HUMAN ANIMALS COMPRISING A HUMANIZED TRKB LOCUS
GCTGCATCC
>OF030864.1 KR 1020200090770-A/106: NON-HUMAN ANIMALS COMPRISING A HUMANIZED TRKB LOCUS
TGGGCATCT
>OF030856.1 KR 1020200090770-A/90: NON-HUMAN ANIMALS COMPRISING A HUMANIZED TRKB LOCUS
GCTGCATCC
>OF030437.1 KR 1020200096758-A/115: POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS
GGAAGCGGA
>OF028223.1 KR 1020200095462-A/75: ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING HBB GENE FUNCTION AND METHODS OF USE THEREOF
GGCAGCGGA
>OF027731.1 KR 1020200088805-A/65: GENOME-EDITED BIRDS
AGATAACGT
>OF026995.1 KR 1020200136354-A/7: A METHOD CODING STANDARDIZATION OF DNA AND A BIOTECHNOLOGICAL USE OF THE METHOD
GCGGTGGCG
>OF026674.1 KR 1020200096893-A/25: Nucleic acid complex pair, competitive structure, PCR kit using the same
GTAACTCGC
>pdb|7OMA|L Chain L, Thosea asigna virus RdRP domain elongation complex
CAAAATTTT
>pdb|7OMA|I Chain I, Thosea asigna virus RdRP domain elongation complex
CAAAATTTT
>pdb|7OMA|G Chain G, Thosea asigna virus RdRP domain elongation complex
CAAAATTTT
>pdb|7OMA|E Chain E, Thosea asigna virus RdRP domain elongation complex
CAAAATTTT
>pdb|7AA6|C3 Chain C3, Erythromycin-stalled E.coli ribosome with Streptococcal MsrDL nascent chain
NTCATGTAA
>pdb|1NTT|A Chain A, 5'(dCPCPUPCPCPUPUP)3':(rAGGAGGAAA)5', where P=propynyl
AAAGGAGGA
>pdb|1NTS|A Chain A, 5'(dCCPUPCPCPUPUP)3':3'(rAGGAGGAAA)5', where P=propynyl
AAAGGAGGA
>MQ109681.1 Sequence 533 from Patent WO2021123902
TGGGCCTCT
>MQ108190.1 Sequence 13 from Patent WO2021133776
GCTGCTTCC
>MQ107805.1 Sequence 30 from Patent WO2021122982
GGTGTAAGG
>MQ106678.1 Sequence 177 from Patent WO2021123996
TACACCTCC
>MQ106677.1 Sequence 176 from Patent WO2021123996
TACACTAGC
>MQ106591.1 Sequence 90 from Patent WO2021123996
TGGGCCTCT
>MQ106547.1 Sequence 46 from Patent WO2021123996
TGGGCCTCT
>MQ105233.1 Sequence 45 from Patent WO2021123074
TTTTTTTTT
>MQ105230.1 Sequence 42 from Patent WO2021123074
GGAAGAGAA
>MQ105229.1 Sequence 41 from Patent WO2021123074
CACACCAAC
>MQ105228.1 Sequence 40 from Patent WO2021123074
ACAGGAGCA
>MQ105205.1 Sequence 17 from Patent WO2021123074
AAAAAAAAA
>MQ105202.1 Sequence 14 from Patent WO2021123074
TTCTCTTCC
>MQ105201.1 Sequence 13 from Patent WO2021123074
GTTGGTGTG
>MQ105200.1 Sequence 12 from Patent WO2021123074
TGCTCCTGT
>MQ102656.1 Sequence 7 from Patent EP3843791
TTCAAGAGA
>MQ099272.1 Sequence 17 from Patent WO2021138678
CAAGTAAGC
>MQ099264.1 Sequence 9 from Patent WO2021138678
CAAGTAAGC
>MQ099260.1 Sequence 5 from Patent WO2021138678
CAAGTAAGT
>MQ099256.1 Sequence 1 from Patent WO2021138678
CAAGTAAGT
>MQ099240.1 Sequence 55 from Patent EP3846857
CCTGTTTTA
>MQ098682.1 Sequence 55 from Patent EP3846822
CCTGTTTTA
>pdb|7M88|P Chain P, Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 300 s
AGCGTCAAA
>pdb|7M87|P Chain P, Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 230 s
AGCGTCAAA
>pdb|7M86|P Chain P, Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 140 s
AGCGTCAAA
>pdb|7M82|P Chain P, Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 300 s
AGCGTCAAA
>pdb|7M81|P Chain P, Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 100 s
AGCGTCAAA
>pdb|7M80|P Chain P, Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 100 s
AGCGTCAAA
>pdb|7M7Z|P Chain P, Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 40 s
AGCGTCAAA
>pdb|7M7S|P Chain P, Human DNA Pol eta S113A with dT-ended primer and 0.1 mM dAMPNPP
TAGCGTCAT
>pdb|7M7Q|P Chain P, Human DNA Pol eta S113A with dT-ended primer and dAMPNPP
TAGCGTCAT
>pdb|7M7P|P Chain P, Human DNA Pol eta S113A with dA-ended primer and dAMPNPP
TAGCGTCAA
>pdb|7M7O|P Chain P, Human DNA Pol eta with dT-ended primer and 0.1 mM dAMPNPP
TAGCGTCAT
>pdb|2NCR|A Chain A, Structural insight for dynamics of r(CGG) motif RNA found in Fragile X syndrome/ Fragile X tremor ataxia at 25 degree C
NCGCGGCGG
>pdb|2NCR|S Chain S, Structural insight for dynamics of r(CGG) motif RNA found in Fragile X syndrome/ Fragile X tremor ataxia at 25 degree C
NCGCGGCGG
>pdb|7COD|T Chain T, Post insertion complex of DNA polymerase Mu (K438A/Q441A) with 1-nt gapped DNA
CGGCTTACG
>pdb|7COC|T Chain T, Ternary complex of DNA polymerase Mu (K438A/Q441A) with 1-nt gapped DNA (T:dGMPNPP)
CGGCTTACG
>pdb|7COB|T Chain T, Ternary complex of DNA polymerase Mu (Q441A) with 1-nt gapped DNA (T:dGMPNPP)
CGGCTTACG
>pdb|7COA|T Chain T, Ternary complex of DNA polymerase Mu with 1-nt gapped DNA (T:dGMPNPP) and Mn
CGGCTTACG
>pdb|7CO9|T Chain T, Ternary complex of DNA polymerase Mu with 1-nt gapped DNA (T:dGMPNPP) and Mg
CGGCTTACG
>pdb|7CO6|T Chain T, Binary complex of DNA polymerase Mu with 1-nt gapped DNA (templating thymine)
CGGCTTACG
>MQ076255.1 Sequence 20 from Patent EP3833690
GCCGCCACC
>MQ082827.1 Sequence 85 from Patent WO2021113701
GCTGCATCC
>MQ082819.1 Sequence 77 from Patent WO2021113701
GCTGCATCC
>MQ082803.1 Sequence 61 from Patent WO2021113701
GCTGCAACC
>MQ082787.1 Sequence 45 from Patent WO2021113701
ACTGCATCC
>MQ082771.1 Sequence 29 from Patent WO2021113701
GCTGCATCC
>MQ082755.1 Sequence 13 from Patent WO2021113701
GCTGCATCC
>MQ079305.1 Sequence 13 from Patent WO2021113707
GCTGCTTCC
>MQ072851.1 Sequence 66 from Patent WO2021108755
ACACTGGAA
>MQ072816.1 Sequence 31 from Patent WO2021108755
ACCCTTGAA
>MQ072557.1 Sequence 207 from Patent WO2021108661
GGAAGCGGA
>MQ065215.1 Sequence 4 from Patent EP3827847
TTTGTAGAT
>MQ055181.1 Sequence 104 from Patent WO2021096980
GATGTCAGT
>MQ055162.1 Sequence 85 from Patent WO2021096980
GATGTCAGT
>MQ055142.1 Sequence 65 from Patent WO2021096980
GATGCATCC
>MQ055122.1 Sequence 45 from Patent WO2021096980
GCTGCATCC
>MQ051734.1 Sequence 100 from Patent WO2021094752
GTGGAGACT
>MQ051666.1 Sequence 32 from Patent WO2021094752
KAGRVVATG
>MQ049115.1 Sequence 33 from Patent WO2021097255
GCAAAACCG
>MQ047462.1 Sequence 29 from Patent WO2021090062
GACGCCTCT
>OG170243.1 WO 2021025104-A/24: Plant RNA
TTCTTCTTC
>OG170233.1 WO 2021025104-A/14: Plant RNA
TCTTCTTCT
>OG170223.1 WO 2021025104-A/4: Plant RNA
CTTCTTCTT
>OG169691.1 WO 2021020564-A/6: Antigen binding molecule
TGGGCATCT
>OG168243.1 JP 2021023222-A/24: Plant RNA
TTCTTCTTC
>OG168233.1 JP 2021023222-A/14: Plant RNA
TCTTCTTCT
>OG168223.1 JP 2021023222-A/4: Plant RNA
CTTCTTCTT
>OG167369.1 JP 2021024792-A/21: agent and method for promoting muscle differentiation, and oligodeoxynucleotide for promoting muscle differentiation
GGGWWGGGG
>pdb|6XLN|R Chain R, Cryo-EM structure of E. coli RNAP-DNA elongation complex 2 (RDe2) in EcmrR-dependent transcription
NCAGTCTGA
>pdb|6XLM|R Chain R, Cryo-EM structure of E.coli RNAP-DNA elongation complex 1 (RDe1) in EcmrR-dependent transcription
NCAGTCTGA
>pdb|7DIC|C Chain C, Mycoplasma genitalium RNase R in complex with single-stranded RNA
NAAAAAAAA
>MP970027.1 Sequence 27 from Patent EP3798301
CTATAAATT
>MP970026.1 Sequence 26 from Patent EP3798301
CTATAAATC
>MP970025.1 Sequence 25 from Patent EP3798301
CTATAAATG
>MP970024.1 Sequence 24 from Patent EP3798301
CTATAAAGA
>MP970023.1 Sequence 23 from Patent EP3798301
CTATAAACA
>MP970022.1 Sequence 22 from Patent EP3798301
CTATAAAAA
>MP970021.1 Sequence 21 from Patent EP3798301
CTATAGATA
>MP970020.1 Sequence 20 from Patent EP3798301
CTATACATA
>MP970019.1 Sequence 19 from Patent EP3798301
CTATATATA
>MP970018.1 Sequence 18 from Patent EP3798301
TAATAAATA
>MP970017.1 Sequence 17 from Patent EP3798301
TCATAAATA
>MP970016.1 Sequence 16 from Patent EP3798301
GTATAAATA
>MP970015.1 Sequence 15 from Patent EP3798301
TTATAAATA
>MP970014.1 Sequence 14 from Patent EP3798301
ATATAAATA
>MP970013.1 Sequence 13 from Patent EP3798301
CTATAAATA
>MP970011.1 Sequence 11 from Patent EP3798301
CTATAWAWA
>MQ040738.1 Sequence 13 from Patent WO2021086899
GCTGCATCC
>MQ038083.1 Sequence 16 from Patent WO2021087084
CGCGACGCG
>MQ036496.1 Sequence 11 from Patent EP3814375
TGGGCCAGC
>MQ032315.1 Sequence 758 from Patent EP3814510
GCAAGAGAC
>MQ032314.1 Sequence 757 from Patent EP3814510
CGCTGGTGA
>MQ032313.1 Sequence 756 from Patent EP3814510
AGCGAAGAT
>MQ032312.1 Sequence 755 from Patent EP3814510
TGGCTCGGA
>MQ032311.1 Sequence 754 from Patent EP3814510
AAGGACATC
>MQ032310.1 Sequence 753 from Patent EP3814510
CAATCTTAT
>MQ032309.1 Sequence 752 from Patent EP3814510
TACTTGTTG
>MQ032308.1 Sequence 751 from Patent EP3814510
CGCTGAGAG
>MQ032307.1 Sequence 750 from Patent EP3814510
ACATTCATG
>MQ032306.1 Sequence 749 from Patent EP3814510
ATATCACCT
>MQ032305.1 Sequence 748 from Patent EP3814510
CCCACGGCT
>MQ032304.1 Sequence 747 from Patent EP3814510
CGTTGTTTT
>MQ032303.1 Sequence 746 from Patent EP3814510
CTCTTATCT
>MQ032302.1 Sequence 745 from Patent EP3814510
CCTGGATGA
>MQ032301.1 Sequence 744 from Patent EP3814510
GAAAATTCC
>MQ031693.1 Sequence 136 from Patent EP3814510
AAATCTGAC
>MQ031692.1 Sequence 135 from Patent EP3814510
CAAGAAAAA
>MQ031619.1 Sequence 62 from Patent EP3814510
GCTCTGCTC
>MQ031618.1 Sequence 61 from Patent EP3814510
TAATCTCCC
>MQ031588.1 Sequence 31 from Patent EP3814510
AACGTGTTC
>MQ031582.1 Sequence 25 from Patent EP3814510
ACTCAGCAC
>MQ031576.1 Sequence 19 from Patent EP3814510
GCGAGGTGT
>MQ023956.1 Sequence 164 from Patent WO2021081440
GGTTCAGGA
>MQ023955.1 Sequence 163 from Patent WO2021081440
GGTGGATCA
>MQ023752.1 Sequence 17 from Patent WO2021078834
GGCGCGCCG
>MQ023341.1 Sequence 390 from Patent WO2021080682
GGGAGCGGT
>MQ023329.1 Sequence 378 from Patent WO2021080682
GGATCAGGT
>MQ023308.1 Sequence 357 from Patent WO2021080682
GCCGCCACC
>MQ021964.1 Sequence 17 from Patent WO2021078833
GGCGCGCCG
>MQ018884.1 Sequence 3 from Patent EP3802836
TTCAAGAGA
>MQ018857.1 Sequence 349 from Patent WO2021081277
GATGCATCC
>MQ018841.1 Sequence 333 from Patent WO2021081277
GGTGCATCC
>MQ018825.1 Sequence 317 from Patent WO2021081277
GATGCATCC
>MQ018809.1 Sequence 301 from Patent WO2021081277
GCTGCATCC
>MQ018769.1 Sequence 261 from Patent WO2021081277
GCTGCATCC
>MQ018753.1 Sequence 245 from Patent WO2021081277
GATGCATCC
>MQ018737.1 Sequence 229 from Patent WO2021081277
GCTGCATCC
>MQ018721.1 Sequence 213 from Patent WO2021081277
AAGGCGTCT
>MQ018705.1 Sequence 197 from Patent WO2021081277
GATGCATCC
>MQ018689.1 Sequence 181 from Patent WO2021081277
ACTGCATCC
>MQ018673.1 Sequence 165 from Patent WO2021081277
ACTGCATCC
>MQ018641.1 Sequence 133 from Patent WO2021081277
GCTGCATCC
>MQ018625.1 Sequence 117 from Patent WO2021081277
GCTGCATCC
>MQ018617.1 Sequence 109 from Patent WO2021081277
GCTGCATCC
>MQ018601.1 Sequence 93 from Patent WO2021081277
GATGCATCG
>MQ018585.1 Sequence 77 from Patent WO2021081277
GCTGCATCC
>MQ018569.1 Sequence 61 from Patent WO2021081277
GCTGCATCC
>MQ018553.1 Sequence 45 from Patent WO2021081277
AAGGCGTCT
>MQ018537.1 Sequence 29 from Patent WO2021081277
GATGCATCC
>MQ018521.1 Sequence 13 from Patent WO2021081277
AAGGCGTCT
>MQ015933.1 Sequence 176 from Patent EP3802615
GGAAGCGGA
>MQ012596.1 Sequence 40 from Patent EP3760727
GGTTACCTC
>MQ012593.1 Sequence 37 from Patent EP3760727
GGTTACCTC
>MQ012590.1 Sequence 34 from Patent EP3760727
GATTACCCC
>MQ012587.1 Sequence 31 from Patent EP3760727
GATTACCCC
>MQ010984.1 Sequence 42 from Patent EP3802572
GATGTCTAT
>MP987028.1 Sequence 47 from Patent WO2021058734
TATTTATAT
>MP987024.1 Sequence 43 from Patent WO2021058734
GTATTAAAA
>MP987020.1 Sequence 39 from Patent WO2021058734
CTATAAAAG
>MP987008.1 Sequence 27 from Patent WO2021058734
CTATAAATT
>MP987007.1 Sequence 26 from Patent WO2021058734
CTATAAATC
>MP987006.1 Sequence 25 from Patent WO2021058734
CTATAAATG
>MP987005.1 Sequence 24 from Patent WO2021058734
CTATAAAGA
>MP987004.1 Sequence 23 from Patent WO2021058734
CTATAAACA
>MP987003.1 Sequence 22 from Patent WO2021058734
CTATAAAAA
>MP987002.1 Sequence 21 from Patent WO2021058734
CTATAGATA
>MP987001.1 Sequence 20 from Patent WO2021058734
CTATACATA
>MP987000.1 Sequence 19 from Patent WO2021058734
CTATATATA
>MP986999.1 Sequence 18 from Patent WO2021058734
TAATAAATA
>MP986998.1 Sequence 17 from Patent WO2021058734
TCATAAATA
>MP986997.1 Sequence 16 from Patent WO2021058734
GTATAAATA
>MP986996.1 Sequence 15 from Patent WO2021058734
TTATAAATA
>MP986995.1 Sequence 14 from Patent WO2021058734
ATATAAATA
>MP986994.1 Sequence 13 from Patent WO2021058734
CTATAAATA
>MP986992.1 Sequence 11 from Patent WO2021058734
CTATAWAWA
>MP977428.1 Sequence 77 from Patent EP3790891
GCGGCCGCT
>MP977404.1 Sequence 53 from Patent EP3790891
AGAGCATGC
>MP977398.1 Sequence 47 from Patent EP3790891
ATGCTCGAG
>MP973915.1 Sequence 637 from Patent WO2021053559
TGGGCCTCT
>MP973870.1 Sequence 533 from Patent WO2021053559
TGGGCCTCT
>MP973980.1 Sequence 755 from Patent WO2021053559
TACACCTCC
>MP973979.1 Sequence 754 from Patent WO2021053559
TACACTAGC
>MP972141.1 Sequence 6 from Patent WO2021053383
CCTAGGGAG
>MP971837.1 Sequence 141 from Patent WO2021055350
GCTGCATCC
>OG162425.1 WO 2020230739-A/13: Method for detecting HLA class I allele-lacking leukocytes
CCCTGAACC
>OG162424.1 WO 2020230739-A/12: Method for detecting HLA class I allele-lacking leukocytes
CCCCGAACC
>pdb|6ZQG|D5 Chain D5, Cryo-EM structure of the 90S pre-ribosome from Saccharomyces cerevisiae, state Dis-C
NTTTTTTTT
>MP733831.1 Sequence 27 from Patent EP3689331
TTAGGGTTA
>MP733830.1 Sequence 26 from Patent EP3689331
GTTAGGGTT
>MP838428.1 Sequence 27 from Patent EP3595676
CCRCCATGG
>MP835256.1 Sequence 33 from Patent EP3740581
GCCGCCACC
>MP728571.1 Sequence 17 from Patent EP3684378
CGTCGGAAG
>MP728568.1 Sequence 14 from Patent EP3684378
GTCGGAAGG
>MP726707.1 Sequence 162 from Patent WO2020128972
TACACCTCC
>MP726706.1 Sequence 161 from Patent WO2020128972
TACACTAGC
>MP726599.1 Sequence 54 from Patent WO2020128972
TGGGCCTCT
>MP726643.1 Sequence 98 from Patent WO2020128972
TGGGCCTCT
>MP726163.1 Sequence 681 from Patent WO2020132483
GCTGCTTCC
>MP726143.1 Sequence 661 from Patent WO2020132483
GCTGCATCC
>MP726123.1 Sequence 641 from Patent WO2020132483
GCTGCATCC
>MP725945.1 Sequence 463 from Patent WO2020132483
GCTGCATCC
>MP725929.1 Sequence 447 from Patent WO2020132483
GCTGCATCC
>MP725913.1 Sequence 431 from Patent WO2020132483
GTTGCATCC
>MP725847.1 Sequence 365 from Patent WO2020132483
GGTGCATCC
>MP725799.1 Sequence 317 from Patent WO2020132483
AAGGCGTCT
>MP725783.1 Sequence 301 from Patent WO2020132483
GCTGCATTC
>MP725767.1 Sequence 285 from Patent WO2020132483
AAGATTTCT
>MP725751.1 Sequence 269 from Patent WO2020132483
GGTGCATCC
>MP725735.1 Sequence 253 from Patent WO2020132483
GCTACATCC
>MP725719.1 Sequence 237 from Patent WO2020132483
GGTGCATCC
>MP725703.1 Sequence 221 from Patent WO2020132483
GGTGCATCC
>MP725687.1 Sequence 205 from Patent WO2020132483
AAGGCGTCT
>MP725671.1 Sequence 189 from Patent WO2020132483
GCTGCATCC
>MP725655.1 Sequence 173 from Patent WO2020132483
GCTGCATCC
>MP725639.1 Sequence 157 from Patent WO2020132483
TATACATCC
>MP725623.1 Sequence 141 from Patent WO2020132483
GCTGCATCC
>MP725607.1 Sequence 125 from Patent WO2020132483
GGTGCATCC
>MP725591.1 Sequence 109 from Patent WO2020132483
GCTGCGTCC
>MP725575.1 Sequence 93 from Patent WO2020132483
GCTGCATCC
>MP725559.1 Sequence 77 from Patent WO2020132483
GCTGCATCC
>MP725543.1 Sequence 61 from Patent WO2020132483
GGTGCATCC
>MP725527.1 Sequence 45 from Patent WO2020132483
GCTGCATCC
>MP725511.1 Sequence 29 from Patent WO2020132483
GCTGCATCC
>MP725495.1 Sequence 13 from Patent WO2020132483
ACTGCATCC
>MP725445.1 Sequence 65 from Patent EP3684172
AGATAACGT
>MP724169.1 Sequence 13 from Patent WO2020132066
GGTGCATCC
>MP724113.1 Sequence 59 from Patent WO2020128015
TACCGACAT
>MP724102.1 Sequence 48 from Patent WO2020128015
GGCCAATCT
>MP724085.1 Sequence 30 from Patent WO2020128015
CTGAGTCAG
>MP724084.1 Sequence 29 from Patent WO2020128015
CCTGAGTCA
>MP724083.1 Sequence 28 from Patent WO2020128015
ATTGACTCA
>MP724082.1 Sequence 27 from Patent WO2020128015
TTTGAGTCA
>MP724081.1 Sequence 26 from Patent WO2020128015
GTGACTCAG
>MP724080.1 Sequence 25 from Patent WO2020128015
ATGACTCAA
>MP724079.1 Sequence 24 from Patent WO2020128015
GTTGACTCA
>MP724078.1 Sequence 23 from Patent WO2020128015
ATTGAGTCA
>MP724077.1 Sequence 22 from Patent WO2020128015
CTGAGTCAA
>MP724076.1 Sequence 21 from Patent WO2020128015
CCTGAGTCA
>MP724075.1 Sequence 20 from Patent WO2020128015
GTTGAGTCA
>MP724074.1 Sequence 19 from Patent WO2020128015
ACTGACTCA
>MP724073.1 Sequence 18 from Patent WO2020128015
ATGACTCAG
>MP724072.1 Sequence 17 from Patent WO2020128015
AATGAGTCA
>MP724071.1 Sequence 16 from Patent WO2020128015
GTGAGTCAG
>MP724037.1 Sequence 18 from Patent WO2020128486
GCCACATCC
>MP932668.1 Sequence 93 from Patent EP3786183
GGCGGCTGC
>MP723818.1 Sequence 18 from Patent WO2020128485
GCCACATCC
>MP723165.1 Sequence 37 from Patent WO2020132024
GCTGCATCC
>MP723141.1 Sequence 13 from Patent WO2020132024
GGTGCATCC
>MP722921.1 Sequence 755 from Patent WO2020128898
TACACCTCC
>MP722920.1 Sequence 754 from Patent WO2020128898
TACACTAGC
>MP722856.1 Sequence 637 from Patent WO2020128898
TGGGCCTCT
>MP722811.1 Sequence 533 from Patent WO2020128898
TGGGCCTCT
>MP722704.1 Sequence 51 from Patent WO2020131632
TCAGTCAGT
>MP829470.1 Sequence 133 from Patent WO2020227642
TAGTAGTAG
>MP829469.1 Sequence 132 from Patent WO2020227642
TAATAATAA
>MP829468.1 Sequence 131 from Patent WO2020227642
TGATGATGA
>MP829467.1 Sequence 130 from Patent WO2020227642
TAATAGTAG
>MP829466.1 Sequence 129 from Patent WO2020227642
TAATGATGA
>MP829465.1 Sequence 128 from Patent WO2020227642
TGATAGTAG
>MP829464.1 Sequence 127 from Patent WO2020227642
TGATAATAA
>MP829463.1 Sequence 126 from Patent WO2020227642
TAATGATAG
>MP829462.1 Sequence 125 from Patent WO2020227642
TGATAGTAA
>MP829461.1 Sequence 124 from Patent WO2020227642
TGATAATAG
>MP829426.1 Sequence 87 from Patent WO2020227642
CCRCCATGG
>MP719550.1 Sequence 63 from Patent WO2020127884
CTTGCATCC
>MP719534.1 Sequence 47 from Patent WO2020127884
CTTGCATCC
>MP719518.1 Sequence 31 from Patent WO2020127884
CTTGCATCC
>MP719502.1 Sequence 15 from Patent WO2020127884
GGGGCTTCC
>MP718390.1 Sequence 8 from Patent WO2020154546
CTACCCATA
>MP718389.1 Sequence 7 from Patent WO2020154546
TATGGGTAG
>MP927431.1 Sequence 165 from Patent WO2021030680
GCTGCATCC
>MP826203.1 Sequence 196 from Patent WO2020227510
CCRCCATGG
>MP825709.1 Sequence 87 from Patent WO2020227615
CCRCCATGG
>MP714736.1 Sequence 358 from Patent WO2020128467
TTGGGTTCT
>MP714676.1 Sequence 298 from Patent WO2020128467
GATGCATCC
>MP714616.1 Sequence 238 from Patent WO2020128467
GATGCATCC
>MP714482.1 Sequence 104 from Patent WO2020128467
GAAGTTTCC
>MP714422.1 Sequence 44 from Patent WO2020128467
TTGGGTTCT
>MP824357.1 Sequence 427 from Patent WO2020219868
GGCTCTGGA
>MP924912.1 Sequence 31 from Patent WO2021028675
GGAAGCGGA
>MP823809.1 Sequence 41 from Patent WO2020227537
CCRCCATGG
>MP713849.1 Sequence 6 from Patent WO2020126595
CATCCGGAA
>MP822437.1 Sequence 6 from Patent EP3735472
GGACCTGGT
>MP818515.1 Sequence 401 from Patent WO2020214784
AGGAGATAA
>MP918922.1 Sequence 13 from Patent EP3781695
TCCCCCCCT
>MP918146.1 Sequence 9 from Patent EP3773506
TTTGTGTAG
>MP918145.1 Sequence 8 from Patent EP3773506
TTCAAGAGA
>MP809361.1 Sequence 136 from Patent WO2020206162
GCTGCATCC
>MP809323.1 Sequence 98 from Patent WO2020206162
GCCGCCAGC
>MP809317.1 Sequence 92 from Patent WO2020206162
GGTGCATCC
>MP809311.1 Sequence 86 from Patent WO2020206162
GGCGCAAGC
>MP806115.1 Sequence 301 from Patent WO2020210551
GCTTCATCC
>MP806099.1 Sequence 285 from Patent WO2020210551
GCTGCATCC
>MP806083.1 Sequence 269 from Patent WO2020210551
AAGGCGTCT
>MP806067.1 Sequence 253 from Patent WO2020210551
GGTGCATCC
>MP806051.1 Sequence 237 from Patent WO2020210551
ACTGCATCC
>MP806035.1 Sequence 221 from Patent WO2020210551
GATGCATCC
>MP806019.1 Sequence 205 from Patent WO2020210551
GCTGCATCC
>MP806003.1 Sequence 189 from Patent WO2020210551
GATGCATCC
>MP805987.1 Sequence 173 from Patent WO2020210551
GCTGCATCC
>MP805971.1 Sequence 157 from Patent WO2020210551
GCTGCTTCC
>MP805955.1 Sequence 141 from Patent WO2020210551
GCTGCATCC
>MP805939.1 Sequence 125 from Patent WO2020210551
GCTGCATCC
>MP805923.1 Sequence 109 from Patent WO2020210551
GCTGCATCC
>MP805907.1 Sequence 93 from Patent WO2020210551
GCTGCATCC
>MP805891.1 Sequence 77 from Patent WO2020210551
AAGGCGTCT
>MP805875.1 Sequence 61 from Patent WO2020210551
GCTGCATCC
>MP805859.1 Sequence 45 from Patent WO2020210551
GATGCATCC
>MP805843.1 Sequence 29 from Patent WO2020210551
TTGGGTTCT
>MP805827.1 Sequence 13 from Patent WO2020210551
GCTGCGTCC
>MP702645.1 Sequence 21 from Patent EP3674327
GATGCATCC
>MP702626.1 Sequence 2 from Patent EP3674327
GCCGCCACC
>MP700086.1 Sequence 21 from Patent EP3674328
GCTGCATCC
>MP700067.1 Sequence 2 from Patent EP3674328
GCCGCCACC
>MP699612.1 Sequence 11 from Patent EP3672636
AAAGTTTCC
>MP802125.1 Sequence 157 from Patent WO2020208017
AAGCCTTCA
>MP802110.1 Sequence 142 from Patent WO2020208017
ATATAAAAG
>MP802085.1 Sequence 117 from Patent WO2020208017
CACCACCAA
>MP696996.1 Sequence 20 from Patent EP3673065
CNCACCNGG
>MP696985.1 Sequence 9 from Patent EP3673065
CACCNGGAG
>MP905619.1 Sequence 62 from Patent WO2021016585
GATGCATCC
>MP905570.1 Sequence 13 from Patent WO2021016585
GCTGCATCC
>MP900893.1 Sequence 140 from Patent EP3775217
CACATACGC
>MP900828.1 Sequence 75 from Patent EP3775217
GGGAAGGGC
>MP900826.1 Sequence 73 from Patent EP3775217
AGACTAGGA
>MP900815.1 Sequence 62 from Patent EP3775217
CCGTGGTGG
>MP900811.1 Sequence 58 from Patent EP3775217
TACTCGGTC
>MP798200.1 Sequence 4 from Patent WO2020202162
TTCCGATCT
>MP898056.1 Sequence 45 from Patent WO2021021661
CATTCTACC
>MP894710.1 Sequence 17 from Patent EP3773649
CTAGGACTG
>MP676319.1 Sequence 6 from Patent EP3662064
AAAGTTAGG
>MP676316.1 Sequence 3 from Patent EP3662064
AAAGTTGGG
>MP676315.1 Sequence 2 from Patent EP3662064
GAAGTTCGG
>MP676314.1 Sequence 1 from Patent EP3662064
AAAGTTCGG
>MP784627.1 Sequence 19 from Patent WO2020198009
GGGGCAAGT
>MP784507.1 Sequence 23 from Patent WO2020191346
GCTGCATCC
>MP781369.1 Sequence 373 from Patent EP3717505
GCGKGGGCG
>MP781067.1 Sequence 34 from Patent EP3717505
AGTGATAGA
>MP672682.1 Sequence 25 from Patent EP3660171
GTAACTCGC
>MP672552.1 Sequence 280 from Patent EP3662932
GGGGACATC
>MP672532.1 Sequence 260 from Patent EP3662932
GGGGACATC
>MP672522.1 Sequence 250 from Patent EP3662932
GGCGACATC
>MP672512.1 Sequence 240 from Patent EP3662932
GGGGACATC
>MP672502.1 Sequence 230 from Patent EP3662932
GGGGACATC
>MP672492.1 Sequence 220 from Patent EP3662932
GGGGACATC
>MP672482.1 Sequence 210 from Patent EP3662932
GGGGACATC
>MP672472.1 Sequence 200 from Patent EP3662932
GGGGACATC
>MP672462.1 Sequence 190 from Patent EP3662932
GGGGACATC
>MP672452.1 Sequence 180 from Patent EP3662932
GGGGACATC
>MP672442.1 Sequence 170 from Patent EP3662932
GGGGACATC
>MP672432.1 Sequence 160 from Patent EP3662932
GGGGACATC
>MP672422.1 Sequence 150 from Patent EP3662932
GGGGACATC
>MP671884.1 Sequence 8 from Patent EP3658682
CTACCCATA
>MP671883.1 Sequence 7 from Patent EP3658682
TATGGGTAG
>MP779157.1 Sequence 22 from Patent EP3719142
CACCGCTGG
>MP670091.1 Sequence 487 from Patent EP3660047
GGTGCATCC
>MP670075.1 Sequence 471 from Patent EP3660047
AAGGCGTCT
>MP670059.1 Sequence 455 from Patent EP3660047
TATGCTTCC
>MP670043.1 Sequence 439 from Patent EP3660047
TGGGCATCT
>MP669985.1 Sequence 381 from Patent EP3660047
TCTGCATCC
>MP669969.1 Sequence 365 from Patent EP3660047
GCTGCATCC
>MP669953.1 Sequence 349 from Patent EP3660047
ACTTCATCC
>MP669937.1 Sequence 333 from Patent EP3660047
GGTGCATCC
>MP669921.1 Sequence 317 from Patent EP3660047
AAGGCGTCT
>MP669905.1 Sequence 301 from Patent EP3660047
TATGCTTCC
>MP669889.1 Sequence 285 from Patent EP3660047
GCTGCATCC
>MP669873.1 Sequence 269 from Patent EP3660047
TATGCTTCC
>MP669857.1 Sequence 253 from Patent EP3660047
TATGCTTCC
>MP669841.1 Sequence 237 from Patent EP3660047
GCTGCATCC
>MP669825.1 Sequence 221 from Patent EP3660047
TATGCTTCC
>MP669809.1 Sequence 205 from Patent EP3660047
TATGCTTCC
>MP669793.1 Sequence 189 from Patent EP3660047
GGTTCTTCC
>MP669777.1 Sequence 173 from Patent EP3660047
GCTGCATCC
>MP669761.1 Sequence 157 from Patent EP3660047
AGGGCGTCT
>MP669745.1 Sequence 141 from Patent EP3660047
GATGCATCC
>MP669729.1 Sequence 125 from Patent EP3660047
AAGACGTCT
>MP669713.1 Sequence 109 from Patent EP3660047
GATGCATCC
>MP669697.1 Sequence 93 from Patent EP3660047
AAGGCGTCT
>MP669681.1 Sequence 77 from Patent EP3660047
TGGACATCT
>MP669665.1 Sequence 61 from Patent EP3660047
GCTGCATCC
>MP669649.1 Sequence 45 from Patent EP3660047
TGGGCATCT
>MP669633.1 Sequence 29 from Patent EP3660047
GCTGCATCC
>MP669617.1 Sequence 13 from Patent EP3660047
GCTGCATCC
>MP669370.1 Sequence 182 from Patent EP3660050
TACACTAGC
>MP669359.1 Sequence 171 from Patent EP3660050
TACACCTCC
>MP669348.1 Sequence 160 from Patent EP3660050
TATACATCC
>MP669337.1 Sequence 149 from Patent EP3660050
TACACATCA
>MP666790.1 Sequence 2 from Patent EP3660166
TCCTTCTTT
>MP770065.1 Sequence 70 from Patent WO2020183131
TAACAATTA
>MP770064.1 Sequence 69 from Patent WO2020183131
TAGCAATTA
>MP770063.1 Sequence 68 from Patent WO2020183131
TGACAATTA
>MP770059.1 Sequence 64 from Patent WO2020183131
TTTTTTTAA
>MP770058.1 Sequence 63 from Patent WO2020183131
TTTTTTTAG
>MP770057.1 Sequence 62 from Patent WO2020183131
TTTTTTTGA
>MP665794.1 Sequence 20 from Patent WO2020099533
TTCTCTTCC
>MP665793.1 Sequence 19 from Patent WO2020099533
GGAAGAGAA
>MP665792.1 Sequence 18 from Patent WO2020099533
CACACCAAC
>MP665791.1 Sequence 17 from Patent WO2020099533
GTTGGTGTG
>MP665784.1 Sequence 10 from Patent WO2020099533
ACAGGAGCA
>MP665783.1 Sequence 9 from Patent WO2020099533
TGCTCCTGT
>MP766076.1 Sequence 11 from Patent EP3712169
AAGGTTTCT
>MP767856.1 Sequence 141 from Patent WO2020172475
GCTGCATCC
>MP964069.1 Sequence 520 from Patent EP3735460
TAATAGTGA
>MP964068.1 Sequence 519 from Patent EP3735460
GCCGCCACC
>MP664188.1 Sequence 13 from Patent WO2020106780
GGTGCATCC
>MP664171.1 Sequence 46 from Patent WO2020102565
ACGAGAGAH
>MP761728.1 Sequence 6 from Patent EP3710594
TTCCGATAT
>MP761727.1 Sequence 5 from Patent EP3710594
AATCGATCT
>MP761726.1 Sequence 4 from Patent EP3710594
GATCGTAGC
>MP879712.1 Sequence 191 from Patent WO2020243031
AAGGCGTCT
>MP879678.1 Sequence 157 from Patent WO2020243031
GTTGCAGCC
>MP879662.1 Sequence 141 from Patent WO2020243031
AAGGTTTCT
>MP879646.1 Sequence 125 from Patent WO2020243031
ACTGCATCC
>MP879630.1 Sequence 109 from Patent WO2020243031
CCTGCATCC
>MP879614.1 Sequence 93 from Patent WO2020243031
ACTACTTCC
>MP879598.1 Sequence 77 from Patent WO2020243031
AAGGCGTCT
>MP879582.1 Sequence 61 from Patent WO2020243031
AAGGCGTCT
>MP879566.1 Sequence 45 from Patent WO2020243031
GCTGCATCC
>MP879550.1 Sequence 29 from Patent WO2020243031
AAGGCGTCT
>MP879534.1 Sequence 13 from Patent WO2020243031
GCTGCATCC
>MP879446.1 Sequence 10 from Patent WO2020239801
TCGGCATCC
>MP662645.1 Sequence 95 from Patent WO2020104782
AGCAAACAG
>MP662639.1 Sequence 89 from Patent WO2020104782
CTGTTTGCT
>MP661343.1 Sequence 56 from Patent WO2020104783
CTGTTTGCT
>MP875955.1 Sequence 61 from Patent WO2020252029
GCTGCATCC
>MP875939.1 Sequence 45 from Patent WO2020252029
ACTGCATCC
>MP875923.1 Sequence 29 from Patent WO2020252029
GCTGCATCC
>MP875907.1 Sequence 13 from Patent WO2020252029
AAGTCGTCT
>MP658513.1 Sequence 17 from Patent EP3656397
TACACATCA
>MP756792.1 Sequence 230 from Patent EP3704239
TTTTTTTTT
>MP656973.1 Sequence 196 from Patent WO2020089815
TACACCTCC
>MP656972.1 Sequence 195 from Patent WO2020089815
TACACTAGC
>MP656909.1 Sequence 132 from Patent WO2020089815
TGGGCCTCT
>MP656865.1 Sequence 88 from Patent WO2020089815
TGGGCCTCT
>MP870716.1 Sequence 13 from Patent WO2020167919
GCTGCATCC
>MP868571.1 Sequence 533 from Patent WO2020165733
TGGGCCTCT
>MP867287.1 Sequence 162 from Patent WO2020165833
TACACCTCC
>MP867286.1 Sequence 161 from Patent WO2020165833
TACACTAGC
>MP867223.1 Sequence 98 from Patent WO2020165833
TGGGCCTCT
>MP867179.1 Sequence 54 from Patent WO2020165833
TGGGCCTCT
>MP754955.1 Sequence 25 from Patent EP3704254
TTTTTTTTT
>MP754691.1 Sequence 78 from Patent EP3708584
TTCGACTAC
>MP752963.1 Sequence 5 from Patent EP3699284
CACCCCTAC
>MP752962.1 Sequence 4 from Patent EP3699284
CTACAGATG
>MP752961.1 Sequence 3 from Patent EP3699284
TGAATGGAC
>MP752960.1 Sequence 2 from Patent EP3699284
CTGCTGTTG
>MP752959.1 Sequence 1 from Patent EP3699284
ACTTACCTG
>MP751087.1 Sequence 91 from Patent EP3697447
CCNCCATGG
>MP750797.1 Sequence 115 from Patent EP3697438
GGAAGCGGA
>MP750678.1 Sequence 17 from Patent EP3682903
CAGTTAGGG
>MP750677.1 Sequence 16 from Patent EP3682903
GGGTTAGAC
>MP863416.1 Sequence 162 from Patent WO2020165834
TACACCTCC
>MP863415.1 Sequence 161 from Patent WO2020165834
TACACTAGC
>MP863352.1 Sequence 98 from Patent WO2020165834
TGGGCCTCT
>MP863308.1 Sequence 54 from Patent WO2020165834
TGGGCCTCT
>MP862043.1 Sequence 38 from Patent WO2020245377
GGAAGAGAA
>MP862042.1 Sequence 37 from Patent WO2020245377
TTCTCTTCC
>MP862035.1 Sequence 30 from Patent WO2020245377
CACACCAAC
>MP862033.1 Sequence 28 from Patent WO2020245377
AAAAAAAAA
>MP862029.1 Sequence 24 from Patent WO2020245377
TTTTTTTTT
>MP862027.1 Sequence 22 from Patent WO2020245377
GTTGGTGTG
>MP862015.1 Sequence 10 from Patent WO2020245377
ACAGGAGCA
>MP862014.1 Sequence 9 from Patent WO2020245377
TGCTCCTGT
>MP648164.1 Sequence 5 from Patent EP3652212
GGAGGATAT
>MP858470.1 Sequence 160 from Patent EP3752614
TTATCTTTT
>MP744240.1 Sequence 30 from Patent WO2020146541
GGTGCATCC
>MP950780.1 Sequence 18 from Patent WO2021044135
GCCACATCC
>MP850097.1 Sequence 10 from Patent EP3744400
TCGGCATCC
>MP948396.1 Sequence 367 from Patent EP3755801
TAGTCTGGA
>MP948387.1 Sequence 358 from Patent EP3755801
AAAAGACTG
>MP948363.1 Sequence 334 from Patent EP3755801
CTGTCTCTT
>MP948270.1 Sequence 241 from Patent EP3755801
CGTCGTTTC
>MP948240.1 Sequence 211 from Patent EP3755801
TGTGAGATA
>MP948216.1 Sequence 187 from Patent EP3755801
TGAGCAAAA
>MP948194.1 Sequence 165 from Patent EP3755801
GACGTTTCT
>MP948184.1 Sequence 155 from Patent EP3755801
ACCTTAAAA
>MP948097.1 Sequence 68 from Patent EP3755801
GACGTTTCT
>MP948071.1 Sequence 42 from Patent EP3755801
AGATGGCTC
>MP948060.1 Sequence 31 from Patent EP3755801
CCGGGGTCA
>MP739690.1 Sequence 20 from Patent WO2020150375
AGGAGCCTG
>MP739517.1 Sequence 33 from Patent WO2020139796
CCTGACCCA
>MP739516.1 Sequence 32 from Patent WO2020139796
TTGTCCGAC
>MP945615.1 Sequence 349 from Patent WO2021034639
GATGCATCC
>MP945599.1 Sequence 333 from Patent WO2021034639
GGTGCATCC
>MP945583.1 Sequence 317 from Patent WO2021034639
GATGCATCC
>MP945567.1 Sequence 301 from Patent WO2021034639
GCTGCATCC
>MP945527.1 Sequence 261 from Patent WO2021034639
GCTGCATCC
>MP945511.1 Sequence 245 from Patent WO2021034639
GATGCATCC
>MP945495.1 Sequence 229 from Patent WO2021034639
GCTGCATCC
>MP945479.1 Sequence 213 from Patent WO2021034639
AAGGCGTCT
>MP945463.1 Sequence 197 from Patent WO2021034639
GATGCATCC
>MP945447.1 Sequence 181 from Patent WO2021034639
ACTGCATCC
>MP945431.1 Sequence 165 from Patent WO2021034639
ACTGCATCC
>MP945399.1 Sequence 133 from Patent WO2021034639
GCTGCATCC
>MP945383.1 Sequence 117 from Patent WO2021034639
GCTGCATCC
>MP945375.1 Sequence 109 from Patent WO2021034639
GCTGCATCC
>MP945359.1 Sequence 93 from Patent WO2021034639
GATGCATCG
>MP945343.1 Sequence 77 from Patent WO2021034639
GCTGCATCC
>MP945327.1 Sequence 61 from Patent WO2021034639
GCTGCATCC
>MP945311.1 Sequence 45 from Patent WO2021034639
AAGGCGTCT
>MP945295.1 Sequence 29 from Patent WO2021034639
GATGCATCC
>MP945279.1 Sequence 13 from Patent WO2021034639
AAGGCGTCT
>MP736411.1 Sequence 21 from Patent WO2020139800
CCTGACCCA
>MP736410.1 Sequence 20 from Patent WO2020139800
TTGTCCGAC
>MP943661.1 Sequence 42 from Patent EP3755802
TCTCTTGAA
>MP943659.1 Sequence 40 from Patent EP3755802
TTCAAGAGA
>MP733839.1 Sequence 35 from Patent EP3689331
GGGTTAGGG
>MP841577.1 Sequence 85 from Patent EP3746090
CCRCCATGG
>MP733838.1 Sequence 34 from Patent EP3689331
GAGTATGAG
>pdb|4V90|AX Chain AX, Thermus thermophilus Ribosome
AAATGTTCA
>pdb|4V8O|AX Chain AX, Crystal structure of the hybrid state of ribosome in complex with the guanosine triphosphatase release factor 3
AAAAAATGT
>pdb|4V7P|DX Chain DX, Recognition of the amber stop codon by release factor RF1.
AATGTAGAA
>OG148623.1 JP 2019510511-A/67: NOVEL pRNA THREE-WAY JUNCTIONS
TGTCACGGG
>OG147487.1 JP 2019509322-A/19: ADMINISTRATION OF AN ANTI-LGR5 MONOCLONAL ANTIBODY
CTGACCAGC
>OG147481.1 JP 2019509322-A/13: ADMINISTRATION OF AN ANTI-LGR5 MONOCLONAL ANTIBODY
CTGACCTCC
>OG144024.1 JP 2019509283-A/23: CONNEXIN (Cx)43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
CTGGTGTCT
>OG144021.1 JP 2019509283-A/20: CONNEXIN (Cx)43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
CTTGTATCC
>OG144018.1 JP 2019509283-A/17: CONNEXIN (Cx)43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
CTTGTATCC
>OG144015.1 JP 2019509283-A/14: CONNEXIN (Cx)43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
GGGGCATCC
>OG143934.1 JP 2019509729-A/39: METHODS FOR EXPANDING AND DIFFERENTIATING B CELLS FOR PRODUCING ANTIBODY
GCTCYTGGA
>OG143194.1 JP 2019504641-A/14: MONOCLONAL ANTIBODY FNAB8 AND APPLICATION THEREOF
GATGCGTCC
>OG143186.1 JP 2019504641-A/6: MONOCLONAL ANTIBODY FNAB8 AND APPLICATION THEREOF
AGTAATAAT
>OG155799.1 WO 2020158687-A/2: Production method for photo-responsive nucleotide analog
ACGGGTGCA
>OG155798.1 WO 2020158687-A/1: Production method for photo-responsive nucleotide analog
TGCANCCGT
>OF010119.1 KR 1020200069388-A/205: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GTTGCATCC
>OF010107.1 KR 1020200069388-A/181: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF010095.1 KR 1020200069388-A/157: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>OF010083.1 KR 1020200069388-A/133: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
AGTGCCTCC
>OF010071.1 KR 1020200069388-A/109: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF010059.1 KR 1020200069388-A/85: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>OF010047.1 KR 1020200069388-A/61: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGTATCC
>OF010035.1 KR 1020200069388-A/37: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF010023.1 KR 1020200069388-A/13: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF010283.1 KR 1020200074248-A/2: METHODS FOR TAGGING DNA-ENCODED LIBRARIES
GCAGCACCC
>OF010143.1 KR 1020200069388-A/253: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>OF010131.1 KR 1020200069388-A/229: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>OF007745.1 KR 1020200068738-A/22: METHOD FOR AMPLIFYING TARGET NUCLEIC ACID AND COMPOSITION FOR AMPLIFYING TARGET NUCLEIC ACID
CACCGCTGG
>OF006302.1 KR 1020200057790-A/142: 5-BROMO-2,6-DI-(LH-PYRAZOL-L-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER
TGGGCCTCT
>OF006291.1 KR 1020200057790-A/131: 5-BROMO-2,6-DI-(LH-PYRAZOL-L-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER
TGGGCCTCC
>OF006277.1 KR 1020200057790-A/117: 5-BROMO-2,6-DI-(LH-PYRAZOL-L-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER
TGGGCATCC
>OF006211.1 KR 1020200067190-A/102: COMPOSITIONS AND METHODS FOR GENE EDITING FOR HEMOPHILIA A
NNNNNGTTT
>OF003300.1 KR 1020200058525-A/165: BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND A STAPHYLOCOCCUS TARGET ANTIGEN AND A COMPLEMENT COMPONENT AND USES THEREOF
GGTGCATCC
>OF003292.1 KR 1020200058525-A/149: BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND A STAPHYLOCOCCUS TARGET ANTIGEN AND A COMPLEMENT COMPONENT AND USES THEREOF
GCTGCATCC
>OF003260.1 KR 1020200058525-A/85: BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND A STAPHYLOCOCCUS TARGET ANTIGEN AND A COMPLEMENT COMPONENT AND USES THEREOF
TCTGCATCC
>OF003256.1 KR 1020200058525-A/77: BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND A STAPHYLOCOCCUS TARGET ANTIGEN AND A COMPLEMENT COMPONENT AND USES THEREOF
GGTGCATCC
>OF003252.1 KR 1020200058525-A/69: BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND A STAPHYLOCOCCUS TARGET ANTIGEN AND A COMPLEMENT COMPONENT AND USES THEREOF
GGTACATCC
>pdb|5KCR|1v Chain 1v, Cryo-EM structure of the Escherichia coli 70S ribosome in complex with antibiotic Avilamycin C, mRNA and P-site tRNA at 3.6A resolution
CGTCTTAGA
>pdb|7A5I|i4 Chain i4, Structure of the human mitoribosome with A- P-and E-site mt-tRNAs
NAAAGTAGT
>pdb|7D0X|A Chain A, NMR solution structures of the DNA minidumbbell formed by 5'-mCTTGXmCTTG-3'
NTTGNNTTG
>MD485744.1 JP 2019054813-A/45971: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGAGATAG
>MD439643.1 JP 2019062898-A/34: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACAGCCTG
>MD439642.1 JP 2019062898-A/33: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CAGGCTGTC
>MD439639.1 JP 2019062898-A/30: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACACCGCA
>MD439638.1 JP 2019062898-A/29: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TGCGGTGTC
>MD439633.1 JP 2019062898-A/24: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CCTCCTCAG
>MD439632.1 JP 2019062898-A/23: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CTGAGGAGG
>MD439625.1 JP 2019062898-A/16: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GTCCCATTA
>MD439624.1 JP 2019062898-A/15: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TAATGGGAC
>MD439617.1 JP 2019062898-A/8: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACAGTTCC
>MD439616.1 JP 2019062898-A/7: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GGAACTGTC
>MD439615.1 JP 2019062898-A/6: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACGTTCTG
>MD439614.1 JP 2019062898-A/5: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CAGAACGTC
>MD439320.1 JP 2019055996-A/3163: Human Antibodies to Influenza Hemagglutinin
ACGGCGTCT
>MD439312.1 JP 2019055996-A/3155: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD439304.1 JP 2019055996-A/3147: Human Antibodies to Influenza Hemagglutinin
GGTGTATCC
>MD439296.1 JP 2019055996-A/3139: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD439288.1 JP 2019055996-A/3131: Human Antibodies to Influenza Hemagglutinin
TTTGCATCC
>MD439280.1 JP 2019055996-A/3123: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD439272.1 JP 2019055996-A/3115: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD439264.1 JP 2019055996-A/3107: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD439256.1 JP 2019055996-A/3099: Human Antibodies to Influenza Hemagglutinin
ATTGCTTCC
>MD439248.1 JP 2019055996-A/3091: Human Antibodies to Influenza Hemagglutinin
GTTGCTTCC
>MD439240.1 JP 2019055996-A/3083: Human Antibodies to Influenza Hemagglutinin
GCTGCATCG
>MD439232.1 JP 2019055996-A/3075: Human Antibodies to Influenza Hemagglutinin
TTTGCCTCC
>MD439224.1 JP 2019055996-A/3067: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD439216.1 JP 2019055996-A/3059: Human Antibodies to Influenza Hemagglutinin
TTTGCATCC
>MD439208.1 JP 2019055996-A/3051: Human Antibodies to Influenza Hemagglutinin
ATTGCTTCC
>MD439200.1 JP 2019055996-A/3043: Human Antibodies to Influenza Hemagglutinin
GCTATATCC
>MD439192.1 JP 2019055996-A/3035: Human Antibodies to Influenza Hemagglutinin
GGTGTTTCC
>MD439184.1 JP 2019055996-A/3027: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD439176.1 JP 2019055996-A/3019: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD439168.1 JP 2019055996-A/3011: Human Antibodies to Influenza Hemagglutinin
GATACATCC
>MD439160.1 JP 2019055996-A/3003: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD439152.1 JP 2019055996-A/2995: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD439144.1 JP 2019055996-A/2987: Human Antibodies to Influenza Hemagglutinin
TTGGGTTTT
>MD439136.1 JP 2019055996-A/2979: Human Antibodies to Influenza Hemagglutinin
GGTATATTT
>MD439128.1 JP 2019055996-A/2971: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD439120.1 JP 2019055996-A/2963: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD439112.1 JP 2019055996-A/2955: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD439104.1 JP 2019055996-A/2947: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD439096.1 JP 2019055996-A/2939: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD439088.1 JP 2019055996-A/2931: Human Antibodies to Influenza Hemagglutinin
GGTACGTCC
>MD439080.1 JP 2019055996-A/2923: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD439072.1 JP 2019055996-A/2915: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD439064.1 JP 2019055996-A/2907: Human Antibodies to Influenza Hemagglutinin
GACACATCC
>MD439056.1 JP 2019055996-A/2899: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD439048.1 JP 2019055996-A/2891: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD439040.1 JP 2019055996-A/2883: Human Antibodies to Influenza Hemagglutinin
GATACATCC
>MD439032.1 JP 2019055996-A/2875: Human Antibodies to Influenza Hemagglutinin
GATACATCC
>MD439024.1 JP 2019055996-A/2867: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD439016.1 JP 2019055996-A/2859: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD439008.1 JP 2019055996-A/2851: Human Antibodies to Influenza Hemagglutinin
AATGCATCC
>MD439000.1 JP 2019055996-A/2843: Human Antibodies to Influenza Hemagglutinin
GGTACATCC
>MD438992.1 JP 2019055996-A/2835: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438984.1 JP 2019055996-A/2827: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438976.1 JP 2019055996-A/2819: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438968.1 JP 2019055996-A/2811: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438960.1 JP 2019055996-A/2803: Human Antibodies to Influenza Hemagglutinin
GGAACATCC
>MD438952.1 JP 2019055996-A/2795: Human Antibodies to Influenza Hemagglutinin
GGTACATCC
>MD438944.1 JP 2019055996-A/2787: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438936.1 JP 2019055996-A/2779: Human Antibodies to Influenza Hemagglutinin
GGTACATCC
>MD438928.1 JP 2019055996-A/2771: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438920.1 JP 2019055996-A/2763: Human Antibodies to Influenza Hemagglutinin
GATTCATCC
>MD438912.1 JP 2019055996-A/2755: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438904.1 JP 2019055996-A/2747: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438896.1 JP 2019055996-A/2739: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438888.1 JP 2019055996-A/2731: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438880.1 JP 2019055996-A/2723: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438872.1 JP 2019055996-A/2715: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438864.1 JP 2019055996-A/2707: Human Antibodies to Influenza Hemagglutinin
GGTGTATCC
>MD438856.1 JP 2019055996-A/2699: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438848.1 JP 2019055996-A/2691: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438840.1 JP 2019055996-A/2683: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438832.1 JP 2019055996-A/2675: Human Antibodies to Influenza Hemagglutinin
ACTGCATCA
>MD438824.1 JP 2019055996-A/2667: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD438816.1 JP 2019055996-A/2659: Human Antibodies to Influenza Hemagglutinin
AAGGTTTCT
>MD438808.1 JP 2019055996-A/2651: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD438800.1 JP 2019055996-A/2643: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD438792.1 JP 2019055996-A/2635: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD438784.1 JP 2019055996-A/2627: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438776.1 JP 2019055996-A/2619: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438768.1 JP 2019055996-A/2611: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD438760.1 JP 2019055996-A/2603: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438752.1 JP 2019055996-A/2595: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD438744.1 JP 2019055996-A/2587: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD438736.1 JP 2019055996-A/2579: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438728.1 JP 2019055996-A/2571: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438720.1 JP 2019055996-A/2563: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438712.1 JP 2019055996-A/2555: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438704.1 JP 2019055996-A/2547: Human Antibodies to Influenza Hemagglutinin
GAGGCGTCT
>MD438696.1 JP 2019055996-A/2539: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD438688.1 JP 2019055996-A/2531: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438680.1 JP 2019055996-A/2523: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438672.1 JP 2019055996-A/2515: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD438664.1 JP 2019055996-A/2507: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438656.1 JP 2019055996-A/2499: Human Antibodies to Influenza Hemagglutinin
GAGGCGTCT
>MD438648.1 JP 2019055996-A/2491: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438640.1 JP 2019055996-A/2483: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD521142.1 JP 2019054813-A/81369: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCGTTAG
>MD438632.1 JP 2019055996-A/2475: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438624.1 JP 2019055996-A/2467: Human Antibodies to Influenza Hemagglutinin
ACTGCCTCC
>MD438616.1 JP 2019055996-A/2459: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438608.1 JP 2019055996-A/2451: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD438600.1 JP 2019055996-A/2443: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD438592.1 JP 2019055996-A/2435: Human Antibodies to Influenza Hemagglutinin
TGGTCATCT
>MD438584.1 JP 2019055996-A/2427: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438576.1 JP 2019055996-A/2419: Human Antibodies to Influenza Hemagglutinin
GAGGCGTCT
>MD438568.1 JP 2019055996-A/2411: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438560.1 JP 2019055996-A/2403: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438552.1 JP 2019055996-A/2395: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD438544.1 JP 2019055996-A/2387: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438536.1 JP 2019055996-A/2379: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438528.1 JP 2019055996-A/2371: Human Antibodies to Influenza Hemagglutinin
AAGGTTTCT
>MD438520.1 JP 2019055996-A/2363: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438512.1 JP 2019055996-A/2355: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438504.1 JP 2019055996-A/2347: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438496.1 JP 2019055996-A/2339: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438488.1 JP 2019055996-A/2331: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438480.1 JP 2019055996-A/2323: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438472.1 JP 2019055996-A/2315: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD438464.1 JP 2019055996-A/2307: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438456.1 JP 2019055996-A/2299: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438448.1 JP 2019055996-A/2291: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438440.1 JP 2019055996-A/2283: Human Antibodies to Influenza Hemagglutinin
GCTTCATCC
>MD438432.1 JP 2019055996-A/2275: Human Antibodies to Influenza Hemagglutinin
GCTTCATCC
>MD438424.1 JP 2019055996-A/2267: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438416.1 JP 2019055996-A/2259: Human Antibodies to Influenza Hemagglutinin
AAGGTTTCT
>MD438408.1 JP 2019055996-A/2251: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD438400.1 JP 2019055996-A/2243: Human Antibodies to Influenza Hemagglutinin
AAGGTTTCT
>MD438392.1 JP 2019055996-A/2235: Human Antibodies to Influenza Hemagglutinin
GTAGCATCC
>MD438384.1 JP 2019055996-A/2227: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438376.1 JP 2019055996-A/2219: Human Antibodies to Influenza Hemagglutinin
GCTGCCTCC
>MD438368.1 JP 2019055996-A/2211: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438360.1 JP 2019055996-A/2203: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438352.1 JP 2019055996-A/2195: Human Antibodies to Influenza Hemagglutinin
TTGAATTCT
>MD438344.1 JP 2019055996-A/2187: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438336.1 JP 2019055996-A/2179: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD438328.1 JP 2019055996-A/2171: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438320.1 JP 2019055996-A/2163: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438312.1 JP 2019055996-A/2155: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438304.1 JP 2019055996-A/2147: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438296.1 JP 2019055996-A/2139: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438288.1 JP 2019055996-A/2131: Human Antibodies to Influenza Hemagglutinin
TTGAATTCT
>MD438280.1 JP 2019055996-A/2123: Human Antibodies to Influenza Hemagglutinin
TCTGCATCC
>MD438272.1 JP 2019055996-A/2115: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438264.1 JP 2019055996-A/2107: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD438256.1 JP 2019055996-A/2099: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD438248.1 JP 2019055996-A/2091: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD438240.1 JP 2019055996-A/2083: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438232.1 JP 2019055996-A/2075: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438224.1 JP 2019055996-A/2067: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD438216.1 JP 2019055996-A/2059: Human Antibodies to Influenza Hemagglutinin
TCTGCATCC
>MD438208.1 JP 2019055996-A/2051: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438200.1 JP 2019055996-A/2043: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438192.1 JP 2019055996-A/2035: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438184.1 JP 2019055996-A/2027: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438176.1 JP 2019055996-A/2019: Human Antibodies to Influenza Hemagglutinin
GGTACATCC
>MD438168.1 JP 2019055996-A/2011: Human Antibodies to Influenza Hemagglutinin
AGTACATCC
>MD438160.1 JP 2019055996-A/2003: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD438152.1 JP 2019055996-A/1995: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438144.1 JP 2019055996-A/1987: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438136.1 JP 2019055996-A/1979: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438128.1 JP 2019055996-A/1971: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438120.1 JP 2019055996-A/1963: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438112.1 JP 2019055996-A/1955: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438104.1 JP 2019055996-A/1947: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438096.1 JP 2019055996-A/1939: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD438088.1 JP 2019055996-A/1931: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD438080.1 JP 2019055996-A/1923: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD438072.1 JP 2019055996-A/1915: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD438064.1 JP 2019055996-A/1907: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD438056.1 JP 2019055996-A/1899: Human Antibodies to Influenza Hemagglutinin
GATGTATCC
>MD438048.1 JP 2019055996-A/1891: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438040.1 JP 2019055996-A/1883: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD438032.1 JP 2019055996-A/1875: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD438024.1 JP 2019055996-A/1867: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD438016.1 JP 2019055996-A/1859: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD438008.1 JP 2019055996-A/1851: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD438000.1 JP 2019055996-A/1843: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437992.1 JP 2019055996-A/1835: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437984.1 JP 2019055996-A/1827: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437976.1 JP 2019055996-A/1819: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437968.1 JP 2019055996-A/1811: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437960.1 JP 2019055996-A/1803: Human Antibodies to Influenza Hemagglutinin
AAGGTTTCT
>MD437952.1 JP 2019055996-A/1795: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437944.1 JP 2019055996-A/1787: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437936.1 JP 2019055996-A/1779: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437928.1 JP 2019055996-A/1771: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437920.1 JP 2019055996-A/1763: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437912.1 JP 2019055996-A/1755: Human Antibodies to Influenza Hemagglutinin
TCTGGATCC
>MD437904.1 JP 2019055996-A/1747: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437896.1 JP 2019055996-A/1739: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437888.1 JP 2019055996-A/1731: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437880.1 JP 2019055996-A/1723: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437872.1 JP 2019055996-A/1715: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437864.1 JP 2019055996-A/1707: Human Antibodies to Influenza Hemagglutinin
GGTGAATCC
>MD437856.1 JP 2019055996-A/1699: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD437848.1 JP 2019055996-A/1691: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437840.1 JP 2019055996-A/1683: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD559339.1 JP 2019054813-A/119566: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>MD437832.1 JP 2019055996-A/1675: Human Antibodies to Influenza Hemagglutinin
GGTGGATCC
>MD437824.1 JP 2019055996-A/1667: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437816.1 JP 2019055996-A/1659: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD437808.1 JP 2019055996-A/1651: Human Antibodies to Influenza Hemagglutinin
GGTGCTTCC
>MD437800.1 JP 2019055996-A/1643: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437792.1 JP 2019055996-A/1635: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437784.1 JP 2019055996-A/1627: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437776.1 JP 2019055996-A/1619: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437768.1 JP 2019055996-A/1611: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437760.1 JP 2019055996-A/1603: Human Antibodies to Influenza Hemagglutinin
GGTGCTTCC
>MD437752.1 JP 2019055996-A/1595: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437744.1 JP 2019055996-A/1587: Human Antibodies to Influenza Hemagglutinin
TCTGGATCC
>MD437736.1 JP 2019055996-A/1579: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437728.1 JP 2019055996-A/1571: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437720.1 JP 2019055996-A/1563: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437712.1 JP 2019055996-A/1555: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437704.1 JP 2019055996-A/1547: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437696.1 JP 2019055996-A/1539: Human Antibodies to Influenza Hemagglutinin
ACTGCATCT
>MD437688.1 JP 2019055996-A/1531: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437680.1 JP 2019055996-A/1523: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437672.1 JP 2019055996-A/1515: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437664.1 JP 2019055996-A/1507: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437656.1 JP 2019055996-A/1499: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437648.1 JP 2019055996-A/1491: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437640.1 JP 2019055996-A/1483: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437632.1 JP 2019055996-A/1475: Human Antibodies to Influenza Hemagglutinin
GCTGCTTCC
>MD437624.1 JP 2019055996-A/1467: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437616.1 JP 2019055996-A/1459: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437608.1 JP 2019055996-A/1451: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437600.1 JP 2019055996-A/1443: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD437592.1 JP 2019055996-A/1435: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD437584.1 JP 2019055996-A/1427: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD437576.1 JP 2019055996-A/1419: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437568.1 JP 2019055996-A/1411: Human Antibodies to Influenza Hemagglutinin
GGTGCGTCC
>MD437560.1 JP 2019055996-A/1403: Human Antibodies to Influenza Hemagglutinin
GGTGCGTCC
>MD437552.1 JP 2019055996-A/1395: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD437544.1 JP 2019055996-A/1387: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD437536.1 JP 2019055996-A/1379: Human Antibodies to Influenza Hemagglutinin
GGTGCGTCC
>MD437528.1 JP 2019055996-A/1371: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD437520.1 JP 2019055996-A/1363: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD437512.1 JP 2019055996-A/1355: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437504.1 JP 2019055996-A/1347: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD437496.1 JP 2019055996-A/1339: Human Antibodies to Influenza Hemagglutinin
GCTGCCTCC
>MD437488.1 JP 2019055996-A/1331: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437480.1 JP 2019055996-A/1323: Human Antibodies to Influenza Hemagglutinin
GGTGCGTCC
>MD437472.1 JP 2019055996-A/1315: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD437464.1 JP 2019055996-A/1307: Human Antibodies to Influenza Hemagglutinin
GGTGCGTCC
>MD437456.1 JP 2019055996-A/1299: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437448.1 JP 2019055996-A/1291: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD437440.1 JP 2019055996-A/1283: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD437432.1 JP 2019055996-A/1275: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD437424.1 JP 2019055996-A/1267: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437416.1 JP 2019055996-A/1259: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437408.1 JP 2019055996-A/1251: Human Antibodies to Influenza Hemagglutinin
GATTCATCC
>MD437400.1 JP 2019055996-A/1243: Human Antibodies to Influenza Hemagglutinin
GATTCATCC
>MD437392.1 JP 2019055996-A/1235: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437384.1 JP 2019055996-A/1227: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437376.1 JP 2019055996-A/1219: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437368.1 JP 2019055996-A/1211: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD437360.1 JP 2019055996-A/1203: Human Antibodies to Influenza Hemagglutinin
GGTGCGTCC
>MD437352.1 JP 2019055996-A/1195: Human Antibodies to Influenza Hemagglutinin
GGTACATTC
>MD437344.1 JP 2019055996-A/1187: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437336.1 JP 2019055996-A/1179: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD437328.1 JP 2019055996-A/1171: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD437320.1 JP 2019055996-A/1163: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD437312.1 JP 2019055996-A/1155: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437304.1 JP 2019055996-A/1147: Human Antibodies to Influenza Hemagglutinin
GATTCATCC
>MD437296.1 JP 2019055996-A/1139: Human Antibodies to Influenza Hemagglutinin
GATTCATCC
>MD437288.1 JP 2019055996-A/1131: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD437280.1 JP 2019055996-A/1123: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437272.1 JP 2019055996-A/1115: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437264.1 JP 2019055996-A/1107: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437256.1 JP 2019055996-A/1099: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD437248.1 JP 2019055996-A/1091: Human Antibodies to Influenza Hemagglutinin
GCTGTATCC
>MD437240.1 JP 2019055996-A/1083: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437232.1 JP 2019055996-A/1075: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD437224.1 JP 2019055996-A/1067: Human Antibodies to Influenza Hemagglutinin
GGTCCATCC
>MD437216.1 JP 2019055996-A/1059: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437208.1 JP 2019055996-A/1051: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437200.1 JP 2019055996-A/1043: Human Antibodies to Influenza Hemagglutinin
GAAACATCC
>MD437192.1 JP 2019055996-A/1035: Human Antibodies to Influenza Hemagglutinin
GAAACATTT
>MD437184.1 JP 2019055996-A/1027: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD437176.1 JP 2019055996-A/1019: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437168.1 JP 2019055996-A/1011: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437160.1 JP 2019055996-A/1003: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437152.1 JP 2019055996-A/995: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437144.1 JP 2019055996-A/987: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437136.1 JP 2019055996-A/979: Human Antibodies to Influenza Hemagglutinin
TATGCTTCC
>MD437128.1 JP 2019055996-A/971: Human Antibodies to Influenza Hemagglutinin
GATGCGTCC
>MD437120.1 JP 2019055996-A/963: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437112.1 JP 2019055996-A/955: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437104.1 JP 2019055996-A/947: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437096.1 JP 2019055996-A/939: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437088.1 JP 2019055996-A/931: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437080.1 JP 2019055996-A/923: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437072.1 JP 2019055996-A/915: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437064.1 JP 2019055996-A/907: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437056.1 JP 2019055996-A/899: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437048.1 JP 2019055996-A/891: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD437040.1 JP 2019055996-A/883: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437032.1 JP 2019055996-A/875: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437024.1 JP 2019055996-A/867: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD437016.1 JP 2019055996-A/859: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437008.1 JP 2019055996-A/851: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD437000.1 JP 2019055996-A/843: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD436992.1 JP 2019055996-A/835: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436984.1 JP 2019055996-A/827: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436976.1 JP 2019055996-A/819: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436968.1 JP 2019055996-A/811: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD436960.1 JP 2019055996-A/803: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436952.1 JP 2019055996-A/795: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD436944.1 JP 2019055996-A/787: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD436936.1 JP 2019055996-A/779: Human Antibodies to Influenza Hemagglutinin
GGTACATCC
>MD436928.1 JP 2019055996-A/771: Human Antibodies to Influenza Hemagglutinin
AAGGTTTCT
>MD436920.1 JP 2019055996-A/763: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436912.1 JP 2019055996-A/755: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD436904.1 JP 2019055996-A/747: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436896.1 JP 2019055996-A/739: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD436888.1 JP 2019055996-A/731: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436880.1 JP 2019055996-A/723: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436872.1 JP 2019055996-A/715: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD436864.1 JP 2019055996-A/707: Human Antibodies to Influenza Hemagglutinin
TCTGCATCC
>MD436856.1 JP 2019055996-A/699: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436848.1 JP 2019055996-A/691: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD436840.1 JP 2019055996-A/683: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD436832.1 JP 2019055996-A/675: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD436824.1 JP 2019055996-A/667: Human Antibodies to Influenza Hemagglutinin
TCTGCATCC
>MD436816.1 JP 2019055996-A/659: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436808.1 JP 2019055996-A/651: Human Antibodies to Influenza Hemagglutinin
TCTGCATCC
>MD436800.1 JP 2019055996-A/643: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436792.1 JP 2019055996-A/635: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436784.1 JP 2019055996-A/627: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436776.1 JP 2019055996-A/619: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436768.1 JP 2019055996-A/611: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436760.1 JP 2019055996-A/603: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436752.1 JP 2019055996-A/595: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436744.1 JP 2019055996-A/587: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436736.1 JP 2019055996-A/579: Human Antibodies to Influenza Hemagglutinin
GAGGCGTCT
>MD436728.1 JP 2019055996-A/571: Human Antibodies to Influenza Hemagglutinin
CTTGCATCC
>MD436720.1 JP 2019055996-A/563: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436712.1 JP 2019055996-A/555: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436704.1 JP 2019055996-A/547: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436696.1 JP 2019055996-A/539: Human Antibodies to Influenza Hemagglutinin
CTTGCATCC
>MD436688.1 JP 2019055996-A/531: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436680.1 JP 2019055996-A/523: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD436672.1 JP 2019055996-A/515: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436664.1 JP 2019055996-A/507: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436656.1 JP 2019055996-A/499: Human Antibodies to Influenza Hemagglutinin
CTTGCATCC
>MD436648.1 JP 2019055996-A/491: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436640.1 JP 2019055996-A/483: Human Antibodies to Influenza Hemagglutinin
GAGGCGTCT
>MD436632.1 JP 2019055996-A/475: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD436624.1 JP 2019055996-A/467: Human Antibodies to Influenza Hemagglutinin
TGGGCATCT
>MD436616.1 JP 2019055996-A/459: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436608.1 JP 2019055996-A/451: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436600.1 JP 2019055996-A/443: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436592.1 JP 2019055996-A/435: Human Antibodies to Influenza Hemagglutinin
GGTACATCC
>MD436584.1 JP 2019055996-A/427: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436576.1 JP 2019055996-A/419: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436568.1 JP 2019055996-A/411: Human Antibodies to Influenza Hemagglutinin
AGTACATCC
>MD436560.1 JP 2019055996-A/403: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436552.1 JP 2019055996-A/395: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436544.1 JP 2019055996-A/387: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD436536.1 JP 2019055996-A/379: Human Antibodies to Influenza Hemagglutinin
AGTTCTTCC
>MD436528.1 JP 2019055996-A/371: Human Antibodies to Influenza Hemagglutinin
AGTACATCC
>MD436520.1 JP 2019055996-A/363: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436512.1 JP 2019055996-A/355: Human Antibodies to Influenza Hemagglutinin
AGTACATCC
>MD436504.1 JP 2019055996-A/347: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436496.1 JP 2019055996-A/339: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436488.1 JP 2019055996-A/331: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436480.1 JP 2019055996-A/323: Human Antibodies to Influenza Hemagglutinin
AGTGAATCC
>MD436472.1 JP 2019055996-A/315: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436464.1 JP 2019055996-A/307: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD436456.1 JP 2019055996-A/299: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436448.1 JP 2019055996-A/291: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436440.1 JP 2019055996-A/283: Human Antibodies to Influenza Hemagglutinin
GATGCATCC
>MD436432.1 JP 2019055996-A/275: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436424.1 JP 2019055996-A/267: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436416.1 JP 2019055996-A/259: Human Antibodies to Influenza Hemagglutinin
ACTACATCC
>MD436408.1 JP 2019055996-A/251: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436400.1 JP 2019055996-A/243: Human Antibodies to Influenza Hemagglutinin
TTGGGTTCT
>MD436392.1 JP 2019055996-A/235: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD436384.1 JP 2019055996-A/227: Human Antibodies to Influenza Hemagglutinin
GAAGCTACT
>MD436376.1 JP 2019055996-A/219: Human Antibodies to Influenza Hemagglutinin
GTTGCATCC
>MD436368.1 JP 2019055996-A/211: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436360.1 JP 2019055996-A/203: Human Antibodies to Influenza Hemagglutinin
GAAGCTACT
>MD436352.1 JP 2019055996-A/195: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436344.1 JP 2019055996-A/187: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436337.1 JP 2019055996-A/180: Human Antibodies to Influenza Hemagglutinin
CAACAGAGT
>MD436336.1 JP 2019055996-A/179: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436328.1 JP 2019055996-A/171: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436320.1 JP 2019055996-A/163: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436312.1 JP 2019055996-A/155: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436272.1 JP 2019055996-A/115: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436264.1 JP 2019055996-A/107: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD436256.1 JP 2019055996-A/99: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436248.1 JP 2019055996-A/91: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436240.1 JP 2019055996-A/83: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436232.1 JP 2019055996-A/75: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436224.1 JP 2019055996-A/67: Human Antibodies to Influenza Hemagglutinin
GCTACATCC
>MD436216.1 JP 2019055996-A/59: Human Antibodies to Influenza Hemagglutinin
AAGATTTCT
>MD436208.1 JP 2019055996-A/51: Human Antibodies to Influenza Hemagglutinin
GGTGCATCC
>MD436200.1 JP 2019055996-A/43: Human Antibodies to Influenza Hemagglutinin
ACTGCATCC
>MD436192.1 JP 2019055996-A/35: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436188.1 JP 2019055996-A/31: Human Antibodies to Influenza Hemagglutinin
GCTGCATCC
>MD436180.1 JP 2019055996-A/23: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD436172.1 JP 2019055996-A/15: Human Antibodies to Influenza Hemagglutinin
GCTGCGTCC
>MD436164.1 JP 2019055996-A/7: Human Antibodies to Influenza Hemagglutinin
AAGGCGTCT
>MD436056.1 JP 2019054819-A/10: ANTIGEN BINDING CONSTRUCTS TO CD8 REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING
GGCGGCTGC
>MD435661.1 JP 2019048880-A/140: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435641.1 JP 2019048880-A/120: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435631.1 JP 2019048880-A/110: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGCGACATC
>MD435621.1 JP 2019048880-A/100: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435611.1 JP 2019048880-A/90: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435601.1 JP 2019048880-A/80: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435591.1 JP 2019048880-A/70: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435581.1 JP 2019048880-A/60: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435571.1 JP 2019048880-A/50: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435561.1 JP 2019048880-A/40: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435551.1 JP 2019048880-A/30: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435541.1 JP 2019048880-A/20: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD435531.1 JP 2019048880-A/10: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MD594737.1 JP 2019054813-A/154964: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>MD556540.1 JP 2019054813-A/116767: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGAGGTAG
>MD430515.1 JP 2019055963-A/127: High Affinity Human Antibodies to Human IL-4R Receptor
GATGCATCC
>MD430503.1 JP 2019055963-A/115: High Affinity Human Antibodies to Human IL-4R Receptor
GATGCATCC
>MD430491.1 JP 2019055963-A/103: High Affinity Human Antibodies to Human IL-4R Receptor
GTTGCATCC
>MD430479.1 JP 2019055963-A/91: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGCATCC
>MD430467.1 JP 2019055963-A/79: High Affinity Human Antibodies to Human IL-4R Receptor
TTGGGTTCT
>MD430455.1 JP 2019055963-A/67: High Affinity Human Antibodies to Human IL-4R Receptor
AGTGCCTCC
>MD430443.1 JP 2019055963-A/55: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGCATCC
>MD430431.1 JP 2019055963-A/43: High Affinity Human Antibodies to Human IL-4R Receptor
TTGGGTTCT
>MD430419.1 JP 2019055963-A/31: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGTATCC
>MD430407.1 JP 2019055963-A/19: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGCATCC
>MD430395.1 JP 2019055963-A/7: High Affinity Human Antibodies to Human IL-4R Receptor
GCTGCATCC
>MD729643.1 JP 2019053088-A/3: ALLERGEN DETECTION
AGCGTGTAA
>MD627336.1 JP 2019054813-A/187563: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCGGTAG
>MD508879.1 JP 2019054813-A/69106: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGCTAG
>MD544277.1 JP 2019054813-A/104504: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGTTAG
>MD579675.1 JP 2019054813-A/139902: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGCTAG
>MD615073.1 JP 2019054813-A/175300: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGCTAG
>MD650471.1 JP 2019054813-A/210698: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGGTAG
>MD488543.1 JP 2019054813-A/48770: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>MD523941.1 JP 2019054813-A/84168: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>MD439621.1 JP 2019062898-A/12: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GGTAGCGAA
>MD439620.1 JP 2019062898-A/11: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TTCGCTACC
>MD439619.1 JP 2019062898-A/10: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACCGTTAT
>MD439618.1 JP 2019062898-A/9: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
ATAACGGTC
>MD439613.1 JP 2019062898-A/4: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACGTTTTG
>MD439612.1 JP 2019062898-A/3: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CAAAACGTC
>MD439611.1 JP 2019062898-A/2: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACAGTTTC
>MD439610.1 JP 2019062898-A/1: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GAAACTGTC
>MD630135.1 JP 2019054813-A/190362: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>MD591938.1 JP 2019054813-A/152165: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCGGTAG
>MD731404.1 JP 2019059793-A/2: MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS
TTATTTANN
>MD402868.1 JP 2019030324-A/2: DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES
GCAGCACCC
>pdb|7DD3|G Chain G, Cryo-EM structure of the pre-mRNA-loaded DEAH-box ATPase/helicase Prp2 in complex with Spp2
NTTTTTTTT
>pdb|7C9C|D Chain D, Human DMC1 pre-synaptic complexes
NTTTTTTTT
>pdb|7C99|E Chain E, Human DMC1 post-synaptic complexes with mismatched dsDNA
NAAAAAAAA
>pdb|7C99|D Chain D, Human DMC1 post-synaptic complexes with mismatched dsDNA
NTTTTTTTT
>pdb|7C98|E Chain E, Human DMC1 post-synaptic complexes
NAAAAAAAA
>pdb|7C98|D Chain D, Human DMC1 post-synaptic complexes
NTTTTTTTT
>pdb|6XQB|F Chain F, SARS-CoV-2 RdRp/RNA complex
NTGGGCCCA
>pdb|6XQB|E Chain E, SARS-CoV-2 RdRp/RNA complex
GTGGGCCCA
>pdb|7KZL|A Chain A, Cyclopentane peptide nucleic acid in complex with DNA
TATCACATC
>pdb|7CD6|B Chain B, mAPE1-recessed dsDNA product complex
GCGTAATAC
>pdb|7CD5|B Chain B, mAPE1-blunt-ended dsDNA product complex
CGTAATACG
>pdb|6V6R|C Chain C, Crystal Structure of a Bromine Derivatized Self-Assembling DNA Crystal Scaffold with Rhombohedral Symmetry.
TGTCAGATG
>pdb|7C9A|E Chain E, Human RAD51 post-synaptic complexes mutant (V273P, D274G)
NAAAAAAAA
>pdb|7C9A|D Chain D, Human RAD51 post-synaptic complexes mutant (V273P, D274G)
NTTTTTTTT
>MD397484.1 WO 2020116423-A/19: Antibodies recognizing activated form of IL-18
GGGGCATCC
>MD397478.1 WO 2020116423-A/13: Antibodies recognizing activated form of IL-18
AAAGTTTCC
>pdb|4CSF|w Chain w, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|u Chain u, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|s Chain s, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|q Chain q, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|o Chain o, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|m Chain m, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|k Chain k, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|i Chain i, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|g Chain g, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|e Chain e, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|c Chain c, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|4CSF|a Chain a, Structural insights into Toscana virus RNA encapsidation
TGTGTTTCT
>pdb|6TZ1|M Chain M, In situ structure of BmCPV RNA-dependent RNA polymerase at early-elongation state
NTTTTTTTT
>pdb|5ODL|D Chain D, Single-stranded DNA-binding protein from bacteriophage Enc34 in complex with ssDNA
NTTTTTTTT
>pdb|5HRL|G Chain G, The crystal structure of AsfvPolX: 1nt-gap(P) DNA2: dGTP ternary complex.
GTGAGTACA
>pdb|5HRL|D Chain D, The crystal structure of AsfvPolX: 1nt-gap(P) DNA2: dGTP ternary complex.
GTGAGTACA
>pdb|5HRK|C Chain C, The crystal structure of AsfvPolX(H115F mutant): 1nt-gap(P) DNA2:dGTP ternary complex
GTGAGTACA
>pdb|5HRK|F Chain F, The crystal structure of AsfvPolX(H115F mutant): 1nt-gap(P) DNA2:dGTP ternary complex
GTGAGTACA
>pdb|5HRI|G Chain G, The crystal structure of AsfvPolX:DNA1 binary complex
GTGAGTACA
>pdb|5HRI|D Chain D, The crystal structure of AsfvPolX:DNA1 binary complex
GTGAGTACA
>pdb|5HRH|G Chain G, The crystal structure of AsfvPolX(H115F/R127A mutant): 1nt-gap(P) DNA2:dGTP ternary complex
GTGAGTACA
>pdb|5HRH|D Chain D, The crystal structure of AsfvPolX(H115F/R127A mutant): 1nt-gap(P) DNA2:dGTP ternary complex
GTGAGTACA
>pdb|5HRF|D Chain D, The crystal structure of AsfvPolX: DNA5: dGTP ternary complex
CAGGATCCT
>pdb|5HRF|C Chain C, The crystal structure of AsfvPolX: DNA5: dGTP ternary complex
CAGGATCCT
>pdb|5HRE|B Chain B, The crystal structure of AsfvPolX:DNA3 binary complex
GAGGATCCT
>pdb|5HRB|E Chain E, The crystal structure of AsfvPolX:DNA1 binary complex
CGGATATCC
>pdb|5HRB|D Chain D, The crystal structure of AsfvPolX:DNA1 binary complex
CGGATATCC
>pdb|5MFX|B Chain B, Zika NS3 helicase:RNA complex
NGACTCCAT
>pdb|5GIN|O Chain O, Crystal structure of box C/D RNP with 12 nt guide regions and 9 nt substrates
CCATGAGTG
>pdb|5GIN|J Chain J, Crystal structure of box C/D RNP with 12 nt guide regions and 9 nt substrates
CCATGAGTG
>pdb|5GIN|I Chain I, Crystal structure of box C/D RNP with 12 nt guide regions and 9 nt substrates
CCATGAGTG
>pdb|5KEO|C Chain C, Structure Determination of a Self-Assembling DNA Crystal
TCTGAGTGT
>pdb|5BZV|B Chain B, Crystal structure of the RNA-binding domain of yeast Puf5p bound to SMX2 RNA
TGTACTATA
>pdb|5BYM|C Chain C, Crystal structure of the RNA-binding domain of yeast Puf5p bound to SMX2 RNA
TGTACTATA
>pdb|5C4X|R Chain R, Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
NCGAGAGGA
>pdb|5C4J|R Chain R, Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
NCGAGAGGA
>pdb|5C44|R Chain R, Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
NCGAGAGGA
>pdb|4R4E|D Chain D, Structure of GlnR-DNA complex
ATTCTGACA
>pdb|4S20|P Chain P, Structural basis for transcription reactivation by RapA
NTCGGCTCA
>pdb|4S20|N Chain N, Structural basis for transcription reactivation by RapA
NTCGGCTCA
>pdb|4PUQ|D Chain D, Mus Musculus Tdp2 reaction product complex with 5'-phosphorylated RNA/DNA, glycerol, and Mg2+
NCGAATTCG
>pdb|4PUQ|C Chain C, Mus Musculus Tdp2 reaction product complex with 5'-phosphorylated RNA/DNA, glycerol, and Mg2+
NCGAATTCG
>pdb|4MDX|C Chain C, Crystal structure of Bacillus subtilis MazF in complex with RNA
TTNACATAA
>pdb|4K1G|O Chain O, Structure of E. coli Nfo(Endo IV)-H69A mutant bound to a cleaved DNA duplex containing a alphadA:T basepair
NCGACGACG
>pdb|4K1G|H Chain H, Structure of E. coli Nfo(Endo IV)-H69A mutant bound to a cleaved DNA duplex containing a alphadA:T basepair
NCGACGACG
>pdb|4K4Y|P Chain P, Coxsackievirus B3 polymerase elongation complex (r2+1_form)
GGGAGATGA
>pdb|4K4Y|L Chain L, Coxsackievirus B3 polymerase elongation complex (r2+1_form)
GGGAGATGA
>pdb|4K4Y|H Chain H, Coxsackievirus B3 polymerase elongation complex (r2+1_form)
GGGAGATGA
>pdb|4K4Y|D Chain D, Coxsackievirus B3 polymerase elongation complex (r2+1_form)
GGGAGATGA
>pdb|4K4Z|P Chain P, Coxsackievirus B3 polymerase elongation complex (r2_Mg_form)
GGGAGATGA
>pdb|4K4Z|H Chain H, Coxsackievirus B3 polymerase elongation complex (r2_Mg_form)
GGGAGATGA
>pdb|4K4Z|L Chain L, Coxsackievirus B3 polymerase elongation complex (r2_Mg_form)
GGGAGATGA
>pdb|4K4Z|D Chain D, Coxsackievirus B3 polymerase elongation complex (r2_Mg_form)
NGGAGATGA
>pdb|4K4X|P Chain P, Coxsackievirus B3 polymerase elongation complex (r2_form), rna
NGGAGATGA
>pdb|4K4X|L Chain L, Coxsackievirus B3 polymerase elongation complex (r2_form), rna
NGGAGATGA
>pdb|4K4X|H Chain H, Coxsackievirus B3 polymerase elongation complex (r2_form), rna
NGGAGATGA
>pdb|4K4X|D Chain D, Coxsackievirus B3 polymerase elongation complex (r2_form), rna
NGGAGATGA
>pdb|4K4T|H Chain H, Poliovirus polymerase elongation complex (r4_form)
GGGAGATGA
>pdb|4K4T|D Chain D, Poliovirus polymerase elongation complex (r4_form)
GGGAGATGA
>pdb|4K4S|H Chain H, Poliovirus polymerase elongation complex (r3_form)
GGGAGATGA
>pdb|4K4S|D Chain D, Poliovirus polymerase elongation complex (r3_form)
GGGAGATGA
>pdb|3UXP|E Chain E, Co-crystal Structure of Rat DNA polymerase beta Mutator I260Q: Enzyme-DNA-ddTTP
NCTCACATA
>pdb|3UXP|T Chain T, Co-crystal Structure of Rat DNA polymerase beta Mutator I260Q: Enzyme-DNA-ddTTP
NCTCACATA
>pdb|4AM3|I Chain I, Crystal structure of C. crescentus PNPase bound to RNA
TAACTTTGG
>pdb|4AM3|H Chain H, Crystal structure of C. crescentus PNPase bound to RNA
TAACTTTGG
>pdb|4AM3|E Chain E, Crystal structure of C. crescentus PNPase bound to RNA
NAACTTTGG
>pdb|4AM3|D Chain D, Crystal structure of C. crescentus PNPase bound to RNA
TAACTTTGG
>pdb|3MJ0|B Chain B, Crystal Structure of Drosophia Ago-PAZ domain in complex with 3'-end 2'-O-methylated RNA
CGTTACGCN
>pdb|3QGC|B Chain B, Crystal structure of FBF-2 R288Y mutant in complex with gld-1 FBEa A7U mutant
TGTGCCTTA
>pdb|3QGB|B Chain B, Crystal structure of FBF-2 R288Y mutant in complex with gld-1 FBEa
TGTGCCATA
>pdb|3QG9|B Chain B, crystal structure of FBF-2/gld-1 FBEa A7U mutant complex
TGTGCCTTA
>pdb|3OLB|P Chain P, Poliovirus polymerase elongation complex with 2',3'-dideoxy-ctp
GGGAGATGA
>pdb|3OLB|L Chain L, Poliovirus polymerase elongation complex with 2',3'-dideoxy-ctp
GGGAGATGA
>pdb|3OLB|H Chain H, Poliovirus polymerase elongation complex with 2',3'-dideoxy-ctp
GGGAGATGA
>pdb|3OLB|D Chain D, Poliovirus polymerase elongation complex with 2',3'-dideoxy-ctp
GGGAGATGA
>pdb|3OLA|P Chain P, Poliovirus polymerase elongation complex with 2'-deoxy-CTP
GGGAGATGA
>pdb|3OLA|L Chain L, Poliovirus polymerase elongation complex with 2'-deoxy-CTP
GGGAGATGA
>pdb|3OLA|H Chain H, Poliovirus polymerase elongation complex with 2'-deoxy-CTP
GGGAGATGA
>pdb|3OLA|D Chain D, Poliovirus polymerase elongation complex with 2'-deoxy-CTP
GGGAGATGA
>pdb|3OL9|P Chain P, Poliovirus polymerase elongation complex with 3'-deoxy-CTP
GGGAGATGA
>pdb|3OL9|L Chain L, Poliovirus polymerase elongation complex with 3'-deoxy-CTP
GGGAGATGA
>pdb|3OL9|H Chain H, Poliovirus polymerase elongation complex with 3'-deoxy-CTP
GGGAGATGA
>pdb|3OL9|D Chain D, Poliovirus polymerase elongation complex with 3'-deoxy-CTP
GGGAGATGA
>pdb|3OL8|P Chain P, Poliovirus polymerase elongation complex with CTP-Mn
GGGAGATGA
>pdb|3OL8|L Chain L, Poliovirus polymerase elongation complex with CTP-Mn
GGGAGATGA
>pdb|3OL8|H Chain H, Poliovirus polymerase elongation complex with CTP-Mn
GGGAGATGA
>pdb|3OL8|D Chain D, Poliovirus polymerase elongation complex with CTP-Mn
GGGAGATGA
>pdb|3OL7|P Chain P, Poliovirus polymerase elongation complex with CTP
GGGAGATGA
>pdb|3OL7|L Chain L, Poliovirus polymerase elongation complex with CTP
GGGAGATGA
>pdb|3OL7|H Chain H, Poliovirus polymerase elongation complex with CTP
GGGAGATGA
>pdb|3OL7|D Chain D, Poliovirus polymerase elongation complex with CTP
GGGAGATGA
>pdb|3OL6|P Chain P, Poliovirus polymerase elongation complex
GGGAGATGA
>pdb|3OL6|L Chain L, Poliovirus polymerase elongation complex
GGGAGATGA
>pdb|3OL6|H Chain H, Poliovirus polymerase elongation complex
GGGAGATGA
>pdb|3OL6|D Chain D, Poliovirus polymerase elongation complex
GGGAGATGA
>pdb|2XBM|F Chain F, Crystal structure of the dengue virus methyltransferase bound to a 5'- capped octameric RNA
NGAACCTGA
>pdb|2XBM|E Chain E, Crystal structure of the dengue virus methyltransferase bound to a 5'- capped octameric RNA
NGAACCTGA
>pdb|3OGD|C Chain C, AlkA Undamaged DNA Complex: Interrogation of a G*:C base pair
CANGACNGC
>pdb|3OGD|B Chain B, AlkA Undamaged DNA Complex: Interrogation of a G*:C base pair
GCAGTCATG
>pdb|2WTF|P Chain P, DNA polymerase eta in complex with the cis-diammineplatinum (II) 1,3- GTG intrastrand cross-link
GTGGTGAGC
>pdb|2WTF|T Chain T, DNA polymerase eta in complex with the cis-diammineplatinum (II) 1,3- GTG intrastrand cross-link
GTGGTGAGC
>pdb|3G4T|I Chain I, Mth0212 (WT) in complex with a 7bp dsDNA
CGTACTACG
>pdb|3G4T|H Chain H, Mth0212 (WT) in complex with a 7bp dsDNA
CGTANTACG
>pdb|3G3Y|I Chain I, Mth0212 in complex with ssDNA in space group P32
CGTANTACG
>pdb|3G3C|I Chain I, Mth0212 (WT) in complex with a 6bp dsDNA containing a single one nucleotide long 3'-overhang
CGTANTACG
>pdb|3G3C|H Chain H, Mth0212 (WT) in complex with a 6bp dsDNA containing a single one nucleotide long 3'-overhang
CGTACTACG
>pdb|3G38|K Chain K, The catalytically inactive mutant Mth0212 (D151N) in complex with an 8 bp dsDNA
CGCGCAGGC
>pdb|3G2D|H Chain H, Complex of Mth0212 and a 4 bp dsDNA with 3'-overhang
CGCGCAGGC
>pdb|3G2D|G Chain G, Complex of Mth0212 and a 4 bp dsDNA with 3'-overhang
CGCGCAGGC
>pdb|3G00|I Chain I, Mth0212 in complex with a 9bp blunt end dsDNA at 1.7 Angstrom
CGTANTACG
>pdb|3G00|H Chain H, Mth0212 in complex with a 9bp blunt end dsDNA at 1.7 Angstrom
CGTATTACG
>pdb|3G78|Z Chain Z, Insight into group II intron catalysis from revised crystal structure
TGTTATTTT
>pdb|3K64|B Chain B, Crystal structure of FBF-2/fem-3 PME complex
TGTGTCATT
>pdb|3K62|B Chain B, Crystal structure of FBF-2/gld-1 FBEb complex
TGTGTTATC
>pdb|3K61|B Chain B, Crystal structure of FBF-2/fog-1 FBEa complex
TGTAAAATC
>pdb|3K5Z|B Chain B, Crystal structure of FBF-2/gld-1 FBEa G4A mutant complex
TGTACCATA
>pdb|3K5Y|B Chain B, Crystal structure of FBF-2/gld-1 FBEa complex
TGTGCCATA
>pdb|3K5Q|B Chain B, Crystal structure of FBF-2/FBE complex
NGTACTATA
>pdb|3HQF|C Chain C, Crystal structure of restriction endonuclease EcoRII N-terminal effector-binding domain in complex with cognate DNA
CGCCAGGGC
>pdb|3HQF|B Chain B, Crystal structure of restriction endonuclease EcoRII N-terminal effector-binding domain in complex with cognate DNA
GCCCTGGCG
>pdb|2E9Z|B Chain B, Foot-and-mouth disease virus RNA-polymerase in complex with a template- primer RNA, ATP and UTP
CATGGGCCC
>pdb|2E9R|A Chain A, Foot-and-mouth disease virus RNA-dependent RNA polymerase in complex with a template-primer RNA and with ribavirin
CATGGGCCC
>pdb|1S76|R Chain R, T7 RNA polymerase alpha beta methylene ATP elongation complex
NCACGGCGA
>pdb|1NK4|B Chain B, Guanine-Guanine Mismatch At The Polymerase Active Site
GCGATCAGG
>pdb|1L1V|A Chain A, Unusual ActdDNA_TA COMPLEX STRUCTURE
GTCACCGAC
>pdb|1CW0|O Chain O, Crystal Structure Analysis Of Very Short Patch Repair (Vsr) Endonuclease In Complex With A Duplex Dna
NAGGTACGT
>pdb|2BDP|P Chain P, Crystal Structure Of Bacillus Dna Polymerase I Fragment Complexed To 9 Base Pairs Of Duplex Dna
GCATGATGC
>pdb|6UEU|E Chain E, Crystal structure of BF DNA polymerase F710Y mutant bound to tetrahydrofuran and dATP
CGATCACGN
>pdb|6UEU|B Chain B, Crystal structure of BF DNA polymerase F710Y mutant bound to tetrahydrofuran and dATP
CGATCACGN
>pdb|6UEF|C Chain C, Crystal Structure of a Self-Assembling DNA Scaffold Containing Sequence Modifications to Attempt to Disrupt Crystal Contacts in a Rhombohedral Lattice.
TGTCCGATG
>pdb|6UDN|C Chain C, Crystal Structure of a Self-Assembling DNA Scaffold Containing TA Sticky Ends and Rhombohedral Symmetry
TATCAGATG
>pdb|6W5C|E Chain E, Cryo-EM structure of Cas12i(E894A)-crRNA-dsDNA complex
NAAGGACTG
>pdb|6U40|C Chain C, Crystal Structure of a Self-Assembling DNA Crystal Scaffold with Rhombohedral Symmetry
TGTCAGATG
>pdb|6M6K|A Chain A, NMR solution structure of a DNA minidumbbell containing an abasic bulge between two CCTG repeats
CCTGNCCTG
>pdb|6M6J|A Chain A, NMR solution structure of a DNA minidumbbell containing an abasic bulge between two CTTG repeats
CTTGNCTTG
>pdb|6UQ2|R Chain R, RNA polymerase II elongation complex with dG in state 1
ATCGAGAGG
>pdb|6UPY|R Chain R, RNA polymerase II elongation complex with 5-guanidinohydantoin lesion in state 2E
NTCGAGAGG
>pdb|6UPX|R Chain R, RNA polymerase II elongation complex with 5-guanidinohydantoin lesion in state 1
NTCGAGAGG
>pdb|6TQI|A Chain A, I-MOTIF STRUCTURE FORMED FROM THE C STRAND OF A HUMAN TELOMERE FRAGMENT
TAACCCTAA
>pdb|6P5C|C Chain C, Bacillus Fragment DNA polymerase mutant I716M
NCGTGATCG
>pdb|6P5C|B Chain B, Bacillus Fragment DNA polymerase mutant I716M
CGATCACGC
>pdb|6US5|E Chain E, DNA polymerase I Large Fragment from Bacillus stearothermophilus with DNA template, 3'-amino primer, dGpNHpp analog, and Mn2+
GCGATCAGN
>pdb|6US5|B Chain B, DNA polymerase I Large Fragment from Bacillus stearothermophilus with DNA template, 3'-amino primer, dGpNHpp analog, and Mn2+
GCGATCAGN
>pdb|6UR9|E Chain E, DNA polymerase I Large Fragment from Bacillus stearothermophilus with DNA template, dideoxy primer, 3'-amino-ddGTP (nGTP), and Ca2+
GCGATCAGN
>pdb|6UR9|B Chain B, DNA polymerase I Large Fragment from Bacillus stearothermophilus with DNA template, dideoxy primer, 3'-amino-ddGTP (nGTP), and Ca2+
GCGATCAGN
>pdb|6UR4|B Chain B, DNA polymerase I Large Fragment from Bacillus stearothermophilus with DNA template and 3'-amino primer
GCGATCAGN
>pdb|6KOP|I Chain I, Mycobacterium tuberculosis initial transcription complex comprising sigma H and 5'-OH RNA of 9 nt
CACCCTCGA
>pdb|5TGG|B Chain B, Solution structure of parallel stranded adenosine duplex
TNNNNANNN
>pdb|5TGG|A Chain A, Solution structure of parallel stranded adenosine duplex
TNNNNANNN
>pdb|6UOM|P Chain P, Y271G DNA polymerase beta ternary complex with templating adenine and incoming r8-oxo-GTP
GCTGATGCG
>pdb|6PH6|P Chain P, Ternary complex crystal structure of DNA polymerase Beta with 2nt-gap with dCTP bound downstream
GCTGATGCG
>pdb|6I1W|B Chain B, Structure of the RNA duplex containing pseudouridine residue (5'-Gp(PSU)pC-3' sequence context)
ACTGACTGA
>pdb|6I1W|A Chain A, Structure of the RNA duplex containing pseudouridine residue (5'-Gp(PSU)pC-3' sequence context)
TCAGNCAGT
>pdb|6I1V|B Chain B, Structure of the RNA duplex containing pseudouridine residue (5'-Cp(PSU)pG-3' sequence context)
ACTCAGTGA
>pdb|6I1V|A Chain A, Structure of the RNA duplex containing pseudouridine residue (5'-Cp(PSU)pG-3' sequence context)
TCACNGAGT
>pdb|6PR5|F Chain F, Cryo-EM structure of HzTransib strand transfer complex (STC)
NTTTCGATC
>pdb|6PIJ|3 Chain 3, Target DNA-bound V. cholerae TniQ-Cascade complex, closed conformation
NCGCCTTAC
>pdb|6P1W|T Chain T, Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing undamaged template dG and bound incoming CMPCPP
CGGCGTACG
>pdb|6P1V|T Chain T, Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing undamaged template dG and bound incoming dCMPNPP
CGGCGTACG
>pdb|6P1U|T Chain T, Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated CMP
CGGCNTACG
>pdb|6P1T|T Chain T, Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound CMPCPP
CGGCNTACG
>pdb|6P1S|T Chain T, Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated AMP
CGGCNTACG
>pdb|6P1R|T Chain T, Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound incoming AMPNPP
CGGCNTACG
>pdb|6P1Q|T Chain T, Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated dCMP
CGGCNTACG
>pdb|6P1P|T Chain T, Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound incoming dCMPNPP
CGGCNTACG
>pdb|6P1O|T Chain T, Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated dAMP
CGGCNTACG
>pdb|6P1N|T Chain T, Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound incoming dAMPNPP
CGGCNTACG
>pdb|6P1M|T Chain T, Binary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG
CGGCNTACG
>pdb|6EEN|I Chain I, Crystal structure of a designer Pentatrico Peptide RNA binding protein, bound to a complex RNA target and featuring an infinite superhelix and microheterogeneity.
NCCCCCCCC
>pdb|6EEN|H Chain H, Crystal structure of a designer Pentatrico Peptide RNA binding protein, bound to a complex RNA target and featuring an infinite superhelix and microheterogeneity.
NAAAAAAAA
>pdb|6EEN|G Chain G, Crystal structure of a designer Pentatrico Peptide RNA binding protein, bound to a complex RNA target and featuring an infinite superhelix and microheterogeneity.
NTTTTTTTT
>pdb|6EEN|F Chain F, Crystal structure of a designer Pentatrico Peptide RNA binding protein, bound to a complex RNA target and featuring an infinite superhelix and microheterogeneity.
NGGGGGGGG
>pdb|6ED9|B Chain B, NMR structure for Sp1 transcription factor duplex 5'-d(TGGGCGGGA)
TCCCGCCCA
>pdb|6ED9|A Chain A, NMR structure for Sp1 transcription factor duplex 5'-d(TGGGCGGGA)
TGGGCGGGA
>pdb|6KIJ|A Chain A, Crystal structure of yedK with ssDNA containing an abasic site
GATTCGTCG
>pdb|6DXM|B Chain B, NMR structure for Sp1 transcription factor duplex 5'-d(TGGGCGGGG)
CCCCGCCCA
>pdb|6DXM|A Chain A, NMR structure for Sp1 transcription factor duplex 5'-d(TGGGCGGGG)
TGGGCGGGG
>pdb|6DVT|B Chain B, NMR structure for Sp1 transcription factor duplex 5'-d(GGGGCGGGA)
TCCCGCCCC
>pdb|6DVT|A Chain A, NMR structure for Sp1 transcription factor duplex 5'-d(GGGGCGGGA)
GGGGCGGGA
>pdb|6O6C|K Chain K, RNA polymerase II elongation complex arrested at a CPD lesion
NTCGAGAGG
>pdb|6IPG|T Chain T, Post-catalytic Complex of Human DNA Polymerase Mu with Templating Cytosine and Mg-8oxodGMP
CGGCCTACG
>pdb|6IPF|T Chain T, Post-catalytic Complex of Human DNA Polymerase Mu with Templating Cytosine and Mn-8oxodGMP
CGGCCTACG
>pdb|6IPE|T Chain T, Post-catalytic Complex of Human DNA Polymerase Mu with Templating Adenine and Mg-8oxodGMP
CGGCATACG
>pdb|6IPD|T Chain T, Post-catalytic Complex of Human DNA Polymerase Mu with Templating Adenine and Mn-8oxodGMP
CGGCATACG
>pdb|6AKH|T Chain T, Pre-catalytic Ternary Complex of Human DNA Polymerase Mu with Templating Adenine and Incoming Mn-dUMPNPP
CGGCATACG
>pdb|6AK9|T Chain T, Pre-catalytic Ternary Complex of Human DNA Polymerase Mu with Templating Cytosine and Incoming Ca-8oxodGTP
CGGCCTACG
>pdb|6AK8|T Chain T, Pre-catalytic Ternary Complex of Human DNA Polymerase Mu with Templating Adenine and Incoming Ca-8oxodGTP
CGGCATACG
>pdb|6DM7|B Chain B, NMR structure for Sp1 transcription factor duplex 5'-d(GGGGCGGGG)
CCCCGCCCC
>pdb|6DM7|A Chain A, NMR structure for Sp1 transcription factor duplex 5'-d(GGGGCGGGG)
GGGGCGGGG
>pdb|6RA4|M Chain M, Human ARGONAUTE-2 PAZ DOMAIN (214-347) IN COMPLEX WITH CGUGACUCU
CGTGACTCT
>pdb|6RA4|L Chain L, Human ARGONAUTE-2 PAZ DOMAIN (214-347) IN COMPLEX WITH CGUGACUCU
CGTGACTCT
>pdb|6OEB|B Chain B, Crystal structure of HMCES SRAP domain in complex with 3' overhang DNA
CCAGACGTT
>pdb|5ZMD|H Chain H, Crystal structure of FTO in complex with m6dA modified ssDNA
NCTNTATCG
>pdb|5ZMD|F Chain F, Crystal structure of FTO in complex with m6dA modified ssDNA
NCTNTATCG
>pdb|5ZMD|D Chain D, Crystal structure of FTO in complex with m6dA modified ssDNA
NCTNTATCG
>pdb|5ZMD|B Chain B, Crystal structure of FTO in complex with m6dA modified ssDNA
NCTNTATCG
>pdb|5ZQF|C Chain C, Crystal structure of human topoisomerase II beta in complex with 5-iodouridine-containing-DNA in space group P3221
NNNNNNNNN
>pdb|6MXO|P Chain P, Structure of HPoleta incorporating dCTP opposite the 3-prime Pt(DACH)-GG
TAGTGTGAG
>pdb|6CST|P Chain P, Structure of human DNA polymerase kappa with DNA
NTACATACC
>pdb|6CST|C Chain C, Structure of human DNA polymerase kappa with DNA
NTACATACC
>pdb|6GVU|A Chain A, NMR structure of the DNA-bound helix bundle domain from the functional pRN1 primase
CTGTGCTCA
>pdb|6GVT|A Chain A, Hybrid structure of the pRN1 helix bundle domain in complex with DNA and 2 ATP molecules
CTGTGCTCA
>pdb|6GVQ|A Chain A, DNA-bound pRN1 helix bundle domain with ATP and magnesium in the interaction buffer
CTGTGCTCA
>pdb|6N4G|B Chain B, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTTAGGCG
>pdb|6N4G|A Chain A, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTTAGGCG
>pdb|6HU6|F Chain F, Structure of ARF1 RNA
NTGGTACTC
>pdb|5ZVB|C Chain C, APOBEC3F Chimeric Catalytic Domain in Complex with DNA(dT9)
ATTTTCAAT
>pdb|6MC4|H Chain H, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTCAGGCG
>pdb|6MC4|G Chain G, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTCAGGCG
>pdb|6MC4|F Chain F, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTCAGGCG
>pdb|6MC4|E Chain E, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTCAGGCG
>pdb|6MC4|D Chain D, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTCAGGCG
>pdb|6MC4|C Chain C, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTCAGGCG
>pdb|6MC4|B Chain B, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTCAGGCG
>pdb|6MC4|A Chain A, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTCAGGCG
>pdb|6MC3|D Chain D, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTGAGGCG
>pdb|6MC3|C Chain C, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTGAGGCG
>pdb|6MC3|B Chain B, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTGAGGCG
>pdb|6MC3|A Chain A, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTGAGGCG
>pdb|6MC2|B Chain B, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTAAGGCG
>pdb|6MC2|A Chain A, Crystal structure of a tetrameric DNA fold-back quadruplex
CGTAAGGCG
>pdb|5YBD|Y Chain Y, X-ray structure of ETS domain of Ergp55 in complex with E74DNA
NCCGGAAGT
>pdb|5YBD|B Chain B, X-ray structure of ETS domain of Ergp55 in complex with E74DNA
NCCGGAAGT
>pdb|6DSW|P Chain P, Bst DNA polymerase I pre-chemistry (n) structure
GCGATCACG
>pdb|6M7V|T Chain T, Human DNA polymerase eta extension complex with cdA at the -1 position
NCTCACACT
>pdb|6D0M|P Chain P, Polymerase Eta post-insertion binary complex with cytarabine (AraC)
AGCACTGTN
>pdb|6DKL|A Chain A, Crystal Structure of a Rationally Designed Six-Fold Symmetric DNA Scaffold
GGATGCACA
>pdb|6BS1|P Chain P, Crystal Structure of Human DNA polymerase kappa in complex with DNA containing the major cisplatin lesion
NTACATACC
>pdb|6BS1|C Chain C, Crystal Structure of Human DNA polymerase kappa in complex with DNA containing the major cisplatin lesion
NTACATACC
>pdb|6BRX|P Chain P, Crystal Structure of Human DNA polymerase kappa in complex with DNA containing the major cisplatin lesion
NACATACAC
>pdb|6BRX|C Chain C, Crystal Structure of Human DNA polymerase kappa in complex with DNA containing the major cisplatin lesion
NACATACAC
>pdb|5ZEN|C Chain C, Crystal structure of human topoisomerase II beta in complex with DNA: a new quaternary conformation showing opening of the protein-linked DNA-gate
NGCTCGGCT
>pdb|5XI1|A Chain A, Structural Insight of Flavonoids binding to CAG repeat RNA that causes Huntington's Disease (HD) and Spinocerebellar Ataxia (SCAs)
NCGCAGCGG
>pdb|5XI1|S Chain S, Structural Insight of Flavonoids binding to CAG repeat RNA that causes Huntington's Disease (HD) and Spinocerebellar Ataxia (SCAs)
NCGCAGCGG
>pdb|6BUX|B Chain B, CRYSTAL STRUCTURE OF APOBEC3G CATALYTIC DOMAIN COMPLEX WITH SUBSTRATE SSDNA
AATCCCAAA
>pdb|5W51|R Chain R, Pol II elongation complex with an N6-methyladenine-containing template and a matched UMPNPP
ATGGAGAGG
>pdb|5W4U|R Chain R, Pol II elongation complex with an N6-methyladenine-containing template
ATGGAGAGG
>pdb|5OND|D Chain D, RfaH from Escherichia coli in complex with ops DNA
GCGGTAGTC
>pdb|5OND|C Chain C, RfaH from Escherichia coli in complex with ops DNA
GCGGTAGTC
>pdb|5XS0|Z Chain Z, Structure of a ssDNA bound to the outer DNA binding site of RAD52
CCCCCCCCC
>pdb|5USN|B Chain B, Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssRNA/ssDNA chimera (rGrGrUTACGGT)
NNNTACGGT
>pdb|5YIV|L Chain L, Caulobacter crescentus GcrA DNA-binding domain(DBD) in complex with methylated dsDNA(crystal form 1)
CCGNATCAG
>pdb|5YIV|K Chain K, Caulobacter crescentus GcrA DNA-binding domain(DBD) in complex with methylated dsDNA(crystal form 1)
CCTGNTTCG
>pdb|5YIV|J Chain J, Caulobacter crescentus GcrA DNA-binding domain(DBD) in complex with methylated dsDNA(crystal form 1)
CCGNATCAG
>pdb|5YIV|I Chain I, Caulobacter crescentus GcrA DNA-binding domain(DBD) in complex with methylated dsDNA(crystal form 1)
CCTGNTTCG
>pdb|5YIV|H Chain H, Caulobacter crescentus GcrA DNA-binding domain(DBD) in complex with methylated dsDNA(crystal form 1)
CCGNATCAG
>pdb|5YIV|G Chain G, Caulobacter crescentus GcrA DNA-binding domain(DBD) in complex with methylated dsDNA(crystal form 1)
CCTGNTTCG
>pdb|5YIV|F Chain F, Caulobacter crescentus GcrA DNA-binding domain(DBD) in complex with methylated dsDNA(crystal form 1)
CCGNATCAG
>pdb|5YIV|E Chain E, Caulobacter crescentus GcrA DNA-binding domain(DBD) in complex with methylated dsDNA(crystal form 1)
CCTGNTTCG
>pdb|5N9E|D Chain D, Crystal Structure of Drosophila DHX36 helicase in complex with TGGGGATTT
NGGGGATTT
>pdb|5N9E|C Chain C, Crystal Structure of Drosophila DHX36 helicase in complex with TGGGGATTT
NGGGGATTT
>pdb|5YKI|C Chain C, Crystal structure of the engineered nine-repeat PUF domain in complex with cognate 9nt-RNA
TGTTGTATA
>pdb|5N9A|D Chain D, Crystal Structure of Drosophila DHX36 helicase in complex with GTTAGGGTT
NTTAGGGTT
>pdb|5N9A|C Chain C, Crystal Structure of Drosophila DHX36 helicase in complex with GTTAGGGTT
NTTAGGGTT
>pdb|5N98|D Chain D, Crystal Structure of Drosophila DHX36 helicase in complex with TAGGGTTTT
NAGGGTTTT
>pdb|5N98|C Chain C, Crystal Structure of Drosophila DHX36 helicase in complex with TAGGGTTTT
NAGGGTTTT
>pdb|5N90|D Chain D, Crystal Structure of Drosophila DHX36 helicase in complex with TTGTGGTGT
NTGTGGTGT
>pdb|5N90|C Chain C, Crystal Structure of Drosophila DHX36 helicase in complex with TTGTGGTGT
NTGTGGTGT
>pdb|5N8Z|D Chain D, Crystal Structure of Drosophila DHX36 helicase in complex with CTCTCCCTT
NTCTCCCTT
>pdb|5N8Z|C Chain C, Crystal Structure of Drosophila DHX36 helicase in complex with CTCTCCCTT
NTCTCCCTT
>pdb|5N8R|D Chain D, Crystal Structure of Drosophilia DHX36 helicase in complex with GAGCACTGC
NAGCACTGC
>pdb|5N8R|C Chain C, Crystal Structure of Drosophilia DHX36 helicase in complex with GAGCACTGC
NAGCACTGC
>pdb|6BQF|R Chain R, Pol II elongation complex with 'dT-AP' at i+1, i-1 position
ATCGAGAGA
>pdb|6BM4|R Chain R, Pol II elongation complex with an abasic lesion at i-1 position,soaking UMPNPP
ATCGAGAGA
>pdb|6BM2|R Chain R, Pol II elongation complex with an abasic lesion at i-1 position
ATCGAGAGA
>pdb|5WN2|D Chain D, APE1 exonuclease substrate complex with phosphoglycolate
GCTGATGCG
>pdb|5WN1|D Chain D, APE1 exonuclease product complex
GCTGATGCG
>pdb|6AZ4|B Chain B, RNA hairpin complex with guanosine dinucleotide ligand G(5')ppp(5')G
CAGCAGCAG
>pdb|2VYE|C Chain C, Crystal Structure of the DnaC-ssDNA complex
TTTTTTTTT
>pdb|6AST|B Chain B, NMR and Restrained Molecular Dynamics Determination of the Structure of an Aza-Benzimidazole Derivative Complex with the DNA Minor Groove of an -AAGATA Sequence
CTATCTTGG
>pdb|6AST|A Chain A, NMR and Restrained Molecular Dynamics Determination of the Structure of an Aza-Benzimidazole Derivative Complex with the DNA Minor Groove of an -AAGATA Sequence
CCAAGATAG
>pdb|6ASF|B Chain B, NMR and Restrained Molecular Dynamics Determination of the Structure of an Aza-Benzimidazole Derivative Complex with the DNA Minor Groove of an -AAGATA- Sequence
CTATCTTGG
>pdb|6ASF|A Chain A, NMR and Restrained Molecular Dynamics Determination of the Structure of an Aza-Benzimidazole Derivative Complex with the DNA Minor Groove of an -AAGATA- Sequence
CCAAGATAG
>pdb|5NW9|C Chain C, Crystal structure of the complex of Tdp1 with duplex DNA
NGCGCAGTA
>pdb|5TVP|N Chain N, SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
NCGAATTCG
>pdb|5TVP|L Chain L, SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
NCGAATTCG
>pdb|5TVP|D Chain D, SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
NCGAATTCG
>pdb|5TVP|C Chain C, SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
NCGAATTCG
>pdb|5TVP|H Chain H, SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
NCGAATTCG
>pdb|5TVP|F Chain F, SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
NCGAATTCG
>pdb|5TVP|P Chain P, SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
NCGAATTCG
>pdb|5TVP|J Chain J, SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
NCGAATTCG
>pdb|6B0B|G Chain G, Crystal structure of human APOBEC3H
TTTTTTTTT
>pdb|6B0B|C Chain C, Crystal structure of human APOBEC3H
TTTTTTTTT
>pdb|5W2C|P Chain P, Structure of human DNA polymerase kappa in complex with Lucidin-derived DNA adduct and incoming dAMPNPP
NGGATCGAC
>pdb|5W2C|C Chain C, Structure of human DNA polymerase kappa in complex with Lucidin-derived DNA adduct and incoming dAMPNPP
NGGATCGAC
>pdb|5W2A|P Chain P, Structure of human DNA polymerase kappa in complex with Lucidin-derived DNA adduct and incoming dCMPNPP
NCGGATCAG
>pdb|5W2A|C Chain C, Structure of human DNA polymerase kappa in complex with Lucidin-derived DNA adduct and incoming dCMPNPP
NCGGATCAG
>pdb|5TYZ|T Chain T, DNA Polymerase Mu Product Complex, Mn2+ (960 min)
CGGCATACG
>pdb|5TYY|T Chain T, DNA Polymerase Mu Product Complex, Mn2+ (60 min)
CGGCATACG
>pdb|5TYX|T Chain T, DNA Polymerase Mu Product Complex, Mn2+ (15 min)
CGGCATACG
>pdb|5TYW|T Chain T, DNA Polymerase Mu Reactant Complex, Mn2+ (10 min)
CGGCATACG
>pdb|5TYV|T Chain T, DNA Polymerase Mu Reactant Complex, Mn2+ (7.5 min)
CGGCATACG
>pdb|5TYU|T Chain T, DNA Polymerase Mu Reactant Complex, Mn2+ (4 min)
CGGCATACG
>pdb|5TYG|T Chain T, DNA Polymerase Mu Product Complex, 10 mM Mg2+ (960 min)
CGGCATACG
>pdb|5TYF|T Chain T, DNA Polymerase Mu Product Complex, 10 mM Mg2+ (270 min)
CGGCATACG
>pdb|5TYE|T Chain T, DNA Polymerase Mu Product Complex, 10 mM Mg2+ (60 min)
CGGCATACG
>pdb|5TYD|T Chain T, DNA Polymerase Mu Reactant Complex, 10 mM Mg2+ (45 min)
CGGCATACG
>pdb|5TYC|T Chain T, DNA Polymerase Mu Reactant Complex, 10mM Mg2+ (15 min)
CGGCATACG
>pdb|5TYB|T Chain T, DNA Polymerase Mu Reactant Complex, 10mM Mg2+ (7.5 min)
CGGCATACG
>pdb|5TXZ|T Chain T, DNA Polymerase Mu Reactant Complex, 100mM Mg2+ (15 min)
CGGCATACG
>pdb|5TXX|T Chain T, DNA Polymerase Mu Pre-Catalytic Ground State Ternary Complex, Ca2+
CGGCATACG
>pdb|5XUZ|H Chain H, Crystal structure of Lachnospiraceae bacterium ND2006 Cpf1 in complex with crRNA and target DNA (CCCA PAM)
CGTCCCCCA
>pdb|5XUZ|D Chain D, Crystal structure of Lachnospiraceae bacterium ND2006 Cpf1 in complex with crRNA and target DNA (CCCA PAM)
CGTCCCCCA
>pdb|5XUU|D Chain D, Crystal structure of Lachnospiraceae bacterium ND2006 Cpf1 in complex with crRNA and target DNA (TCCA PAM)
CGTCCTCCA
>pdb|5XUT|D Chain D, Crystal structure of Lachnospiraceae bacterium ND2006 Cpf1 in complex with crRNA and target DNA (TCTA PAM)
CGTCCTCTA
>pdb|5XUS|D Chain D, Crystal structure of Lachnospiraceae bacterium ND2006 Cpf1 in complex with crRNA and target DNA (TTTA PAM)
CGTCCTTTA
>pdb|5O63|F Chain F, Crystal structure of UbaLAI restriction endonuclease B3 domain domain (mutant L24M L53M L95M) with cognate DNA
CGCCAGGGC
>pdb|5O63|E Chain E, Crystal structure of UbaLAI restriction endonuclease B3 domain domain (mutant L24M L53M L95M) with cognate DNA
GCCCTGGCG
>pdb|5O63|D Chain D, Crystal structure of UbaLAI restriction endonuclease B3 domain domain (mutant L24M L53M L95M) with cognate DNA
CGCCAGGGC
>pdb|5O63|C Chain C, Crystal structure of UbaLAI restriction endonuclease B3 domain domain (mutant L24M L53M L95M) with cognate DNA
GCCCTGGCG
>pdb|5UUH|C Chain C, Bacillus cereus DNA glycosylase AlkD bound to a yatakemycin-adenine nucleobase adduct and DNA containing a fluorinated abasic site (9-mer product complex)
TGCTTTGCC
>pdb|5UUH|B Chain B, Bacillus cereus DNA glycosylase AlkD bound to a yatakemycin-adenine nucleobase adduct and DNA containing a fluorinated abasic site (9-mer product complex)
AGGCANAGC
>pdb|5UUG|C Chain C, Bacillus cereus DNA glycosylase AlkD bound to a yatakemycin-adenine nucleobase adduct and DNA containing an abasic site (9-mer product complex)
TGCTTTGCC
>pdb|5UUG|B Chain B, Bacillus cereus DNA glycosylase AlkD bound to a yatakemycin-adenine nucleobase adduct and DNA containing an abasic site (9-mer product complex)
AGGCANAGC
>pdb|5VZI|T Chain T, Post-catalytic complex of human Polymerase Mu (W434H) mutant with incoming dTTP
CGGCATACG
>pdb|5VZH|T Chain T, Post-catalytic complex of human Polymerase Mu (W434H) mutant with incoming UTP
CGGCATACG
>pdb|5VZG|T Chain T, Pre-catalytic ternary complex of human Polymerase Mu (W434H) mutant with incoming nonhydrolyzable UMPNPP
CGGCATACG
>pdb|5VZF|T Chain T, Post-catalytic complex of human Polymerase Mu (W434A) mutant with incoming dTTP
CGGCATACG
>pdb|5VZE|T Chain T, Post-catalytic complex of human Polymerase Mu (W434A) mutant with incoming UTP
CGGCATACG
>pdb|5VZD|T Chain T, Pre-catalytic ternary complex of human Polymerase Mu (W434A) mutant with incoming nonhydrolyzable UMPNPP
CGGCATACG
>pdb|5VZC|T Chain T, Post-catalytic complex of human Polymerase Mu (G433S) mutant with incoming dTTP
CGGCATACG
>pdb|5VZB|T Chain T, Post-catalytic complex of human Polymerase Mu (G433S) mutant with incoming UTP
CGGCATACG
>pdb|5VZA|T Chain T, Pre-catalytic ternary complex of human Polymerase Mu (G433S) mutant with incoming nonhydrolyzable UMPNPP
CGGCATACG
>pdb|5VZ9|T Chain T, Post-catalytic complex of human Polymerase Mu (G433A) mutant with incoming dTTP
CGGCATACG
>pdb|5VZ8|T Chain T, Post-catalytic complex of human Polymerase Mu (G433A) mutant with incoming UTP
CGGCATACG
>pdb|5VZ7|T Chain T, Pre-catalytic ternary complex of human Polymerase Mu (G433A) mutant with incoming nonhydrolyzable UMPNPP
CGGCATACG
>pdb|5TWS|T Chain T, Post-catalytic complex of human Polymerase Mu (H329A) with newly incorporated UTP
CGGCATACG
>pdb|5TWR|T Chain T, Pre-catalytic ternary complex of human Polymerase Mu (H329A) mutant with incoming nonhydrolyzable UMPNPP
CGGCATACG
>pdb|5TWQ|T Chain T, Post-catalytic nicked complex of human Polymerase Mu with newly incorporated UTP
CGGCATACG
>pdb|5TWP|T Chain T, Pre-catalytic ternary complex of human Polymerase Mu with incoming nonhydrolyzable UMPNPP
CGGCATACG
>pdb|5V0D|B Chain B, Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (f2II)
NTACTAGCG
>pdb|5V0B|B Chain B, Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rIX)
NGACTAGCG
>pdb|5V0A|B Chain B, Crystal structure of human exonuclease 1 Exo1 (D225A) in complex with 5' recessed-end DNA (rVIII)
NGACTAGCG
>pdb|5T5C|F Chain F, A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
GCACGTCAG
>pdb|5T5C|E Chain E, A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
NTGACGTGC
>pdb|5T5C|D Chain D, A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
GCACGTCAG
>pdb|5T5C|C Chain C, A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
NTGACGTGC
>pdb|5T4I|F Chain F, A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
GCACGTCAG
>pdb|5T4I|E Chain E, A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
NTGACGTGC
>pdb|5T4I|D Chain D, A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
GCACGTCAG
>pdb|5T4I|C Chain C, A Novel domain in human EXOG converts apoptotic endonuclease to DNA-repair enzyme
NTGACGTGC
>pdb|2NCQ|A Chain A, Structural insights of r(CGG) motif found in Fragile X Syndrome and Fragile-X associated tremor/ataxia syndrome (FXTAS) at 45 degree C
NCGCGGCGG
>pdb|2NCQ|S Chain S, Structural insights of r(CGG) motif found in Fragile X Syndrome and Fragile-X associated tremor/ataxia syndrome (FXTAS) at 45 degree C
NCGCGGCGG
>pdb|5I8Q|C Chain C, S. cerevisiae Prp43 in complex with RNA and ADPNP
TTTTTTTTT
>pdb|5T14|P Chain P, DNA polymerase kappa extending beyond a bulky major benzo[a]pyrene adduct
NGGATCGAC
>pdb|5T14|C Chain C, DNA polymerase kappa extending beyond a bulky major benzo[a]pyrene adduct
NGGATCGAC
>pdb|2N5P|B Chain B, Universal base control oligonucleotide structure
GAGCTCCAT
>pdb|2N5P|A Chain A, Universal base control oligonucleotide structure
ATGGAGCTC
>pdb|2N5O|B Chain B, Universal Base oligonucleotide structure
GAGCTCCAT
>pdb|2N5O|A Chain A, Universal Base oligonucleotide structure
ATGGNGCTC
>pdb|5KT6|T Chain T, Teranry complex of human DNA polymerase iota(1-445) inserting dCMPNPP opposite template G in the presence of Mg2+
NGGGGTCCT
>pdb|5KIH|B Chain B, Structural impact of single ribonucleotides in DNA
NAGGCCTAN
>pdb|5KIH|A Chain A, Structural impact of single ribonucleotides in DNA
NTAGNCCTG
>pdb|5KIF|B Chain B, Structural impact of single ribonucleotides in DNA
NTACCGGAT
>pdb|5KIF|A Chain A, Structural impact of single ribonucleotides in DNA
NTCCNGTAG
>pdb|5KIE|B Chain B, Structural impact of single ribonucleotides in DNA
NAGCTCCAT
>pdb|5KIE|A Chain A, Structural impact of single ribonucleotides in DNA
NTGGANCTC
>pdb|5KIB|B Chain B, Structural impact of single ribonucleotides in DNA
NAGGCCTAN
>pdb|5KIB|A Chain A, Structural impact of single ribonucleotides in DNA
NTAGNCCTG
>pdb|5KI7|B Chain B, Structural impact of single ribonucleotides in DNA
NTACCGGAT
>pdb|5KI7|A Chain A, Structural impact of single ribonucleotides in DNA
NTCCNGTAG
>pdb|5KI5|B Chain B, Structural impact of single ribonucleotides in DNA
NAGGCCTAN
>pdb|5KI5|A Chain A, Structural impact of single ribonucleotides in DNA
NTAGGCCTG
>pdb|5KI4|B Chain B, Structural impact of single ribonucleotides in DNA
NTACCGGAT
>pdb|5KI4|A Chain A, Structural impact of single ribonucleotides in DNA
NTCCGGTAG
>pdb|5KGV|B Chain B, Structural impact of single ribonucleotides in DNA
NAGCTCCAT
>pdb|5KGV|A Chain A, Structural impact of single ribonucleotides in DNA
NTGGANCTC
>pdb|5KEK|C Chain C, Structure Determination of a Self-Assembling DNA Crystal
TCTGAGTGT
>pdb|5DQI|P Chain P, Crystal Structure of Human DNA Polymerase Eta Extending an O4-Ethylthymidine : dA Pair By Inserting dCTP Opposite dG
AGCGTCAAC
>pdb|5KG6|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Ca2+ for 60s
AGCGTCATA
>pdb|5KG0|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 22 degree
AGCGTCATA
>pdb|5KFQ|P Chain P, Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 10 mM Mn2+ for 600s
AGCGTCATN
>pdb|5KFI|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 120s
AGCGTCATA
>pdb|4YFT|B Chain B, HUab-20bp
NCCCCACAC
>pdb|4YEW|B Chain B, HUab-19bp
NCCCCACAC
>pdb|5L9X|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 60s
AGCGTCATA
>pdb|5KG7|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Zn2+ for 60s
AGCGTCATA
>pdb|5KG5|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Cd2+ for 60s
AGCGTCATA
>pdb|5KG4|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Mg2+ for 60s
AGCGTCATA
>pdb|5KG3|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Mn2+ for 60s
AGCGTCATA
>pdb|5KG2|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 37 degree
AGCGTCATA
>pdb|5KG1|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 30 degree
AGCGTCATA
>pdb|5KFZ|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 14 degree
AGCGTCATA
>pdb|5KFX|P Chain P, Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 300s
AGCGTCATA
>pdb|5KFW|P Chain P, Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 200s
AGCGTCATA
>pdb|5KFR|P Chain P, Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 20 mM Mn2+ for 600s
AGCGTCATN
>pdb|5KFP|P Chain P, Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 20 mM Mg2+ for 600s
AGCGTCATN
>pdb|5KFL|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 600s
AGCGTCATA
>pdb|5KFK|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 300s
AGCGTCATA
>pdb|5KFJ|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 180s
AGCGTCATA
>pdb|5KFH|P Chain P, Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 90s
AGCGTCATA
>pdb|5F56|C Chain C, Structure of RecJ complexed with DNA and SSB-ct
CTGATGGCA
>pdb|4REB|D Chain D, Structural Insights into 5' Flap DNA Unwinding and Incision by the Human FAN1 Dimer
NTGGCGAGC
>pdb|5A0M|L Chain L, THE CRYSTAL STRUCTURE OF I-SCEI IN COMPLEX WITH ITS TARGET DNA IN THE PRESENCE OF MN
NCCTAGCGT
>pdb|5A0M|I Chain I, THE CRYSTAL STRUCTURE OF I-SCEI IN COMPLEX WITH ITS TARGET DNA IN THE PRESENCE OF MN
NCCTAGCGT
>pdb|5INQ|D Chain D, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Ca2+ complex
NCGAATTCG
>pdb|5INQ|C Chain C, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Ca2+ complex
NCGAATTCG
>pdb|5INP|D Chain D, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Mn2+ complex
NCGAATTCG
>pdb|5INP|C Chain C, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Mn2+ complex
NCGAATTCG
>pdb|5INO|C Chain C, Human Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex
NCGAATTCG
>pdb|5INO|D Chain D, Human Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex
NCGAATTCG
>pdb|5INL|D Chain D, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex with deoxyadenosine
NCGAATTCG
>pdb|5INL|C Chain C, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex with deoxyadenosine
NCGAATTCG
>pdb|5INK|D Chain D, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-abasic/THF-Mg2+ complex
NCGAATTCG
>pdb|5INK|C Chain C, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-abasic/THF-Mg2+ complex
NCGAATTCG
>pdb|5EV4|B Chain B, Structure IV of Intact U2AF65 Recognizing the 3' Splice Site Signal
NTTNTTNNC
>pdb|5EV1|B Chain B, Structure I of Intact U2AF65 Recognizing a 3' Splice Site Signal
TTTNNNNTT
>pdb|4U7C|P Chain P, Structure of DNA polymerase kappa in complex with benzopyrene adducted DNA
NCGGATCAG
>pdb|4U7C|C Chain C, Structure of DNA polymerase kappa in complex with benzopyrene adducted DNA
NCGGATCAG
>pdb|4U6P|P Chain P, Structural mechanism of error-free bypass of major benzo[a]pyrene adduct by human polymerase kappa
NCGGATCAC
>pdb|4U6P|C Chain C, Structural mechanism of error-free bypass of major benzo[a]pyrene adduct by human polymerase kappa
NCGGATCAC
>pdb|4XW1|C Chain C, Crystal structure of (GCCU(G-LNA)CCUG)2 duplex
GCCTNCCTG
>pdb|3JAA|P Chain P, HUMAN DNA POLYMERASE ETA in COMPLEX WITH NORMAL DNA AND INCO NUCLEOTIDE (NRM)
TAGCGTCAT
>pdb|5A8L|R Chain R, Human eRF1 and the hCMV nascent peptide in the translation termination complex
NCTTAAAAA
>pdb|5FJ8|T Chain T, Cryo-EM structure of yeast RNA polymerase III elongation complex at 3. 9 A
NGACCAGGC
>pdb|5CLC|C Chain C, Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog (9-mer B)
TGGGTGGCT
>pdb|5CLC|B Chain B, Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog (9-mer B)
AAGCCNCCC
>pdb|5CLB|C Chain C, Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog (9-mer A)
TGGTTTGCT
>pdb|5CLB|B Chain B, Alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-methyladenine analog (9-mer A)
AAGCANACC
>pdb|5C4A|R Chain R, Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
NCGAGAGGA
>pdb|5C3E|R Chain R, Crystal structure of a transcribing RNA Polymerase II complex reveals a complete transcription bubble
NCGAGAGGA
>pdb|4Y7N|R Chain R, The Structure Insight into 5-Carboxycytosine Recognition by RNA Polymerase II during Transcription Elongation.
ATGGAGAGG
>pdb|4Y52|R Chain R, Crystal structure of 5-Carboxycytosine Recognition by RNA Polymerase II during Transcription Elongation.
ATGGAGAGG
>pdb|4RHD|H Chain H, DNA Duplex with Novel ZP Base Pair
GNGTNACAC
>pdb|4RHD|G Chain G, DNA Duplex with Novel ZP Base Pair
GNGTNACAC
>pdb|4RHD|F Chain F, DNA Duplex with Novel ZP Base Pair
GNGTNACAC
>pdb|4RHD|E Chain E, DNA Duplex with Novel ZP Base Pair
GNGTNACAC
>pdb|4RHD|D Chain D, DNA Duplex with Novel ZP Base Pair
GNGTNACAC
>pdb|4RHD|C Chain C, DNA Duplex with Novel ZP Base Pair
GNGTNACAC
>pdb|4RHD|B Chain B, DNA Duplex with Novel ZP Base Pair
GNGTNACAC
>pdb|4RHD|A Chain A, DNA Duplex with Novel ZP Base Pair
GNGTNACAC
>pdb|2MXK|A Chain A, Structural features of a 3' splice site influenza A: 19-nt duplex
GCAGGCCCA
>pdb|4XVM|T Chain T, Binary complex of human polymerase nu and DNA with the finger domain closed and thumb domain rotated out
NTAGCGTCA
>pdb|4X67|R Chain R, Crystal structure of elongating yeast RNA polymerase II stalled at oxidative Cyclopurine DNA lesions.
NTCGAGATA
>pdb|4X6A|R Chain R, Crystal structure of yeast RNA polymerase II encountering oxidative Cyclopurine DNA lesions
NTCGAGAGT
>pdb|2MS5|A Chain A, Structural dynamics of double-helical RNA having CAG motif
NCGCAGCGG
>pdb|2MS5|S Chain S, Structural dynamics of double-helical RNA having CAG motif
NCGCAGCGG
>pdb|4WT8|2 Chain 2, Crystal Structure of bactobolin A bound to 70S ribosome-tRNA complex
NAATGTTCA
>pdb|4TYY|B Chain B, DEAD-box helicase Mss116 bound to ssRNA and CDP-BeF
NAAAAAAAA
>pdb|4RIA|I Chain I, FAN1 Nuclease bound to 5' phosphorylated nicked DNA
NGACTCCTC
>pdb|4RIA|K Chain K, FAN1 Nuclease bound to 5' phosphorylated nicked DNA
NGACTCCTC
>pdb|4CR1|X Chain X, Thermus Thermophilus Ribosome
AAATGTTCA
>pdb|2MFH|D Chain D, Csr/Rsm protein-RNA recognition - A molecular affinity ruler: RsmZ(36-44)/RsmE(dimer) 2:1 complex
TCAGGACAT
>pdb|2MFH|B Chain B, Csr/Rsm protein-RNA recognition - A molecular affinity ruler: RsmZ(36-44)/RsmE(dimer) 2:1 complex
TCAGGACAT
>pdb|4M0A|T Chain T, Human DNA Polymerase Mu post-catalytic complex
CGGCATACG
>pdb|4M04|T Chain T, Human DNA Polymerase Mu ternary complex
CGGCATACG
>pdb|4LZG|T Chain T, Binary complex of human DNA Polymerase Mu with DNA
CGGCATACG
>pdb|4KPY|N Chain N, DNA binding protein and DNA complex structure
TATACAACC
>pdb|4KPY|M Chain M, DNA binding protein and DNA complex structure
TATACAACC
>pdb|4IUF|B Chain B, Crystal Structure of Human TDP-43 RRM1 Domain in Complex with a Single-stranded DNA
GTTGNGCGT
>pdb|4NCB|H Chain H, Structure of Thermus thermophilus Argonaute bound to guide DNA and 19-mer target DNA with Mg2+
TATACAACC
>pdb|4NCB|P Chain P, Structure of Thermus thermophilus Argonaute bound to guide DNA and 19-mer target DNA with Mg2+
TATACAACC
>pdb|4F4K|E Chain E, DNA Polymerase I Large Fragment Complex 6
CCTGACTCN
>pdb|4F4K|B Chain B, DNA Polymerase I Large Fragment Complex 6
CCTGACTCN
>pdb|4F3O|E Chain E, DNA Polymerase I Large Fragment Complex 5
CCTGACTCN
>pdb|4F3O|B Chain B, DNA Polymerase I Large Fragment Complex 5
CCTGACTCN
>pdb|4F2S|E Chain E, DNA Polymerase I Large Fragment complex 4
CCTGACTCN
>pdb|4F2S|B Chain B, DNA Polymerase I Large Fragment complex 4
CCTGACTCN
>pdb|4F2R|E Chain E, DNA Polymerase I Large Fragment complex 3
CCTGACTCN
>pdb|4F2R|B Chain B, DNA Polymerase I Large Fragment complex 3
CCTGACTCN
>pdb|4EZ9|E Chain E, Bacillus DNA Polymerase I Large Fragment Complex 2
CCTGACTCN
>pdb|4EZ9|B Chain B, Bacillus DNA Polymerase I Large Fragment Complex 2
CCTGACTCN
>pdb|4EZ6|E Chain E, Bacillus DNA Polymerase I Large Fragment Complex 1
CCTGACTCN
>pdb|4EZ6|B Chain B, Bacillus DNA Polymerase I Large Fragment Complex 1
CCTGACTCN
>pdb|4F8R|E Chain E, Bacillus DNA Polymerase I Large Fragment complex 7
CCTGACTCN
>pdb|4F8R|B Chain B, Bacillus DNA Polymerase I Large Fragment complex 7
CCTGACTCN
>pdb|4HIV|B Chain B, Structure of actinomycin D d(ATGCGGCAT) complex
ATGCGGCAT
>pdb|4HIV|A Chain A, Structure of actinomycin D d(ATGCGGCAT) complex
ATGCGGCAT
>pdb|4J9S|P Chain P, Human DNA polymerase eta-DNA translocated binary complex: with TA base pair
TACGTCATA
>pdb|4J9R|P Chain P, Human DNA polymerase eta-DNA translocated binary complex with TG mispair
NACGTCATG
>pdb|4J9O|P Chain P, Human DNA polymerase eta-DNA ternary complex: primer extension after a T:G mispair
TACGTCATG
>pdb|4J9N|P Chain P, Human DNA polymerase eta-DNA ternary complex: misincorporation G opposite T after a G at the primer 3' end (GA/G)
TAGCGTCAG
>pdb|4J9M|P Chain P, Human DNA polymerase eta-DNA ternary complex: misincorporation G opposite T after an A at the primer 3' end (AA/G)
TACGTCATA
>pdb|4J9L|P Chain P, Human DNA polymerase eta-DNA ternary complex: misincorporation G opposite T after a C at the primer 3' end (CA/G)
TACGTCATC
>pdb|4J9K|P Chain P, Human DNA polymerase eta-DNA ternary complex: misincorporation G opposite T after a T at the primer 3' end (TA/G)
TAGCGTCAT
>pdb|2LVY|B Chain B, Solution Structure of a RNA Duplex Containing a 2'-O-Pivaloyloxymethyl Modification
GCGTAGCGN
>pdb|2LVY|A Chain A, Solution Structure of a RNA Duplex Containing a 2'-O-Pivaloyloxymethyl Modification
CGCNACGCN
>pdb|4DSI|C Chain C, Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus with duplex DNA, Se-dGTP and Calcium
CCTGACTCG
>pdb|4HJ8|B Chain B, Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTTACGCT)
GGTTACGCT
>pdb|4HJ7|B Chain B, Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTTAGGGT)
GGTTAGGGT
>pdb|4HJ5|B Chain B, Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTTTCGGT)
GGTTTCGGT
>pdb|4HIO|B Chain B, Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTAACGGT)
GGTAACGGT
>pdb|4HIM|B Chain B, Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGATACGGT)
GGATACGGT
>pdb|4HIK|B Chain B, Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GGTTACGGT)
GGTTACGGT
>pdb|4HID|B Chain B, Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (GCTTACGGT)
GCTTACGGT
>pdb|4DR6|W Chain W, Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with codon, near-cognate transfer RNA anticodon stem-loop mismatched at the first codon position and streptomycin bound
NTGAGGNGG
>pdb|4GZ1|D Chain D, Mus Musculus Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex at 1.5 Angstroms resolution
NCGAATTCG
>pdb|4GZ1|C Chain C, Mus Musculus Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex at 1.5 Angstroms resolution
NCGAATTCG
>pdb|4GZ0|J Chain J, Mus Musculus Tdp2-DNA Substrate Analog (5'-6-aminohexanol) Complex
NCGAATTCG
>pdb|4GZ0|H Chain H, Mus Musculus Tdp2-DNA Substrate Analog (5'-6-aminohexanol) Complex
NCGAATTCG
>pdb|4GZ0|L Chain L, Mus Musculus Tdp2-DNA Substrate Analog (5'-6-aminohexanol) Complex
NCGAATTCG
>pdb|4GZ0|F Chain F, Mus Musculus Tdp2-DNA Substrate Analog (5'-6-aminohexanol) Complex
NCGAATTCG
>pdb|4GZ0|D Chain D, Mus Musculus Tdp2-DNA Substrate Analog (5'-6-aminohexanol) Complex
NCGAATTCG
>pdb|4GZ0|C Chain C, Mus Musculus Tdp2-DNA Substrate Analog (5'-6-aminohexanol) Complex
NCGAATTCG
>pdb|4B3G|H Chain H, crystal structure of Ighmbp2 helicase in complex with RNA
NAAAAAAAA
>pdb|4B3G|G Chain G, crystal structure of Ighmbp2 helicase in complex with RNA
NAAAAAAAA
>pdb|4ED8|P Chain P, Human DNA polymerase eta - DNA ternary complex: Reaction in the TG crystal at pH 7.0, Normal translocation
TGCGTCATA
>pdb|4ED6|P Chain P, Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 6.7 for 15 hr, Sideway translocation
AGCGTCATA
>pdb|4ECX|P Chain P, Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 300 sec
AGCGTCATA
>pdb|4ECW|P Chain P, Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 250 sec
AGCGTCATA
>pdb|4ECV|P Chain P, Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 230 sec
AGCGTCATA
>pdb|4ECU|P Chain P, Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 200 sec
AGCGTCATA
>pdb|4ECT|P Chain P, Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 140 sec
AGCGTCATA
>pdb|4ECS|P Chain P, Human DNA polymerase eta - DNA ternary complex: Reaction in the AT crystal at pH 7.0 for 80 sec
AGCGTCATA
>pdb|4ECQ|P Chain P, Human DNA polymerase eta- DNA ternary complex: AT crystal at pH6.8(K+ MES) with 1 Ca2+ ion
AGCGTCATA
>pdb|4F1N|F Chain F, Crystal structure of Kluyveromyces polysporus Argonaute with a guide RNA
NAAAAAAAA
>pdb|4F1N|E Chain E, Crystal structure of Kluyveromyces polysporus Argonaute with a guide RNA
NAAAAAAAA
>pdb|4EBE|T Chain T, Conformationally Restrained North-methanocarba-2'-deoxyadenosine Corrects the Error-Prone Nature of Human DNA Polymerase Iota
NTGGGTCCT
>pdb|4EBD|T Chain T, Conformationally Restrained North-methanocarba-2'-deoxyadenosine Corrects the Error-Prone Nature of Human DNA Polymerase Iota
NTGGGTCCT
>pdb|4EBC|T Chain T, Conformationally Restrained North-methanocarba-2'-deoxyadenosine Corrects the Error-Prone Nature of Human DNA Polymerase Iota
NTGGGTCCT
>pdb|4E0D|B Chain B, Binary complex of Bacillus DNA Polymerase I Large Fragment E658A and duplex DNA
CCTGACTCN
>pdb|4DSF|E Chain E, Ternary complex of Bacillus DNA Polymerase I Large Fragment F710Y, DNA duplex, and rCTP (paired with dG of template) in presence of Mn2+
CCTGACTCN
>pdb|4DSF|B Chain B, Ternary complex of Bacillus DNA Polymerase I Large Fragment F710Y, DNA duplex, and rCTP (paired with dG of template) in presence of Mn2+
CCTGACTCN
>pdb|4DSE|E Chain E, Ternary complex of Bacillus DNA Polymerase I Large Fragment F710Y, DNA duplex, and rCTP (paired with dG of template) in presence of Mg2+
CCTGACTCN
>pdb|4DSE|B Chain B, Ternary complex of Bacillus DNA Polymerase I Large Fragment F710Y, DNA duplex, and rCTP (paired with dG of template) in presence of Mg2+
CCTGACTCN
>pdb|4DS5|E Chain E, Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and rCTP in presence of Mg2+
CCTGACTCC
>pdb|4DS5|B Chain B, Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and rCTP in presence of Mg2+
CCTGACTCC
>pdb|4DS4|E Chain E, Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and rCTP in presence of Mn2+
CCTGACTCN
>pdb|4DS4|B Chain B, Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and rCTP in presence of Mn2+
CCTGACTCN
>pdb|4DQR|E Chain E, Ternary complex of Bacillus DNA Polymerase I Large Fragment E658A, DNA duplex, and rCTP (paired with dG of template) in presence of Mn2+
CCTGACTCN
>pdb|4DQR|B Chain B, Ternary complex of Bacillus DNA Polymerase I Large Fragment E658A, DNA duplex, and rCTP (paired with dG of template) in presence of Mn2+
CCTGACTCN
>pdb|4DQQ|E Chain E, Ternary complex of Bacillus DNA Polymerase I Large Fragment E658A, DNA duplex, and rCTP (paired with dG of template) in presence of Mg2+
CCTGACTCN
>pdb|4DQQ|B Chain B, Ternary complex of Bacillus DNA Polymerase I Large Fragment E658A, DNA duplex, and rCTP (paired with dG of template) in presence of Mg2+
CCTGACTCN
>pdb|4DQP|E Chain E, Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and ddCTP (paired with dG of template)
CCTGACTCN
>pdb|4DQP|B Chain B, Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and ddCTP (paired with dG of template)
CCTGACTCN
>pdb|4DQI|E Chain E, Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and dCTP (paired with dG of template)
CCTGACTCN
>pdb|4DQI|B Chain B, Ternary complex of Bacillus DNA Polymerase I Large Fragment, DNA duplex, and dCTP (paired with dG of template)
CCTGACTCN
>pdb|4EEY|P Chain P, Crystal structure of human DNA polymerase eta in ternary complex with a cisplatin DNA adduct
TGGAGGAGA
>pdb|4DL7|P Chain P, Human DNA polymerase eta fails to extend primer 2 nucleotide after cisplatin crosslink (Pt-GG4).
TAGTGACCG
>pdb|4DL6|P Chain P, Human DNA polymerase eta extending primer immediately after cisplatin crosslink (Pt-GG3).
TAGTGTGCC
>pdb|4DL5|P Chain P, Human DNA polymerase eta inserting dCMPNPP opposite the 5'G of cisplatin crosslinked Gs (Pt-GG2).
NAGTGTGAC
>pdb|4DL4|P Chain P, Human DNA polymerase eta inserting dCMPNPP opposite the 3'G of cisplatin crosslinked Gs (Pt-GG1).
TAGTGTGAG
>pdb|4DL3|P Chain P, Human DNA polymerase eta inserting dCMPNPP opposite GG template (GG0b).
TAGTGTGAC
>pdb|4DL2|P Chain P, Human DNA polymerase eta inserting dCMPNPP opposite CG template (GG0a)
TAGTGTGAG
>pdb|4DZS|D Chain D, Crystal structure of yeast Puf4p RNA binding domain in complex with HO-4BE mutant RNA
TGTATCATA
>pdb|4DZS|C Chain C, Crystal structure of yeast Puf4p RNA binding domain in complex with HO-4BE mutant RNA
TGTATCATA
>pdb|3TQ1|P Chain P, Human DNA Polymerase eta in binary complex with DNA
TAGCGTCAT
>pdb|3AVX|G Chain G, Structure of viral RNA polymerase complex 5
GGGTCCATC
>pdb|3TI0|E Chain E, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddGTP-dC in Closed Conformation
CCTGACTCN
>pdb|3TI0|B Chain B, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddGTP-dC in Closed Conformation
CCTGACTCN
>pdb|3THV|E Chain E, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddATP-dT in Closed Conformation
CCTGACTCN
>pdb|3THV|B Chain B, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddATP-dT in Closed Conformation
CCTGACTCN
>pdb|3PX6|E Chain E, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddCTP-dA Mismatch (tautomer) in Closed Conformation
CCTGACTCN
>pdb|3PX6|B Chain B, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddCTP-dA Mismatch (tautomer) in Closed Conformation
CCTGACTCN
>pdb|3PX4|E Chain E, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddCTP-dA Mismatch (wobble) in Ajar Conformation
CCTGACTCN
>pdb|3PX4|B Chain B, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddCTP-dA Mismatch (wobble) in Ajar Conformation
CCTGACTCN
>pdb|3PX0|E Chain E, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and dCTP-dA Mismatch (tautomer) in Closed Conformation
CCTGACTCN
>pdb|3PX0|B Chain B, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and dCTP-dA Mismatch (tautomer) in Closed Conformation
CCTGACTCN
>pdb|3PV8|E Chain E, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddTTP-dA in Closed Conformation
CCTGACTCN
>pdb|3PV8|B Chain B, Crystal Structure of Bacillus DNA Polymerase I Large Fragment Bound to DNA and ddTTP-dA in Closed Conformation
CCTGACTCN
>pdb|2LAR|B Chain B, DNA / RNA Hybrid containing a central stereo specific Rp borano phosphate linkage
GAGCACCAT
>pdb|2LAR|A Chain A, DNA / RNA Hybrid containing a central stereo specific Rp borano phosphate linkage
ATGGTNCTC
>pdb|3S17|R Chain R, RNA Polymerase II Initiation Complex with a 9-nt RNA
ATCGAGAGG
>pdb|3SI8|P Chain P, Human DNA polymerase eta - DNA ternary complex with the 5'T of a CPD in the active site (TT2)
TGCGTCATA
>pdb|2YH1|B Chain B, Model of human U2AF65 tandem RRM1 and RRM2 domains with eight-site uridine binding
TTTTTTTTT
>pdb|2LB4|B Chain B, DNA / RNA Hybrid containing a central stereo specific Sp borano phosphate linkage
GAGCACCAT
>pdb|2LB4|A Chain A, DNA / RNA Hybrid containing a central stereo specific Sp borano phosphate linkage
ATGGTNCTC
>pdb|3QRP|B Chain B, Structure of Thermus Thermophilus Cse3 bound to an RNA representing a product mimic complex
GTCCCCACN
>pdb|2XZL|B Chain B, Upf1-RNA complex
NTTTTTTTT
>pdb|3PKM|R Chain R, Crystal structure of Cas6 with its substrate RNA
NTACAATAA
>pdb|3PGW|M Chain M, Crystal structure of human U1 snRNP
AGGTAAGTA
>pdb|3PGW|D Chain D, Crystal structure of human U1 snRNP
AGGTAAGTA
>pdb|3MQK|E Chain E, Cbf5-Nop10-Gar1 complex binding with 17mer RNA containing ACA trinucleotide
NGATCCACA
>pdb|3P22|H Chain H, Crystal structure of the ENE, a viral RNA stability element, in complex with A9 RNA
AAAAAAAAA
>pdb|3P22|F Chain F, Crystal structure of the ENE, a viral RNA stability element, in complex with A9 RNA
AAAAAAAAA
>pdb|3P22|D Chain D, Crystal structure of the ENE, a viral RNA stability element, in complex with A9 RNA
AAAAAAAAA
>pdb|3P22|B Chain B, Crystal structure of the ENE, a viral RNA stability element, in complex with A9 RNA
AAAAAAAAA
>pdb|2XGQ|Q Chain Q, Structure of yeast DNA polymerase eta in complex with C8-N-acetyl-2- aminoanthracene containing DNA
GTGGATGAG
>pdb|2XGQ|P Chain P, Structure of yeast DNA polymerase eta in complex with C8-N-acetyl-2- aminoanthracene containing DNA
GTGGATGAG
>pdb|2XGP|Q Chain Q, Yeast DNA polymerase eta in complex with C8-2-acetylaminofluorene containing DNA
GTGGATGAG
>pdb|2XGP|P Chain P, Yeast DNA polymerase eta in complex with C8-2-acetylaminofluorene containing DNA
GTGGATGAG
>pdb|3OQG|D Chain D, Restriction endonuclease HPY188I in complex with substrate DNA
GTTCAGATC
>pdb|3OQG|C Chain C, Restriction endonuclease HPY188I in complex with substrate DNA
GATCTGAAC
>pdb|3NKB|A Chain A, A 1.9A crystal structure of the HDV ribozyme precleavage suggests both Lewis acid and general acid mechanisms contribute to phosphodiester cleavage
NNNCTTGCA
>pdb|3N1L|B Chain B, Crystal Structure of a StWhy2-rcERE32 complex
NAAAAAAAA
>pdb|3N1K|B Chain B, Crystal Structure of a StWhy2-cERE32 complex
NAAAAAAAA
>pdb|3N1J|B Chain B, Crystal structure of a StWhy2-dT32 complex
NTTTTTTTT
>pdb|3N1I|B Chain B, Crystal Structure of a StWhy2-ERE32 complex
NTTTTTTTT
>pdb|3IMB|L Chain L, Alternative binding mode of restriction endonuclease BcnI to cognate DNA
CGCCCGGAC
>pdb|3IMB|K Chain K, Alternative binding mode of restriction endonuclease BcnI to cognate DNA
GTCCGGGCG
>pdb|3IMB|J Chain J, Alternative binding mode of restriction endonuclease BcnI to cognate DNA
CGCCCGGAC
>pdb|3IMB|I Chain I, Alternative binding mode of restriction endonuclease BcnI to cognate DNA
GTCCGGGCG
>pdb|3IMB|H Chain H, Alternative binding mode of restriction endonuclease BcnI to cognate DNA
CGCCCGGAC
>pdb|3IMB|G Chain G, Alternative binding mode of restriction endonuclease BcnI to cognate DNA
GTCCGGGCG
>pdb|3IMB|F Chain F, Alternative binding mode of restriction endonuclease BcnI to cognate DNA
CGCCCGGAC
>pdb|3IMB|E Chain E, Alternative binding mode of restriction endonuclease BcnI to cognate DNA
GTCCGGGCG
>pdb|2XHB|E Chain E, Crystal structure of DNA polymerase from Thermococcus gorgonarius in complex with hypoxanthine-containing DNA
NAAAAAAAA
>pdb|3L2P|C Chain C, Human DNA Ligase III Recognizes DNA Ends by Dynamic Switching Between Two DNA Bound States
NTCGGACTG
>pdb|3MR6|P Chain P, Human DNA polymerase eta - DNA ternary complex with a CPD 2bp upstream of the active site (TT4)
TCTCGTAAT
>pdb|3MR5|P Chain P, Human DNA polymerase eta - DNA ternary complex with a CPD 1bp upstream of the active site (TT3)
ACGTCATAA
>pdb|3MR3|P Chain P, Human DNA polymerase eta - DNA ternary complex with the 3'T of a CPD in the active site (TT1)
CAGCGTCAT
>pdb|3MR2|P Chain P, Human DNA polymerase eta in complex with normal DNA and incoming nucleotide (Nrm)
TAGCGTCAT
>pdb|3GIB|H Chain H, Crystal Structure of the Complex of the E. coli Hfq with Poly(A)
NAAAAAAAA
>pdb|3HR3|A Chain A, Interplay of Structure, Hydration and Thermal Stability in Formacetal Modified Oligonucleotides: RNA May Tolerate Hydrophobic Modifications Better than DNA
GCGNNACGC
>pdb|3H4D|T Chain T, Ternary complex of human DNA polymerase iota with template U/T and incoming dGTP
TNGGGTCCT
>pdb|3H4B|T Chain T, Ternary complex of human DNA polymerase iota with template U/T and incoming dATP
TNGGGTCCT
>pdb|3H40|T Chain T, Binary complex of human DNA polymerase iota with template U/T
TNGGGTCCT
>pdb|3H15|B Chain B, Crystal structure of replication initiation factor MCM10-ID bound to ssDNA
CCCCCCCCC
>pdb|3GV8|T Chain T, Human DNA polymerase iota in complex with T template DNA and incoming dGTP
ATGGGTCCT
>pdb|3GV7|T Chain T, Human DNA polymerase iota in complex with T template DNA and incoming dTTP
NTGGGTCCT
>pdb|3GV5|E Chain E, Human DNA polymerase iota in complex with T template DNA and incoming ddADP
GTGGATGAG
>pdb|3GV5|P Chain P, Human DNA polymerase iota in complex with T template DNA and incoming ddADP
GTGGATGAG
>pdb|2W35|F Chain F, Structures of endonuclease V with DNA reveal initiation of deaminated adenine repair
ATGCGACNG
>pdb|2W35|C Chain C, Structures of endonuclease V with DNA reveal initiation of deaminated adenine repair
ATGCGNCNG
>pdb|3EQ4|A Chain A, Model of tRNA(Leu)-EF-Tu in the ribosomal pre-accommodated state revealed by cryo-EM
NGCGGTAAT
>pdb|3EQ3|A Chain A, Model of tRNA(Trp)-EF-Tu in the ribosomal pre-accommodated state revealed by cryo-EM
NGCGGTAAT
>pdb|3EP2|A Chain A, Model of Phe-tRNA(Phe) in the ribosomal pre-accommodated state revealed by cryo-EM
NGCGGTAAT
>pdb|3C0W|D Chain D, I-SceI in complex with a bottom nicked DNA substrate
NCCTAGCGT
>pdb|3BSB|C Chain C, Crystal Structure of Human Pumilio1 in Complex with CyclinB reverse RNA
TTTAATGTT
>pdb|3BX2|D Chain D, Puf4 RNA binding domain bound to HO endonuclease RNA 3' UTR recognition sequence
TGTATATTA
>pdb|3BX2|C Chain C, Puf4 RNA binding domain bound to HO endonuclease RNA 3' UTR recognition sequence
TGTATATTA
>pdb|2R8K|P Chain P, Structure of the Eukaryotic DNA Polymerase eta in complex with 1,2-d(GpG)-cisplatin containing DNA
GTGGTGAGC
>pdb|2R8K|Q Chain Q, Structure of the Eukaryotic DNA Polymerase eta in complex with 1,2-d(GpG)-cisplatin containing DNA
GTGGTGAGC
>pdb|2R8J|P Chain P, Structure of the Eukaryotic DNA Polymerase eta in complex with 1,2-d(GpG)-cisplatin containing DNA
GTGGATGAG
>pdb|2R8J|Q Chain Q, Structure of the Eukaryotic DNA Polymerase eta in complex with 1,2-d(GpG)-cisplatin containing DNA
GTGGATGAG
>pdb|2OYT|B Chain B, Crystal Structure of UNG2/DNA(TM)
TGTNATCTT
>pdb|2OXM|B Chain B, Crystal structure of a UNG2/modified DNA complex that represent a stabilized short-lived extrahelical state in ezymatic DNA base flipping
TGTTATCTT
>pdb|485D|B Chain B, A Sulfate Pocket Formed By Three Gou Pairs In The Structure Of A Nonameric Rna
NGTGATCGN
>pdb|485D|A Chain A, A Sulfate Pocket Formed By Three Gou Pairs In The Structure Of A Nonameric Rna
NGTGATCGN
>pdb|1SI2|B Chain B, Crystal structure of the PAZ domain of human eIF2c1 in complex with a 9-mer siRNA-like duplex of deoxynucleotide overhang
CGTGACTNN
>pdb|1KSB|A Chain A, Relationship of Solution and Protein-Bound Structures of DNA Duplexes with the Major Intrastrand Cross-Link Lesions Formed on Cisplatin Binding to DNA
CTCCGGCCT
>pdb|2DQQ|B Chain B, Crystal Structure of d(CXCTXCTTC):r(gaagaagag) Where X is 5-(N-aminohexyl)carbamoyl-2'-O-methyluridine
GAAGAAGAG
>pdb|2DQQ|A Chain A, Crystal Structure of d(CXCTXCTTC):r(gaagaagag) Where X is 5-(N-aminohexyl)carbamoyl-2'-O-methyluridine
CNCTNCTTC
>pdb|2DQP|B Chain B, Structural analyses of DNA:DNA and RNA:DNA duplexes containing 5-(N-aminohexyl)carbamoyl modified uridines
GAAGAAGAG
>pdb|2DQP|A Chain A, Structural analyses of DNA:DNA and RNA:DNA duplexes containing 5-(N-aminohexyl)carbamoyl modified uridines
CNCTNCTTC
>pdb|2DQO|B Chain B, Crystal Structure of d(CXCTXCTTC):r(gaagaagag) Where X is 5-(N-aminohexyl)carbamoyl-2'-O-methyluridine
GAAGAAGAG
>pdb|2DQO|A Chain A, Crystal Structure of d(CXCTXCTTC):r(gaagaagag) Where X is 5-(N-aminohexyl)carbamoyl-2'-O-methyluridine
CNCTNCTTC
>pdb|2G91|B Chain B, Crystal Structure Analysis of the an RNA nonamer r(GGUGCGC)d(BrC)r(C)
GGTGCGCNC
>pdb|2G91|A Chain A, Crystal Structure Analysis of the an RNA nonamer r(GGUGCGC)d(BrC)r(C)
GGTGCGCNC
>pdb|2HVI|E Chain E, ddCTP:G pair in the polymerase active site (0 position)
CCTGACTCN
>pdb|2HVI|B Chain B, ddCTP:G pair in the polymerase active site (0 position)
CCTGACTCN
>pdb|2HVH|E Chain E, ddCTP:O6MeG pair in the polymerase active site (0 position)
CCTGACTCN
>pdb|2HVH|B Chain B, ddCTP:O6MeG pair in the polymerase active site (0 position)
CCTGACTCN
>pdb|2HHX|B Chain B, O6-methyl-guanine in the polymerase template preinsertion site
CCTGACTCG
>pdb|2HHW|B Chain B, ddTTP:O6-methyl-guanine pair in the polymerase active site, in the closed conformation
CCTGACTCN
>pdb|2HHW|E Chain E, ddTTP:O6-methyl-guanine pair in the polymerase active site, in the closed conformation
CCTGACTCN
>pdb|2E2J|R Chain R, RNA polymerase II elongation complex in 5 mM Mg+2 with GMPCPP
NTCGAGAGG
>pdb|2GUN|B Chain B, RNA-Binding Affinities and Crystal Structure of Oligonucleotides containing Five-Atom Amide-Based Backbone Structures
GAAGAAGAA
>pdb|2DPJ|T Chain T, structure of hPoli with DNA and dTTP
TNGGGTCCT
>pdb|2DPI|T Chain T, Ternary complex of hPoli with DNA and dCTP
TNGGGTCCT
>pdb|1ZH5|D Chain D, Structural basis for recognition of UUUOH 3'-terminii of nascent RNA pol III transcripts by La autoantigen
TGCTGTTTT
>pdb|1ZH5|C Chain C, Structural basis for recognition of UUUOH 3'-terminii of nascent RNA pol III transcripts by La autoantigen
TGCTGTTTT
>pdb|1YTY|D Chain D, Structural basis for recognition of UUUOH 3'-terminii of nascent RNA pol III transcripts by La autoantigen
TGCTGTTTT
>pdb|1YTY|C Chain C, Structural basis for recognition of UUUOH 3'-terminii of nascent RNA pol III transcripts by La autoantigen
TGCTGTTTT
>pdb|2ALZ|T Chain T, Ternary Complex of hPoli with DNA and dCTP
TGGGGTCCT
>pdb|1Y8Z|D Chain D, alpha-glucosyltransferase in complex with UDP and a 13-mer DNA containing a HMU base at 1.9 A resolution
CTATCTGAG
>pdb|1XJY|B Chain B, The crystal structures of the DNA binding sites of the RUNX1 transcription factor
TGACCGCAG
>pdb|1XJY|A Chain A, The crystal structures of the DNA binding sites of the RUNX1 transcription factor
TCTGCGGTC
>pdb|1XJX|B Chain B, The crystal structures of the DNA binding sites of the RUNX1 transcription factor
TGACCGCAG
>pdb|1XJX|A Chain A, The crystal structures of the DNA binding sites of the RUNX1 transcription factor
TCTGCGGTC
>pdb|1XOK|B Chain B, crystal structure of alfalfa mosaic virus RNA 3'UTR in complex with coat protein N terminal peptide
NAGGGATGC
>pdb|1TEZ|L Chain L, COMPLEX BETWEEN DNA AND THE DNA PHOTOLYASE FROM ANACYSTIS NIDULANS
NGAAGCCGA
>pdb|1TEZ|J Chain J, COMPLEX BETWEEN DNA AND THE DNA PHOTOLYASE FROM ANACYSTIS NIDULANS
NGAAGCCGA
>pdb|1SI3|B Chain B, Crystal structure of the PAZ domain of human eIF2c1 in complex with a 9-mer siRNA-like duplex
CGTGACTCT
>pdb|1Q3F|B Chain B, Uracil DNA glycosylase bound to a cationic 1-aza-2'-deoxyribose-containing DNA
TGTNATCTT
>pdb|1NK6|B Chain B, Cytosine-Cytosine Mismatch At The Polymerase Active Site
GCATGATCC
>pdb|1UE2|A Chain A, Crystal structure of d(GC38GAAAGCT)
GNGAAAGCT
>pdb|1RXW|C Chain C, Crystal structure of A. fulgidus FEN-1 bound to DNA
TAGCATCGG
>pdb|1RXV|D Chain D, Crystal Structure of A. Fulgidus FEN-1 bound to DNA
TAGCATCGG
>pdb|1RXV|C Chain C, Crystal Structure of A. Fulgidus FEN-1 bound to DNA
TAGCATCGG
>pdb|1JZV|D Chain D, Crystal structure of a bulged RNA from the SL2 stem-loop of the HIV-1 psi-RNA
CAGTACGNC
>pdb|1JZV|B Chain B, Crystal structure of a bulged RNA from the SL2 stem-loop of the HIV-1 psi-RNA
CAGTACGNC
>pdb|1OKF|B Chain B, NMR structure of an alpha-L-LNA:RNA hybrid
GCATATCAG
>pdb|1OKF|A Chain A, NMR structure of an alpha-L-LNA:RNA hybrid
CNGANANGC
>pdb|1OCI|B Chain B, [3.2.0]bcANA:DNA
GCATATCAG
>pdb|1OCI|A Chain A, [3.2.0]bcANA:DNA
CTGANATGC
>pdb|1H0Q|B Chain B, NMR solution structure of a fully modified locked nucleic acid (LNA) hybridized to RNA
GCATATCAG
>pdb|1L3S|B Chain B, Crystal Structure of Bacillus DNA Polymerase I Fragment complexed to 9 base pairs of duplex DNA.
GCGATCACG
>pdb|1IXJ|A Chain A, Crystal Structure of d(GCGAAAGCT) Containing Parallel-stranded Duplex with Homo Base Pairs and Anti-Parallel Duplex with Watson-Crick Base pairs
GCGAAAGCT
>pdb|1MNV|B Chain B, Actinomycin D binding to ATGCTGCAT
ATGCTGCAT
>pdb|1MNV|A Chain A, Actinomycin D binding to ATGCTGCAT
ATGCTGCAT
>pdb|1HHX|A Chain A, Solution structure of LNA3:RNA hybrid
CNGANANGC
>pdb|1HHX|B Chain B, Solution structure of LNA3:RNA hybrid
GCATATCAG
>pdb|1HHW|B Chain B, Solution structure of LNA1:RNA hybrid
GCATATCAG
>pdb|1HHW|A Chain A, Solution structure of LNA1:RNA hybrid
CTGANATGC
>pdb|1KSB|B Chain B, Relationship of Solution and Protein-Bound Structures of DNA Duplexes with the Major Intrastrand Cross-Link Lesions Formed on Cisplatin Binding to DNA
AGGCCGGAG
>pdb|1HG9|B Chain B, Solution structure of DNA:RNA hybrid
GCATATCAG
>pdb|1HG9|A Chain A, Solution structure of DNA:RNA hybrid
CTGATATGC
>pdb|1GM5|Z Chain Z, Structure of RecG bound to three-way DNA junction
GAGCACTGC
>pdb|1J9H|D Chain D, Crystal Structure of an RNA Duplex with Uridine Bulges
GTGTCGNAC
>pdb|1J9H|C Chain C, Crystal Structure of an RNA Duplex with Uridine Bulges
GTGTCGNAC
>pdb|1J9H|B Chain B, Crystal Structure of an RNA Duplex with Uridine Bulges
GTGTCGNAC
>pdb|1J9H|A Chain A, Crystal Structure of an RNA Duplex with Uridine Bulges
GTGTCGNAC
>pdb|1QC0|A Chain A, CRYSTAL STRUCTURE OF A 19 BASE PAIR COPY CONTROL RELATED RNA DUPLEX
NAGCGGTGC
>pdb|1IDW|B Chain B, STRUCTURE OF THE HYBRID RNA/DNA R-GCUUCGGC-D[CL]U IN PRESENCE OF RH(NH3)6+++
GCTTCGGCN
>pdb|1IDW|A Chain A, STRUCTURE OF THE HYBRID RNA/DNA R-GCUUCGGC-D[CL]U IN PRESENCE OF RH(NH3)6+++
GCTTCGGCN
>pdb|1I6H|R Chain R, RNA POLYMERASE II ELONGATION COMPLEX
NACCAGGCA
>pdb|1IHA|B Chain B, Structure of the Hybrid RNA/DNA R-GCUUCGGC-D[BR]U in Presence of RH(NH3)6+++
GCTTCGGCN
>pdb|1IHA|A Chain A, Structure of the Hybrid RNA/DNA R-GCUUCGGC-D[BR]U in Presence of RH(NH3)6+++
GCTTCGGCN
>pdb|1FXL|B Chain B, Crystal Structure Of Hud And Au-Rich Element Of The C-Fos Rna
NTTTATTTT
>pdb|1DQH|A Chain A, Crystal Structure Of Helix Ii Of The X. Laevis Somatic 5s Rrna With A Cytosine Bulge In Two Conformations
GCCACCCTG
>pdb|1DQF|A Chain A, Crystal Structure Of Helix Ii Of The X. Laevis Somatic 5s Rrna With A Cytosine Bulge In Two Conformations
GCCACCCTG
>pdb|1EMJ|B Chain B, Uracil-dna Glycosylase Bound To Dna Containing A 4'-thio- 2'deoxyuridine Analog Product
TGTNATCTT
>pdb|1EMH|B Chain B, Crystal Structure Of Human Uracil-dna Glycosylase Bound To Uncleaved Substrate-containing Dna
TGTNATCTT
>pdb|479D|B Chain B, Crystal Structure A Dna:rna Hybrid Duplex, A Dynamic Model For Rnase H Recognition
GAAGAAGAG
>pdb|479D|A Chain A, Crystal Structure A Dna:rna Hybrid Duplex, A Dynamic Model For Rnase H Recognition
CTCTTCTTC
>pdb|1EFO|A Chain A, Crystal Structure Of An Adenine Bulge In The Rna Chain Of A Dna/rna Hybrid, D(ctcctcttc)/r(gaagagagag)
CTCCTCTTC
>pdb|1ENN|B Chain B, Solvent Organization In An Oligonucleotide Crystal: The Structure Of D(Gcgaattcg)2 At Atomic Resolution
GCGAATTCG
>pdb|1ENN|A Chain A, Solvent Organization In An Oligonucleotide Crystal: The Structure Of D(Gcgaattcg)2 At Atomic Resolution
GCGAATTCG
>pdb|421D|B Chain B, 5'-D(TpTpCpTpTp(Bro)cpTpTpC)-3', 5'- R(GpApApGpApApGpApA)-3'
GAAGAAGAA
>pdb|421D|A Chain A, 5'-D(TpTpCpTpTp(Bro)cpTpTpC)-3', 5'- R(GpApApGpApApGpApA)-3'
TTCTTNTTC
>pdb|1DE9|W Chain W, Human Ape1 Endonuclease With Bound Abasic Dna And Mn2+ Ion
GATCGGTAG
>pdb|1DE9|Z Chain Z, Human Ape1 Endonuclease With Bound Abasic Dna And Mn2+ Ion
GATCGGTAG
>pdb|1D3R|D Chain D, Crystal Structure Of Triplex Dna
CGCGCGGAG
>pdb|1D3R|B Chain B, Crystal Structure Of Triplex Dna
CGCGCGGAG
>pdb|376D|A Chain A, A Zipper-Like Dna Duplex D(Gcgaaagct)
GNGAAAGCT
>pdb|1MJP|D Chain D, METHIONINE APOREPRESSOR MUTANT (Q44K) COMPLEXED TO THE MINIMAL MET CONSENSUS OPERATOR
AGACGTCTA
>pdb|438D|B Chain B, Structure Of An Rna Duplex R(Gggcgcucc)2 With Non-Adjacent G.U Base Pairs
GGGCGCTCC
>pdb|438D|A Chain A, Structure Of An Rna Duplex R(Gggcgcucc)2 With Non-Adjacent G.U Base Pairs
GGGCGCTCC
>pdb|253D|A Chain A, Crystal Structure Of The B-Dna Nonamer D(Gcgtacgcg) With A Novel D[g(G.C)] Base-Triplet Involving The Minor Groove
GCGTACGCG
>pdb|1PNN|D Chain D, Peptide Nucleic Acid (Pna) Complexed With Dna
GAAGAAGAG
>pdb|1PNN|B Chain B, Peptide Nucleic Acid (Pna) Complexed With Dna
GAAGAAGAG
>pdb|1CMA|D Chain D, MET REPRESSOR/DNA COMPLEX + S-ADENOSYL-METHIONINE
NGACGTCTA
>pdb|208D|B Chain B, High-Resolution Structure Of A Dna Helix Forming (C.G)G Base Triplets
GCGAATTCG
>pdb|208D|A Chain A, High-Resolution Structure Of A Dna Helix Forming (C.G)G Base Triplets
GCGAATTCG
>pdb|165D|B Chain B, THE STRUCTURE OF A MISPAIRED RNA DOUBLE HELIX AT 1.6 ANGSTROMS RESOLUTION AND IMPLICATIONS FOR THE PREDICTION OF RNA SECONDARY STRUCTURE
GCTTCGGCN
>pdb|165D|A Chain A, THE STRUCTURE OF A MISPAIRED RNA DOUBLE HELIX AT 1.6 ANGSTROMS RESOLUTION AND IMPLICATIONS FOR THE PREDICTION OF RNA SECONDARY STRUCTURE
GCTTCGGCN
>pdb|1DN6|B Chain B, The Crystal Structure Of D(Ggatgggag). An Essential Part Of The Binding Site For Transcription Factor Iiia
CTCCCATCC
>pdb|1DN6|A Chain A, The Crystal Structure Of D(Ggatgggag). An Essential Part Of The Binding Site For Transcription Factor Iiia
GGATGGGAG
>pdb|6YMM|D Chain D, Crystal structure of the SAM-SAH riboswitch with SAM from space group P312
ATTGGAGCA
>pdb|6YMM|B Chain B, Crystal structure of the SAM-SAH riboswitch with SAM from space group P312
ATTGGAGCA
>pdb|6YML|D Chain D, Crystal structure of the SAM-SAH riboswitch with decarboxylated SAH
ATTGGAGCA
>pdb|6YML|B Chain B, Crystal structure of the SAM-SAH riboswitch with decarboxylated SAH
ATTGGAGCA
>pdb|6YMK|P Chain P, Crystal structure of the SAM-SAH riboswitch with AMP
ATTGGAGCA
>pdb|6YMK|N Chain N, Crystal structure of the SAM-SAH riboswitch with AMP
ATTGGAGCA
>pdb|6YMK|J Chain J, Crystal structure of the SAM-SAH riboswitch with AMP
ATTGGAGCA
>pdb|6YMK|G Chain G, Crystal structure of the SAM-SAH riboswitch with AMP
ATTGGAGCA
>pdb|6YMK|D Chain D, Crystal structure of the SAM-SAH riboswitch with AMP
ATTGGAGCA
>pdb|6YMK|B Chain B, Crystal structure of the SAM-SAH riboswitch with AMP
ATTGGAGCA
>pdb|6YLB|P Chain P, Crystal structure of the SAM-SAH riboswitch with SAM
ATTGGAGCA
>pdb|6YLB|N Chain N, Crystal structure of the SAM-SAH riboswitch with SAM
ATTGGAGCA
>pdb|6YLB|J Chain J, Crystal structure of the SAM-SAH riboswitch with SAM
ATTGGAGCA
>pdb|6YLB|G Chain G, Crystal structure of the SAM-SAH riboswitch with SAM
ATTGGAGCA
>pdb|6YLB|D Chain D, Crystal structure of the SAM-SAH riboswitch with SAM
ATTGGAGCA
>pdb|6YLB|B Chain B, Crystal structure of the SAM-SAH riboswitch with SAM
ATTGGAGCA
>pdb|6TYG|I Chain I, Crystal structure of MTB sigma L transcription initiation complex with 9 nt long RNA primer
NACCCTCGA
>pdb|5B2Q|D Chain D, Crystal structure of Francisella novicida Cas9 RHA in complex with sgRNA and target DNA (TGG PAM)
TGGTATCGG
>pdb|5B2P|D Chain D, Crystal structure of Francisella novicida Cas9 in complex with sgRNA and target DNA (TGA PAM)
TGATATCGG
>pdb|5B2O|D Chain D, Crystal structure of Francisella novicida Cas9 in complex with sgRNA and target DNA (TGG PAM)
TGGTATCGG
>pdb|1PH2|D Chain D, Crystal Structure Of The Oxytricha Nova Telomere End- Binding Protein Complexed With Noncognate Ssdna Ggggttttg
GGGGTTTTG
>MD388298.1 WO 2020067199-A/13: Immunodeficient mouse
CGCTATGCT
>MD388297.1 WO 2020067199-A/12: Immunodeficient mouse
ACGCTAAGC
>LY976686.1 KR 1020200024905-A/76567: NOVEL NUCLEIC ACID MOLECULES
GCCGCTTAC
>LY976681.1 KR 1020200024905-A/76562: NOVEL NUCLEIC ACID MOLECULES
CCCGCCAGC
>LY976611.1 KR 1020200024905-A/76492: NOVEL NUCLEIC ACID MOLECULES
GCCGCCTAC
>LY976606.1 KR 1020200024905-A/76487: NOVEL NUCLEIC ACID MOLECULES
CCCGCCAGC
>LY804369.1 KR 1020200040407-A/18: NOVEL ANTI-C-KIT ANTIBODY
CTGGGCTCC
>LY804361.1 KR 1020200040407-A/10: NOVEL ANTI-C-KIT ANTIBODY
TTGGGTTCT
>LY803302.1 KR 1020200025249-A/15: Aptamer for DEHP detection and DEHP detecting device using the same
GCTTCCGTT
>LY838142.1 KR 1020200012956-A/45: YEAST EXPRESSING A SYNTHETIC CALVIN CYCLE
TCTAAGTTG
>LY838141.1 KR 1020200012956-A/44: YEAST EXPRESSING A SYNTHETIC CALVIN CYCLE
TCCAAGTTG
>LY837262.1 KR 1020200018503-A/33: CRYSTALLINE FORMS OF 5-BROMO-2,6-DI(1 H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE AND NEW SALTS
TGGGCCTCT
>LY836775.1 KR 1020200010498-A/5: RECOMBINANT ADENOVIRUSES CARRYING TRANSGENES
CTAGGACTG
>LY836033.1 KR 1020200007040-A/54: COMPOSITIONS COMPRISING NAPHTHYRIDINE DERIVATIVES AND ALUMINIUM ADJUVANT FOR USE IN TREATING SOLID TUMORS
TGGGCCTCT
>LY834567.1 KR 1020200005660-A/768: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTCACGTAA
>LY834566.1 KR 1020200005660-A/767: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATTGTCGCA
>LY834565.1 KR 1020200005660-A/766: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGTACCGTT
>LY834564.1 KR 1020200005660-A/765: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATAGACGCA
>LY834563.1 KR 1020200005660-A/764: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GATAGTGTG
>LY834562.1 KR 1020200005660-A/763: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAATTGCGC
>LY834561.1 KR 1020200005660-A/762: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGTCCTGTT
>LY834560.1 KR 1020200005660-A/761: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CCATGTACT
>LY834559.1 KR 1020200005660-A/760: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATTCGCACA
>LY834558.1 KR 1020200005660-A/759: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AATCAGGAC
>LY834557.1 KR 1020200005660-A/758: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTGAACGCT
>LY834556.1 KR 1020200005660-A/757: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AACATTGCG
>LY834555.1 KR 1020200005660-A/756: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGTACGTCT
>LY834554.1 KR 1020200005660-A/755: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAATGTCAC
>LY834553.1 KR 1020200005660-A/754: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAGAACGGT
>LY834552.1 KR 1020200005660-A/753: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AACTACGGT
>LY834551.1 KR 1020200005660-A/752: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TACTTACGC
>LY834550.1 KR 1020200005660-A/751: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATACAGCAC
>LY834549.1 KR 1020200005660-A/750: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATGTCGACA
>LY834548.1 KR 1020200005660-A/749: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTCGTATAC
>LY834547.1 KR 1020200005660-A/748: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAACGTTAC
>LY834546.1 KR 1020200005660-A/747: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TATCACGTG
>LY834545.1 KR 1020200005660-A/746: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGTATACCT
>LY834544.1 KR 1020200005660-A/745: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CATAACGAG
>LY834543.1 KR 1020200005660-A/744: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TACTAACCG
>LY834542.1 KR 1020200005660-A/743: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGTCACAGA
>LY834541.1 KR 1020200005660-A/742: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAGCGATTA
>LY834540.1 KR 1020200005660-A/741: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GATGCGATA
>LY834539.1 KR 1020200005660-A/740: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GATGACGTA
>LY834538.1 KR 1020200005660-A/739: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TATGTGCAC
>LY834537.1 KR 1020200005660-A/738: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AATTCACGC
>LY834536.1 KR 1020200005660-A/737: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATACAGTCC
>LY834535.1 KR 1020200005660-A/736: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGAGAGTAT
>LY834534.1 KR 1020200005660-A/735: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGTCGTTAT
>LY834533.1 KR 1020200005660-A/734: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTGTTATCG
>LY834532.1 KR 1020200005660-A/733: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GACACTGAA
>LY834531.1 KR 1020200005660-A/732: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTGTTAACG
>LY834530.1 KR 1020200005660-A/731: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTCGCGTTA
>LY834529.1 KR 1020200005660-A/730: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGCCTTACA
>LY834528.1 KR 1020200005660-A/729: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAGCGTTAT
>LY834527.1 KR 1020200005660-A/728: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGCATAGTG
>LY834526.1 KR 1020200005660-A/727: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGACGGT
>LY834525.1 KR 1020200005660-A/726: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CATCATGTC
>LY834524.1 KR 1020200005660-A/725: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCGTTAGTC
>LY834523.1 KR 1020200005660-A/724: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AATCACGTG
>LY834522.1 KR 1020200005660-A/723: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AATGCCGTA
>LY834521.1 KR 1020200005660-A/722: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGACACG
>LY834520.1 KR 1020200005660-A/721: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATCACCGTA
>LY834519.1 KR 1020200005660-A/720: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACTTAGACG
>LY834518.1 KR 1020200005660-A/719: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATATCTGCG
>LY834517.1 KR 1020200005660-A/718: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GATAAGCGT
>LY834516.1 KR 1020200005660-A/717: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATGCGCATA
>LY834515.1 KR 1020200005660-A/716: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CCGATAACA
>LY834514.1 KR 1020200005660-A/715: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TATGACGCA
>LY834513.1 KR 1020200005660-A/714: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTACGTTGT
>LY834512.1 KR 1020200005660-A/713: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATAACGTGC
>LY834511.1 KR 1020200005660-A/712: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATGCCGTTA
>LY834510.1 KR 1020200005660-A/711: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTAATCGTG
>LY834509.1 KR 1020200005660-A/710: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACTTAGCGT
>LY834508.1 KR 1020200005660-A/709: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATCACGTGT
>LY834507.1 KR 1020200005660-A/708: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTACCTTAG
>LY834506.1 KR 1020200005660-A/707: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTAATCGAG
>LY834505.1 KR 1020200005660-A/706: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGTCCGTAA
>LY834504.1 KR 1020200005660-A/705: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGCGACTTA
>LY834503.1 KR 1020200005660-A/704: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGACTGTAC
>LY834502.1 KR 1020200005660-A/703: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAGTGTTAC
>LY834501.1 KR 1020200005660-A/702: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTCGTGCAT
>LY834500.1 KR 1020200005660-A/701: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGCACGTAC
>LY834499.1 KR 1020200005660-A/700: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATCGTCAGG
>LY834498.1 KR 1020200005660-A/699: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TACACTGCG
>LY834497.1 KR 1020200005660-A/698: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GACGTCTGA
>LY834496.1 KR 1020200005660-A/697: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATGTCGACG
>LY834495.1 KR 1020200005660-A/696: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATGGTGAGG
>LY834494.1 KR 1020200005660-A/695: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTCGAGATC
>LY834493.1 KR 1020200005660-A/694: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATACCTGGC
>LY834492.1 KR 1020200005660-A/693: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TATAAGCGT
>LY834491.1 KR 1020200005660-A/692: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AAGACGTTA
>LY834490.1 KR 1020200005660-A/691: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAGGACAAT
>LY834489.1 KR 1020200005660-A/690: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATTAACGCT
>LY834488.1 KR 1020200005660-A/689: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TATGACACT
>LY834487.1 KR 1020200005660-A/688: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTAGCGTTA
>LY834486.1 KR 1020200005660-A/687: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGTATACAC
>LY834485.1 KR 1020200005660-A/686: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATTATGCGA
>LY834484.1 KR 1020200005660-A/685: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATGACGTTA
>LY834483.1 KR 1020200005660-A/684: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGTAACTGT
>LY834482.1 KR 1020200005660-A/683: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATATCTACG
>LY834481.1 KR 1020200005660-A/682: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CATATTACG
>LY834480.1 KR 1020200005660-A/681: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACATTAAGC
>LY834479.1 KR 1020200005660-A/680: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACTGCATTA
>LY834478.1 KR 1020200005660-A/679: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TATACACTG
>LY834477.1 KR 1020200005660-A/678: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GACTGTAAT
>LY834476.1 KR 1020200005660-A/677: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CACACTTAT
>LY834475.1 KR 1020200005660-A/676: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCAATAACG
>LY834474.1 KR 1020200005660-A/675: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CAGTATGTA
>LY834473.1 KR 1020200005660-A/674: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAACGTATG
>LY834472.1 KR 1020200005660-A/673: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTGCTACAT
>LY999908.1 KR 1020200058480-A/1129: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999905.1 KR 1020200058480-A/1123: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999902.1 KR 1020200058480-A/1117: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999899.1 KR 1020200058480-A/1111: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999896.1 KR 1020200058480-A/1105: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999893.1 KR 1020200058480-A/1099: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999890.1 KR 1020200058480-A/1093: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999887.1 KR 1020200058480-A/1087: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999884.1 KR 1020200058480-A/1081: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999881.1 KR 1020200058480-A/1075: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999878.1 KR 1020200058480-A/1069: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999875.1 KR 1020200058480-A/1063: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999872.1 KR 1020200058480-A/1057: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999869.1 KR 1020200058480-A/1051: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999866.1 KR 1020200058480-A/1045: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999863.1 KR 1020200058480-A/1039: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999860.1 KR 1020200058480-A/1033: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999857.1 KR 1020200058480-A/1027: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999854.1 KR 1020200058480-A/1021: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999851.1 KR 1020200058480-A/1015: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999848.1 KR 1020200058480-A/1009: ANTI-TAU ANTIBODIES AND USES THEREOF
AAAGTTTCC
>LY999325.1 KR 1020200051035-A/1129: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999322.1 KR 1020200051035-A/1123: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999319.1 KR 1020200051035-A/1117: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999316.1 KR 1020200051035-A/1111: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999313.1 KR 1020200051035-A/1105: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999310.1 KR 1020200051035-A/1099: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999307.1 KR 1020200051035-A/1093: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999304.1 KR 1020200051035-A/1087: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999301.1 KR 1020200051035-A/1081: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999298.1 KR 1020200051035-A/1075: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999295.1 KR 1020200051035-A/1069: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999292.1 KR 1020200051035-A/1063: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999289.1 KR 1020200051035-A/1057: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999286.1 KR 1020200051035-A/1051: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999283.1 KR 1020200051035-A/1045: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999280.1 KR 1020200051035-A/1039: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999277.1 KR 1020200051035-A/1033: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999274.1 KR 1020200051035-A/1027: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999271.1 KR 1020200051035-A/1021: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999268.1 KR 1020200051035-A/1015: ANTI-TAU ANTIBODIES AND USES THEREOF
AAGGTGTCC
>LY999265.1 KR 1020200051035-A/1009: ANTI-TAU ANTIBODIES AND USES THEREOF
AAAGTTTCC
>LY832373.1 KR 1020200012892-A/301: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GGTGCATCC
>LY832357.1 KR 1020200012892-A/269: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GCTGCATCC
>LY832349.1 KR 1020200012892-A/253: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GAAGCATCT
>LY832341.1 KR 1020200012892-A/237: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GGTTCATCC
>LY832333.1 KR 1020200012892-A/221: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GGTGCGTCC
>LY832325.1 KR 1020200012892-A/205: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GGTGTATCC
>LY832317.1 KR 1020200012892-A/189: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GATGCTTTT
>LY832309.1 KR 1020200012892-A/173: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
TTGGGTTCT
>LY832301.1 KR 1020200012892-A/157: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GATGCATCC
>LY832293.1 KR 1020200012892-A/141: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GAGGCGTCC
>LY832285.1 KR 1020200012892-A/125: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GCTACATCC
>LY832277.1 KR 1020200012892-A/109: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
AGTGCATCC
>LY832269.1 KR 1020200012892-A/93: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
AAGGCGTCT
>LY832261.1 KR 1020200012892-A/77: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GCTGCATCC
>LY832253.1 KR 1020200012892-A/61: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GCTGCATCC
>LY832245.1 KR 1020200012892-A/45: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
TGGGCATCT
>LY832237.1 KR 1020200012892-A/29: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
AGTGCATCC
>LY832229.1 KR 1020200012892-A/13: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
TTGAGTTCT
>LY830099.1 KR 1020200014319-A/40: THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE TYPE III
ATAAGTGAA
>LY996767.1 KR 1020200044145-A/35: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GGGTTAGGG
>LY996766.1 KR 1020200044145-A/34: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GAGTATGAG
>LY996759.1 KR 1020200044145-A/27: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
TTAGGGTTA
>LY996758.1 KR 1020200044145-A/26: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTT
>LY996497.1 KR 1020200053558-A/280: METHODS AND SYSTEMS FOR PERFORMING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE WITH CHAIN-OF-CUSTODY AND CHAIN-OF-IDENTITY BIOLOGICAL SAMPLE TRACKING
GCCGCTGCC
>LY996489.1 KR 1020200053558-A/258: METHODS AND SYSTEMS FOR PERFORMING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE WITH CHAIN-OF-CUSTODY AND CHAIN-OF-IDENTITY BIOLOGICAL SAMPLE TRACKING
GCCGCTGCC
>LY996467.1 KR 1020200053558-A/198: METHODS AND SYSTEMS FOR PERFORMING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE WITH CHAIN-OF-CUSTODY AND CHAIN-OF-IDENTITY BIOLOGICAL SAMPLE TRACKING
GCCGCTGCC
>LY996459.1 KR 1020200053558-A/170: METHODS AND SYSTEMS FOR PERFORMING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE WITH CHAIN-OF-CUSTODY AND CHAIN-OF-IDENTITY BIOLOGICAL SAMPLE TRACKING
GCGGCCGCA
>LY992079.1 KR 1020200036041-A/53: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGGCAGGC
>LY992073.1 KR 1020200036041-A/47: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
GCAGCAGCA
>LY992069.1 KR 1020200036041-A/43: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
AGCAGCAGC
>LY992065.1 KR 1020200036041-A/39: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGCAGCAG
>LY927682.1 KR 1020200024905-A/3049: NOVEL NUCLEIC ACID MOLECULES
CRRRRRRRR
>LY927666.1 KR 1020200024905-A/3033: NOVEL NUCLEIC ACID MOLECULES
CRRRRRRRC
>LY915495.1 KR 1020200015939-A/15: EXPRESSION OF NOVEL CELL TAGS
GGAAGCGGA
>LY845589.1 KR 1020200015932-A/73: COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES
GGTGCATCC
>LY845581.1 KR 1020200015932-A/57: COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES
GGTGCATCC
>LY845573.1 KR 1020200015932-A/41: COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES
GGTGGATCC
>LY845565.1 KR 1020200015932-A/25: COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES
GGTGTATTC
>LY980668.1 KR 1020200032189-A/501: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY980660.1 KR 1020200032189-A/485: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY980652.1 KR 1020200032189-A/469: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980644.1 KR 1020200032189-A/453: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTGCTTTC
>LY980636.1 KR 1020200032189-A/437: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTACATCC
>LY980628.1 KR 1020200032189-A/421: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
ACTACAGCC
>LY980620.1 KR 1020200032189-A/405: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980612.1 KR 1020200032189-A/389: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980604.1 KR 1020200032189-A/373: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTGCATAC
>LY980596.1 KR 1020200032189-A/357: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY980588.1 KR 1020200032189-A/341: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980580.1 KR 1020200032189-A/325: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTGCGTCC
>LY980568.1 KR 1020200032189-A/301: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY980560.1 KR 1020200032189-A/285: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980552.1 KR 1020200032189-A/269: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980544.1 KR 1020200032189-A/253: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LY980536.1 KR 1020200032189-A/237: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980528.1 KR 1020200032189-A/221: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
AAGGTTTCT
>LY980520.1 KR 1020200032189-A/205: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980512.1 KR 1020200032189-A/189: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
ACTGCATCC
>LY980504.1 KR 1020200032189-A/173: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTACATCC
>LY980496.1 KR 1020200032189-A/157: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980488.1 KR 1020200032189-A/141: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GATGCATCC
>LY980480.1 KR 1020200032189-A/125: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTGCATTC
>LY980472.1 KR 1020200032189-A/109: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GATGCATCC
>LY980464.1 KR 1020200032189-A/93: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
TTGGGTTCT
>LY980456.1 KR 1020200032189-A/77: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY980448.1 KR 1020200032189-A/61: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GGTACATCC
>LY980440.1 KR 1020200032189-A/45: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY980432.1 KR 1020200032189-A/29: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
GCTACAGCC
>LY980424.1 KR 1020200032189-A/13: ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
ACTACATCC
>LY844833.1 KR 1020200043322-A/3: Method for Diagnosing Alzheimer's disease Using microRNA-485-3p
GTGTATGAC
>LY978729.1 KR 1020200031645-A/13: ANTI-CD8 ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY978823.1 KR 1020200031659-A/754: DOSAGE REGIMENS OF ANTI-LAG-3 ANTIBODIES AND USES THEREOF
TACACTAGC
>LY978787.1 KR 1020200031659-A/637: DOSAGE REGIMENS OF ANTI-LAG-3 ANTIBODIES AND USES THEREOF
TGGGCCTCT
>LY978824.1 KR 1020200031659-A/755: DOSAGE REGIMENS OF ANTI-LAG-3 ANTIBODIES AND USES THEREOF
TACACCTCC
>LY978768.1 KR 1020200031659-A/533: DOSAGE REGIMENS OF ANTI-LAG-3 ANTIBODIES AND USES THEREOF
TGGGCCTCT
>LY978235.1 KR 1020200028982-A/2: TARGETING THE HDAC2-SP3 COMPLEX TO ENHANCE SYNAPTIC FUNCTION
TTCAAGAGA
>LY927637.1 KR 1020200024905-A/3004: NOVEL NUCLEIC ACID MOLECULES
GGGTTTGGG
>LY927626.1 KR 1020200024905-A/2993: NOVEL NUCLEIC ACID MOLECULES
GGTTTTTGG
>LY824029.1 KR 1020200005549-A/71: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
ATGAAAAKA
>LY824026.1 KR 1020200005549-A/65: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
ATGAGAAGA
>LY823779.1 KR 1020200003370-A/520: METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
TAATAGTGA
>LY823778.1 KR 1020200003370-A/519: METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
GCCGCCACC
>LY823775.1 KR 1020200003370-A/516: METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
CCGCCANGN
>LY823774.1 KR 1020200003370-A/515: METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
CCACCANGN
>LY821324.1 KR 1020200044711-A/124: Anti-L1CAM Antibody or Antigen Binding Fragment Thereof, and Chimeric Antigen Receptor Comprising The Same
GCGGCCGCA
>LY821229.1 KR 1020200044709-A/1: Nucleic acid variant with improved therapeutic efficacy and anticancer pharmaceutical composition comprising the same
TGGTTGTGG
>LY820720.1 KR 1020200024736-A/2: Method and kit for detecting target material
TAATGAAGA
>LY988582.1 KR 1020200032761-A/78: BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
TTCGACTAC
>LY819418.1 KR 1020200012786-A/4: A gene editing of anticoagulant factors
TTTGTAGAT
>LY922117.1 KR 1020200022447-A/755: DOSAGE REGIMENS FOR ANTI-TIM-3 ANTIBODIES AND USES THEREOF
TACACCTCC
>LY922116.1 KR 1020200022447-A/754: DOSAGE REGIMENS FOR ANTI-TIM-3 ANTIBODIES AND USES THEREOF
TACACTAGC
>LY923121.1 KR 1020200022467-A/533: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATTC
>LY923113.1 KR 1020200022467-A/517: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGTTTCC
>LY923105.1 KR 1020200022467-A/501: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY923097.1 KR 1020200022467-A/485: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY923089.1 KR 1020200022467-A/469: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY923081.1 KR 1020200022467-A/453: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
ACTGCATCC
>LY923073.1 KR 1020200022467-A/437: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY923065.1 KR 1020200022467-A/421: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY923057.1 KR 1020200022467-A/405: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GGTGTATCC
>LY923049.1 KR 1020200022467-A/389: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
TGGTCATCT
>LY923041.1 KR 1020200022467-A/373: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GGTGCATCC
>LY923033.1 KR 1020200022467-A/357: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
TTGGGTTCT
>LY923017.1 KR 1020200022467-A/325: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY923009.1 KR 1020200022467-A/309: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY923001.1 KR 1020200022467-A/293: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922993.1 KR 1020200022467-A/277: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922985.1 KR 1020200022467-A/261: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922977.1 KR 1020200022467-A/245: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922969.1 KR 1020200022467-A/229: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTACATCC
>LY922957.1 KR 1020200022467-A/205: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922949.1 KR 1020200022467-A/189: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922941.1 KR 1020200022467-A/173: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GGTGCAACC
>LY922933.1 KR 1020200022467-A/157: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922925.1 KR 1020200022467-A/141: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922917.1 KR 1020200022467-A/125: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922909.1 KR 1020200022467-A/109: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922901.1 KR 1020200022467-A/93: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922893.1 KR 1020200022467-A/77: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922885.1 KR 1020200022467-A/61: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGTATCC
>LY922080.1 KR 1020200022447-A/637: DOSAGE REGIMENS FOR ANTI-TIM-3 ANTIBODIES AND USES THEREOF
TGGGCCTCT
>LY922061.1 KR 1020200022447-A/533: DOSAGE REGIMENS FOR ANTI-TIM-3 ANTIBODIES AND USES THEREOF
TGGGCCTCT
>LY818576.1 KR 1020200011899-A/4: Genome editing for treating autoimmune disease
TTTGTAGAT
>LY922877.1 KR 1020200022467-A/45: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATCC
>LY922869.1 KR 1020200022467-A/29: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGCATTC
>LY922861.1 KR 1020200022467-A/13: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
GCTGTTTCC
>LY921601.1 KR 1020200019722-A/35: METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS
GCCGCCACC
>LY921566.1 KR 1020200021087-A/755: ANTIBODY MOLECULES TO CD73 AND USES THEREOF
TACACCTCC
>LY921565.1 KR 1020200021087-A/754: ANTIBODY MOLECULES TO CD73 AND USES THEREOF
TACACTAGC
>LY921529.1 KR 1020200021087-A/637: ANTIBODY MOLECULES TO CD73 AND USES THEREOF
TGGGCCTCT
>LY921510.1 KR 1020200021087-A/533: ANTIBODY MOLECULES TO CD73 AND USES THEREOF
TGGGCCTCT
>LY817720.1 KR 1020200076345-A/6: Attenuated vaccinia virus expressing Mycobacterium tuberculosis divalent antigen and vaccine for preventing Mycobacterium tuberculosis comprising the same
GGGTCCGGC
>LY817714.1 KR 1020200076335-A/7: Attenuated adeno virus expressing Mycobacterium tuberculosis multivalent antigen and vaccine for preventing Mycobacterium tuberculosis comprising the same
GGGTCCGGA
>LY817713.1 KR 1020200076335-A/6: Attenuated adeno virus expressing Mycobacterium tuberculosis multivalent antigen and vaccine for preventing Mycobacterium tuberculosis comprising the same
GATGTCGCA
>LY921336.1 KR 1020200017493-A/44: ANTIBODY DRUG CONJUGATES THAT BIND LGR5
CTGACCAGC
>LY921330.1 KR 1020200017493-A/32: ANTIBODY DRUG CONJUGATES THAT BIND LGR5
CTGACCTCC
>LY919925.1 KR 1020200017476-A/3830: METHODS FOR MODIFYING RNA SPLICING
TCTAGGAGA
>LY815007.1 KR 1020200059381-A/14: Monoclonal Antibodies for detecting Foot and Mouth Disease Virus and using the same
CTTGTATCC
>LY729772.1 KR 1020190091290-A/397: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GCTGCATCC
>LY729764.1 KR 1020190091290-A/381: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GATGCGTCC
>LY729756.1 KR 1020190091290-A/365: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GGTGCATCC
>LY729748.1 KR 1020190091290-A/349: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GGTGCATCC
>LY729740.1 KR 1020190091290-A/333: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GTTGCATCC
>LY729732.1 KR 1020190091290-A/317: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GGTGCGTCC
>LY729724.1 KR 1020190091290-A/301: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GCTGCATCC
>LY729716.1 KR 1020190091290-A/285: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
TGGTCATCT
>LY729708.1 KR 1020190091290-A/269: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GGTGCATCC
>LY729700.1 KR 1020190091290-A/253: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
TTTGCATCC
>LY729692.1 KR 1020190091290-A/237: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
ACTGCATCC
>LY729684.1 KR 1020190091290-A/221: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
TGGTCATCT
>LY729676.1 KR 1020190091290-A/205: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GGTACATCC
>LY729668.1 KR 1020190091290-A/189: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
AGGGCGTCT
>LY729660.1 KR 1020190091290-A/173: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GCTGCATCC
>LY729652.1 KR 1020190091290-A/157: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
AAGGCGTCT
>LY729644.1 KR 1020190091290-A/141: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GCTGCATCC
>LY729636.1 KR 1020190091290-A/125: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
TGGGCATCT
>LY729628.1 KR 1020190091290-A/109: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
TTTGCATCC
>LY729620.1 KR 1020190091290-A/93: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
AAGGCGTCT
>LY729612.1 KR 1020190091290-A/77: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
AAGGCGTCT
>LY729604.1 KR 1020190091290-A/61: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GCTGCGTCC
>LY729596.1 KR 1020190091290-A/45: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GCTGCATCC
>LY729588.1 KR 1020190091290-A/29: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
GGTACATCC
>LY729580.1 KR 1020190091290-A/13: METHODS OF TREATING PRLR POSITIVE BREAST CANCER
AGTGCATCC
>LY728223.1 KR 1020190078650-A/253: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
GCTGCATCC
>LY728215.1 KR 1020190078650-A/237: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
TTGGGTTCT
>LY728207.1 KR 1020190078650-A/221: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
GATGCATCC
>LY728199.1 KR 1020190078650-A/205: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
TGGGCATCT
>LY728191.1 KR 1020190078650-A/189: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
GATGCTTCC
>LY728183.1 KR 1020190078650-A/173: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
GATGCATCC
>LY728175.1 KR 1020190078650-A/157: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
GCTGCATCC
>LY728167.1 KR 1020190078650-A/141: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
TCTGCATCC
>LY728159.1 KR 1020190078650-A/125: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
TTGGGTTCT
>LY728151.1 KR 1020190078650-A/109: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
AAGATTTCT
>LY728143.1 KR 1020190078650-A/93: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
GCTGCATCC
>LY728135.1 KR 1020190078650-A/77: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
TGGGCATCT
>LY728127.1 KR 1020190078650-A/61: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
AAGATTTTT
>LY728119.1 KR 1020190078650-A/45: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
GCTGCATCC
>LY728111.1 KR 1020190078650-A/29: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
AAGGCGTCT
>LY728103.1 KR 1020190078650-A/13: METHODS OF TREATING OBESITY WITH ANTI-ANGPTL8 ANTIBODIES
GCTGCATCC
>LY728050.1 KR 1020190090386-A/141: ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
GCTGCATCC
>LY727803.1 KR 1020190104519-A/4: METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION
CGCGAAGCG
>LY727680.1 KR 1020190096989-A/101: METHODS FOR PROCESSING NUCLEIC ACID SAMPLES
AGCGTCGTG
>LY724781.1 KR 1020190086471-A/319: METHODS OF TREATING INFLAMMATORY CONDITIONS
TGGGCATCT
>LY724773.1 KR 1020190086471-A/301: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCA
>LY724765.1 KR 1020190086471-A/285: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCTTCC
>LY724757.1 KR 1020190086471-A/269: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724749.1 KR 1020190086471-A/253: METHODS OF TREATING INFLAMMATORY CONDITIONS
GTTGCATCC
>LY724741.1 KR 1020190086471-A/237: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCGTCC
>LY724733.1 KR 1020190086471-A/221: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724725.1 KR 1020190086471-A/205: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724717.1 KR 1020190086471-A/189: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724709.1 KR 1020190086471-A/173: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCGTCC
>LY724701.1 KR 1020190086471-A/157: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCAGCC
>LY724693.1 KR 1020190086471-A/141: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724685.1 KR 1020190086471-A/125: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724677.1 KR 1020190086471-A/109: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724669.1 KR 1020190086471-A/93: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724661.1 KR 1020190086471-A/77: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724653.1 KR 1020190086471-A/61: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724645.1 KR 1020190086471-A/45: METHODS OF TREATING INFLAMMATORY CONDITIONS
GGTGCATCC
>LY724637.1 KR 1020190086471-A/29: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY724629.1 KR 1020190086471-A/13: METHODS OF TREATING INFLAMMATORY CONDITIONS
GCTGCATCC
>LY795796.1 KR 1020190140472-A/755: ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES
TACACCTCC
>LY795795.1 KR 1020190140472-A/754: ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES
TACACTAGC
>LY795759.1 KR 1020190140472-A/637: ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES
TGGGCCTCT
>LY795740.1 KR 1020190140472-A/533: ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES
TGGGCCTCT
>LY722249.1 KR 1020190142289-A/3: Method for Diagnosing Alzheimer's disease Using microRNA-485-3p
GTGTATGAC
>LY721515.1 KR 1020190106954-A/10: Novel Brassica juncea Czern 'MISO' useful hybridizing rape
ACCTCAGCT
>LY720389.1 KR 1020190137015-A/55: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTTCTT
>LY720388.1 KR 1020190137015-A/54: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTGCTT
>LY720387.1 KR 1020190137015-A/53: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTTCTG
>LY720386.1 KR 1020190137015-A/52: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTGCTT
>LY720385.1 KR 1020190137015-A/51: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTTCTG
>LY720384.1 KR 1020190137015-A/50: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTGCTG
>LY720383.1 KR 1020190137015-A/49: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTTCTT
>LY720382.1 KR 1020190137015-A/48: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAAGTTCTT
>LY720381.1 KR 1020190137015-A/47: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTGCTT
>LY720380.1 KR 1020190137015-A/46: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGTTATT
>LY720379.1 KR 1020190137015-A/45: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATGTATT
>LY720378.1 KR 1020190137015-A/44: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATTTAGT
>LY720377.1 KR 1020190137015-A/43: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGGTATT
>LY720376.1 KR 1020190137015-A/42: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGTTAGT
>LY720375.1 KR 1020190137015-A/41: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTATGTAGT
>LY720374.1 KR 1020190137015-A/40: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGGTATT
>LY720373.1 KR 1020190137015-A/39: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGTTAGT
>LY720372.1 KR 1020190137015-A/38: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATGTAGT
>LY720371.1 KR 1020190137015-A/37: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGGTAGT
>LY720370.1 KR 1020190137015-A/36: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTTTCCC
>LY720369.1 KR 1020190137015-A/35: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTGTTCCC
>LY720368.1 KR 1020190137015-A/34: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTGTCCC
>LY720367.1 KR 1020190137015-A/33: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTTTT
>LY720366.1 KR 1020190137015-A/32: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTGTT
>LY720365.1 KR 1020190137015-A/31: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTTTG
>LY720364.1 KR 1020190137015-A/30: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTGTT
>LY720363.1 KR 1020190137015-A/29: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTTTG
>LY720362.1 KR 1020190137015-A/28: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTATTGTG
>LY720361.1 KR 1020190137015-A/27: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTGTT
>LY720360.1 KR 1020190137015-A/26: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTTTG
>LY720359.1 KR 1020190137015-A/25: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGATTGTG
>LY720358.1 KR 1020190137015-A/24: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAGTGTG
>LY720357.1 KR 1020190137015-A/23: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTGTT
>LY720356.1 KR 1020190137015-A/22: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTTTG
>LY720355.1 KR 1020190137015-A/21: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTGTG
>LY720354.1 KR 1020190137015-A/20: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTGTG
>LY720353.1 KR 1020190137015-A/19: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTGTG
>LY720352.1 KR 1020190137015-A/18: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAATTTA
>LY720351.1 KR 1020190137015-A/17: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAATTTA
>LY720350.1 KR 1020190137015-A/16: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAATTTA
>LY720349.1 KR 1020190137015-A/15: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAATGTA
>LY720348.1 KR 1020190137015-A/14: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAATTTA
>LY720347.1 KR 1020190137015-A/13: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAATGTA
>LY720346.1 KR 1020190137015-A/12: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAATGTA
>LY720345.1 KR 1020190137015-A/11: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTCACG
>LY720344.1 KR 1020190137015-A/10: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAAGTCACG
>LY720343.1 KR 1020190137015-A/9: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATGCACG
>LY752361.1 KR 1020190117638-A/486: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
TACGCATCA
>LY752345.1 KR 1020190117638-A/454: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
TACGCTAGC
>LY752329.1 KR 1020190117638-A/422: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
TATGCCAGC
>LY752313.1 KR 1020190117638-A/390: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
TACGCCTCT
>LY752297.1 KR 1020190117638-A/358: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
AAAGTATCC
>LY752281.1 KR 1020190117638-A/326: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
AAGGTTAGT
>LY751201.1 KR 1020190112801-A/142: DOSING SCHEDULE OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN COMBINATION
TGGGCCTCT
>LY751180.1 KR 1020190123738-A/565: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY751172.1 KR 1020190123738-A/549: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCATCC
>LY751164.1 KR 1020190123738-A/533: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCATCC
>LY751160.1 KR 1020190123738-A/525: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY751120.1 KR 1020190123738-A/445: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
TTGGTTTCT
>LY751112.1 KR 1020190123738-A/429: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GATGCATCC
>LY751104.1 KR 1020190123738-A/413: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCATCC
>LY751096.1 KR 1020190123738-A/397: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GATGCATCC
>LY751088.1 KR 1020190123738-A/381: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
AAGATTTCT
>LY751080.1 KR 1020190123738-A/365: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCA
>LY751072.1 KR 1020190123738-A/349: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GATGCATCC
>LY751064.1 KR 1020190123738-A/333: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
TTGGTTTCT
>LY751056.1 KR 1020190123738-A/317: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY751048.1 KR 1020190123738-A/301: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
TGGGCATCT
>LY751040.1 KR 1020190123738-A/285: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
TGGGCATCT
>LY751032.1 KR 1020190123738-A/269: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
TGGGCATCT
>LY751024.1 KR 1020190123738-A/253: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCATCC
>LY751016.1 KR 1020190123738-A/237: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY751008.1 KR 1020190123738-A/221: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTACATCC
>LY751000.1 KR 1020190123738-A/205: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTTCATCC
>LY750992.1 KR 1020190123738-A/189: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GATGCATCC
>LY750984.1 KR 1020190123738-A/173: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GATGCATCC
>LY750976.1 KR 1020190123738-A/157: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GATGCATCC
>LY750968.1 KR 1020190123738-A/141: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCTTCC
>LY750960.1 KR 1020190123738-A/125: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
AAGGTTTCT
>LY750952.1 KR 1020190123738-A/109: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCGTCC
>LY750944.1 KR 1020190123738-A/93: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTACATCC
>LY750936.1 KR 1020190123738-A/77: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCATCC
>LY750928.1 KR 1020190123738-A/61: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY750920.1 KR 1020190123738-A/45: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCATCC
>LY750912.1 KR 1020190123738-A/29: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY750904.1 KR 1020190123738-A/13: RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY750876.1 KR 1020190115053-A/33: 1-(4-AMINO-5-BROMO-6-(1 H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)-1 H-PYRAZOL-4-OL AND USE THEREOF IN THE TREATMENT OF CANCER
TGGGCCTCT
>LY713838.1 KR 1020190096149-A/19: Skin-penetrating Delivery Carrier Comprising Nucleic Acid Complex and Uses thereof
TAGTCGGTG
>LY713700.1 KR 1020190096030-A/9: DNA aptamer binding to edifenphos with specificity and Uses thereof
CTCCACGTG
>LY750300.1 KR 1020190128633-A/7: TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS
CTAGGACTG
>LY748422.1 KR 1020190107719-A/142: DOSING SCHEDULE FOR A COMBINATION OF CERITINIB AND AN ANTI-PD-1 ANTIBODY MOLECULE
TGGGCCTCT
>LY745157.1 KR 1020190102259-A/3: MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS
GGAAGCGGA
>LY743292.1 KR 1020190101435-A/273: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GCTGCATCC
>LY743282.1 KR 1020190101435-A/253: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
AAGGCGTCT
>LY743272.1 KR 1020190101435-A/233: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GCTGCATCC
>LY743262.1 KR 1020190101435-A/213: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GCTGCATCC
>LY743252.1 KR 1020190101435-A/193: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
ACTACATCC
>LY743242.1 KR 1020190101435-A/173: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GCTGCATCT
>LY743232.1 KR 1020190101435-A/153: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
ACTGCATCC
>LY743222.1 KR 1020190101435-A/133: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GAGGCGTCT
>LY743212.1 KR 1020190101435-A/113: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GGTACATCC
>LY743202.1 KR 1020190101435-A/93: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GCTGCATCC
>LY743192.1 KR 1020190101435-A/73: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GCTACATCC
>LY743182.1 KR 1020190101435-A/53: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GCAACATCC
>LY743172.1 KR 1020190101435-A/33: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GCTGCATCC
>LY743162.1 KR 1020190101435-A/13: HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
GTGGCATCC
>LY739370.1 KR 1020190090055-A/733: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>LY739358.1 KR 1020190090055-A/709: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LY739346.1 KR 1020190090055-A/685: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LY739334.1 KR 1020190090055-A/661: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LY739322.1 KR 1020190090055-A/637: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LY739310.1 KR 1020190090055-A/613: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LY739298.1 KR 1020190090055-A/589: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GATGCATCC
>LY739286.1 KR 1020190090055-A/565: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LY739274.1 KR 1020190090055-A/541: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LY739262.1 KR 1020190090055-A/517: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>LY739250.1 KR 1020190090055-A/493: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LY739238.1 KR 1020190090055-A/469: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LY739226.1 KR 1020190090055-A/445: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LY739214.1 KR 1020190090055-A/421: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LY739202.1 KR 1020190090055-A/397: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LY739190.1 KR 1020190090055-A/373: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LY739178.1 KR 1020190090055-A/349: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LY739166.1 KR 1020190090055-A/325: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LY739154.1 KR 1020190090055-A/301: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>LY739142.1 KR 1020190090055-A/277: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>LY739130.1 KR 1020190090055-A/253: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>LY739118.1 KR 1020190090055-A/229: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>LY739106.1 KR 1020190090055-A/205: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>LY739094.1 KR 1020190090055-A/181: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>LY739082.1 KR 1020190090055-A/157: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LY739070.1 KR 1020190090055-A/133: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GCTGCATCC
>LY739058.1 KR 1020190090055-A/109: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GCTGCATCC
>LY739046.1 KR 1020190090055-A/85: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TGGGCATCT
>LY739034.1 KR 1020190090055-A/61: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TGGGCCTCT
>LY739022.1 KR 1020190090055-A/37: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LY739010.1 KR 1020190090055-A/13: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LY730122.1 KR 1020190101975-A/277: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY730114.1 KR 1020190101975-A/261: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GTTGTGTCC
>LY730106.1 KR 1020190101975-A/245: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY730098.1 KR 1020190101975-A/229: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY730090.1 KR 1020190101975-A/213: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY730082.1 KR 1020190101975-A/197: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY730070.1 KR 1020190101975-A/173: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY730062.1 KR 1020190101975-A/157: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCATCC
>LY730054.1 KR 1020190101975-A/141: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY730046.1 KR 1020190101975-A/125: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY730038.1 KR 1020190101975-A/109: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GTTGCATCC
>LY730030.1 KR 1020190101975-A/93: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GTTGCATCC
>LY730022.1 KR 1020190101975-A/77: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
AAGATTTCT
>LY730014.1 KR 1020190101975-A/61: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
AAGGTTTCT
>LY730006.1 KR 1020190101975-A/45: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>LY729998.1 KR 1020190101975-A/29: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
ACTGCATCC
>LY729990.1 KR 1020190101975-A/13: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
AAGGCGTCT
>LY729964.1 KR 1020190090820-A/13: A PHARMACEUTICAL COMPOSITION FOR AVERTING OPIOID ADDICTION
GCTGCATTC
>MD243812.1 JP 2020513839-A/49: CHIMERIC ANTIGEN RECEPTORS TARGETING TIM-1
TATGCTTCC
>MD243800.1 JP 2020513839-A/37: CHIMERIC ANTIGEN RECEPTORS TARGETING TIM-1
GCTGCATCC
>MD243498.1 JP 2020513777-A/3: MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS
GGAAGCGGA
>MD240716.1 JP 2020513404-A/159: Methods of Treating Inflammatory Conditions
TGGGCATCT
>MD240708.1 JP 2020513404-A/151: Methods of Treating Inflammatory Conditions
GCTGCATCA
>MD240700.1 JP 2020513404-A/143: Methods of Treating Inflammatory Conditions
GCTGCTTCC
>MD240692.1 JP 2020513404-A/135: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240684.1 JP 2020513404-A/127: Methods of Treating Inflammatory Conditions
GTTGCATCC
>MD240676.1 JP 2020513404-A/119: Methods of Treating Inflammatory Conditions
GCTGCGTCC
>MD240668.1 JP 2020513404-A/111: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240660.1 JP 2020513404-A/103: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240652.1 JP 2020513404-A/95: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240644.1 JP 2020513404-A/87: Methods of Treating Inflammatory Conditions
GCTGCGTCC
>MD240636.1 JP 2020513404-A/79: Methods of Treating Inflammatory Conditions
GCTGCAGCC
>MD240628.1 JP 2020513404-A/71: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240620.1 JP 2020513404-A/63: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240612.1 JP 2020513404-A/55: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240604.1 JP 2020513404-A/47: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240596.1 JP 2020513404-A/39: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240588.1 JP 2020513404-A/31: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240580.1 JP 2020513404-A/23: Methods of Treating Inflammatory Conditions
GGTGCATCC
>MD240572.1 JP 2020513404-A/15: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD240564.1 JP 2020513404-A/7: Methods of Treating Inflammatory Conditions
GCTGCATCC
>MD234321.1 JP 2020510416-A/153: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
TACGCATCA
>MD234305.1 JP 2020510416-A/137: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
TACGCTAGC
>MD234289.1 JP 2020510416-A/121: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
TATGCCAGC
>MD234273.1 JP 2020510416-A/105: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
TACGCCTCT
>MD234257.1 JP 2020510416-A/89: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
AAAGTATCC
>MD234241.1 JP 2020510416-A/73: MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
AAGGTTAGT
>MD233861.1 JP 2020512286-A/104: METHODS OF TREATING CANCERS CONTAINING FUSION GENES
TCAGAAACA
>MD233855.1 JP 2020512286-A/98: METHODS OF TREATING CANCERS CONTAINING FUSION GENES
CGACGAGGC
>MD233851.1 JP 2020512286-A/94: METHODS OF TREATING CANCERS CONTAINING FUSION GENES
TCAGAAACA
>MD233171.1 JP 2020512281-A/139: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>MD233163.1 JP 2020512281-A/131: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GTTGTGTCC
>MD233155.1 JP 2020512281-A/123: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>MD233147.1 JP 2020512281-A/115: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>MD233139.1 JP 2020512281-A/107: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>MD233131.1 JP 2020512281-A/99: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>MD233119.1 JP 2020512281-A/87: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>MD233111.1 JP 2020512281-A/79: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GGTGCATCC
>MD233103.1 JP 2020512281-A/71: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>MD233095.1 JP 2020512281-A/63: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>MD233087.1 JP 2020512281-A/55: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GTTGCATCC
>MD233079.1 JP 2020512281-A/47: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GTTGCATCC
>MD233071.1 JP 2020512281-A/39: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
AAGATTTCT
>MD233063.1 JP 2020512281-A/31: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
AAGGTTTCT
>MD233055.1 JP 2020512281-A/23: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
GCTGCATCC
>MD233047.1 JP 2020512281-A/15: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
ACTGCATCC
>MD233039.1 JP 2020512281-A/7: RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
AAGGCGTCT
>MD233002.1 JP 2020510409-A/119: ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND USES THEREOF
TCGGCATCC
>MD232979.1 JP 2020510409-A/96: ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND USES THEREOF
GCTGCATCC
>MD232954.1 JP 2020510409-A/71: ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND USES THEREOF
CATGCAAAA
>MD232927.1 JP 2020510409-A/44: ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND USES THEREOF
CTTGCATCC
>MD232912.1 JP 2020510409-A/29: ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND USES THEREOF
AATGCAAAA
>MD232885.1 JP 2020510409-A/2: ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND USES THEREOF
TACACATCA
>MC403578.1 JP 2018162306-A/88: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCT
>MC403567.1 JP 2018162306-A/77: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCC
>MC403553.1 JP 2018162306-A/63: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCATCC
>MC403424.1 JP 2018154648-A/127: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GATGCATCC
>MC403412.1 JP 2018154648-A/115: Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
GATGCATCC
